

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Biological and Clinical Correlates of the Patient Health Questionnaire-9

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054741
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2021
Complete List of Authors:	Califf, Robert; Verily Life Sciences LLC Wong, Celeste; Verily Life Sciences LLC Doraiswamy, Murali; Duke University Medical Center, Psychiatry; Duke University Medical Center, Brain Sciences Hong, David ; Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences Miller, David; Verily Life Sciences LLC Mega, Jessica; Verily Life Sciences LLC
Keywords:	MENTAL HEALTH, PUBLIC HEALTH, Depression & mood disorders < PSYCHIATRY, Anxiety disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

ORIGINAL RESEARCH**Biological and Clinical Correlates of the Patient Health Questionnaire-9****Running title:** Biological and Clinical Correlates of PHQ-9Robert M. Califf, MD¹; Celeste Wong, MPH¹; P. Murali Doraiswamy, MBBS²;David S. Hong, MD³; David P. Miller, MS¹; Jessica L. Mega, MD, MPH¹; for the Baseline Study Group¹Verily Life Sciences, San Francisco, CA; ²Department of Psychiatry and Behavioral Sciences and the Duke Institute for Brain Sciences, Duke University School of Medicine, Durham, NC;³Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA.**Address for correspondence:** Robert M. Califf, MD; Verily Life Sciences, 269 E Grand Ave., South San Francisco, CA 94080; Email: robert.califf@duke.edu**Number of references:** 37**Number of tables:** 3**Number of figures:** 1**Number of appendices:** 1 (7 eTables, 1 eFigure w/5 parts)**Text word count:** 2492**Abstract word count:** 247**Key words:** Patient Health Questionnaire-9; measures of health and disease; effective clinical intervention

ABSTRACT

Objectives: The most common screening tool for depression is the Patient Health Questionnaire-9 (PHQ-9). We assessed the relationship between the PHQ-9 at intake and other measurements intended to assess biological factors, markers of disease, and health status.

Design, setting, and participants: We performed a cross-sectional analysis of 2365 participants from the Baseline Health Study (BHS), a prospective cohort of adults selected to represent major demographic groups in the United States. Participants underwent deep phenotyping on demographic, clinical, laboratory, functional, and imaging findings.

Importance: Despite extensive research on the clinical implications of the PHQ-9, data are limited on the relationship between PHQ-9 scores and other measures of health and disease; this study seeks to better understand this relationship.

Interventions: None.

Main outcomes and measures: Cross-sectional measures of medical illnesses, gait, balance strength, activities of daily living, imaging, and laboratory tests.

Results: Higher PHQ-9 scores were associated with female sex, younger participants, and those with compromised physical status and chronic conditions. Within physical health, increasing PHQ-9 score was associated with a higher frequency of many comorbidities and active symptoms.

Conclusions: BHS data confirm findings in the literature regarding the relationship between PHQ-9 and measures of chronic disease, psychological well-being, social well-being, socioeconomic status, and poor physical performance. Our study highlights how even subthreshold depressive symptoms (measured by PHQ-9) may serve as an entree into a variety of

1
2
3 individual- and population-level concerns that demand more attention. Furthermore, our findings
4
5 underscore that depression should be considered a comorbidity in common disease.
6
7

8 **Clinical trial registration:** <https://clinicaltrials.gov/ct2/show/NCT03154346>
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations of this study

- This study included deep phenotyping on demographic, clinical, laboratory, functional, and imaging findings of 2365 participants from the Baseline Health Study (BHS).
- This study provides important data on the relationship between PHQ-9 scores and other measures of health and disease.
- The cross-sectional nature of this study limits our ability to assess the time course of these findings; however, follow-up is currently accruing.
- People with significant depression are less likely to volunteer, thereby limiting the breadth of depression observed in this study.
- The study population is generally representative of adult age, sex, race, and ethnicity, but it is not a fully representative sample of the population.

1
2
3 Depression is a complex, chronic condition that affects hundreds of millions of people
4 worldwide.¹ Bidirectional relationships have been reported between depression and many
5
6 chronic illnesses²; however, most studies have focused on specific conditions, such as diabetes,
7
8 stroke, or congestive heart failure, as opposed to a multidimensional deep phenotyping approach.
9
10 Findings from previous studies highlight the need to more fully characterize the relationship
11
12 between depression and physical health. Furthermore, it would be helpful to better understand
13
14 whether these relationships exist only above a certain threshold or across the entire continuum.
15
16

17
18
19 The most common screening tool for depression is the Patient Health Questionnaire-9
20
21 (PHQ-9), whose operating characteristics are well known³ and have been validated in a variety
22
23 of contexts.^{4,5} Despite extensive research on the clinical and behavioral implications of PHQ-9,^{6,7}
24
25 the results of this questionnaire are often used in a dichotomous manner (e.g., cut-off of 10)
26
27 without evaluating the full relationship between PHQ-9 scores and measures of health and
28
29 disease.
30
31

32
33 The Baseline Health Study (BHS)⁸ is a prospective cohort study of an adult population
34
35 selected to represent major demographic groups in the U.S. In BHS, deep phenotyping of
36
37 numerous demographic, clinical, laboratory, functional, and imaging findings is coupled with
38
39 ongoing longitudinal follow-up. The purpose of our study was to assess the relationship between
40
41 the entire spectrum of depression, measured by PHQ-9, and a broad array of measurements
42
43 intended to assess health status.
44
45
46
47
48

49 **METHODS**

50 **The Baseline Health Study**

1
2
3 BHS methods have been previously described,^{8,9} including entry and exclusion criteria, the
4 institutional review board and participant consent procedures, the data collection scheme, and
5 key components of study procedures. Additional details of the effects of social determinants on
6 health in the BHS study have been previously reported.⁹ BHS is enrolling a large number of
7 participants, beginning with intensive measurement of the first 2502 people (the deeply
8 phenotyped cohort) in whom a large volume of multimodal data are collected. Four clinical BHS
9 sites in the U.S. have begun enrollment.

10
11
12
13
14
15
16
17
18
19 The participants were enrolled through a virtual online registry with selection of
20 participants for the deep phenotyping cohort included in this report using an algorithm intended
21 to produce a representative sample of U.S. adult age, race, and ethnicity. People in good health
22 and with medical conditions were included and the sampling method was designed to over-
23 represent people at risk of heart disease or cancer. The PHQ-9 in this report was collected at the
24 initial study visit in person or online.

25
26
27
28
29
30
31
32
33 A pre-BHS pilot study, which tested clinical assessment workflows, was conducted in
34 200 healthy participants prior to initiation of the primary study. BHS is funded by Verily (San
35 Francisco, CA) and is managed in collaboration with Stanford University (Stanford, CA), Duke
36 University (Durham, NC), and the California Health and Longevity Institute (Westlake Village,
37 CA) with enrolling sites in Durham, NC; Kannapolis, NC; Los Angeles, CA; and Palo Alto, CA.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The extended studies have governance approaches specific to the needs of each study. Herein,
we examine a cross-sectional analysis of the first BHS time point PHQ-9 scores.

Statistical methods

1
2
3 The statistical methods used in this manuscript have been described previously.⁹ Distributional
4 measures; medians and 25th, 75th percentiles for continuous variables; and counts and
5 percentages for categorical variables were computed and summarized across each of 5 PHQ-9
6 severity groups³ (0, 1–4, 5–9, 10–14, >14), divided by convention to be consistent with prior
7 studies. The Cochran-Armitage trend test for binomial variables,^{10,11} and the Spearman rank
8 correlation test for continuous variables¹² or categorical variables that are ordinal in nature (e.g.,
9 education and income), were used to test for linear trend across severity group. Multiple tests
10 were not adjusted for, given the exploratory nature of this study. Subsequent studies with pre-
11 planned hypotheses are needed to confirm results.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Penalized regression using the least absolute shrinkage and selection operator (LASSO)
was conducted to model physical, phenotypic, and symptom factors that could predict the PHQ-9
score (logarithm of PHQ-9 + 1). Data were randomly split into a training set (approximately 70%
of the data), which was used to build the models, and an independent test set, which was used to
evaluate model performance. The final linear model was trained on the full training set, retaining
all predictors with coefficients not equal to zero, and was evaluated on the held-aside test set.

Since inference rather than prediction is the goal of this analysis, we considered 5 sets of
sequential “adjustment” models, consisting of smaller-to-larger covariate lists that were entered
into a LASSO regression model. The LASSO-predicted values resulting from each of the 5
models were used to estimate a covariate-adjusted effect for all other candidate variables.
Separate regressions for *each* of the candidate variables that are not included in a given model
were performed to obtain coefficients and confidence intervals (i.e., only the LASSO-predicted
value and the candidate variable to be evaluated were included in each model).

1
2
3 The LASSO adjustment models comprise the following covariates: 1) Model 1: age, sex,
4 and age \times sex interaction; 2) Model 2: variables from Model 1, plus race and ethnicity,
5 socioeconomic-related variables (highest education completed, household income, marital status,
6 employment status, and health insurance), and behavioral-related variables (smoking status,
7 pack-years smoked, and the Alcohol Use Disorders Identification Test-Consumption [AUDIT-C]
8 sum score); 3) Model 3: variables from Model 2 plus medical conditions except mental health
9 disorder diagnoses or disorders directly related to mental health or depression (major depressive
10 disorder, generalized anxiety disorder, attention deficit hyperactivity disorder, post-traumatic
11 stress disorder, bipolar disorder, alcohol abuse, drug abuse, and concussion or loss of
12 consciousness); 4) Model 4: variables from Model 3, plus symptoms and allergies, except those
13 symptoms that are directly related to mental health or depression (i.e., nervousness, mood
14 changes, fatigue, lack of energy, change in sleep patterns, change in appetite, and difficulty
15 concentrating); and 5) Model 5: variables from Model 4, plus all physical health metrics. The
16 key variables included in each covariate model can be found in **eTable 1**.

17
18
19 Since LASSO regression techniques require an input dataset with complete data, missing
20 data were addressed using iterative regression-based imputation, where predictors were first
21 grouped by data type, then the groups were rank-ordered by the most missing to the least missing
22 data. The rank of the whole group was based on the amount of missingness of the majority
23 ($\geq 50\%$) of the fields within that group), and then at each imputation step, the grouped predictors
24 were used in a regression model to predict the missing data. The PHQ-9 score was imputed in the
25 last step along with other patient-reported outcome scores and, therefore, all 2502 participants
26 were included in the LASSO models.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

To summarize key model findings adjusted for known demographic and socioeconomic-related risk factors of PHQ-9, 4 groups were created based on the LASSO-predicted value using Model 1 (age, sex, and age \times sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). For both models, “high risk” was defined as the top 50% of the predicted value, while “low risk” was defined as the bottom 50% of the predicted value. The 2 risk groups from each model were combined to create the following 4 groups: 1) high risk Model 1 + high risk Model 2; 2) high risk Model 1 + low risk Model 2; 3) low risk Model 1 + high risk Model 2; and 4) low risk Model 1 + low risk Model 2.

Patient and public involvement statement

From the beginning, BHS has used participant and community engagement methods. Participants have been involved in feedback sessions, and return of results is a commitment of the project. Community meetings have also been held to assure broad feedback on the goals and conduct of the project.

RESULTS

The relationship between the PHQ-9 score and key demographic characteristics and vital signs is shown in **Table 1**. Younger participants, women, people of color, and those of Hispanic ethnicity had higher PHQ-9 scores. While no difference was observed in blood pressure or temperature, higher PHQ-9 scores were found in participants with higher resting heart rates, larger body mass index, greater waist circumference, and higher respiratory rates.

PHQ-9 scores as a function of medical history and symptoms are shown in **Table 2** and **eTable 2**. As expected, participants with other chronic conditions, particularly gastroesophageal

1
2
3 reflux disease, anxiety, and asthma, had higher PHQ-9 scores. A history of diagnosed depression
4 was highly correlated with elevated PHQ-9. Various symptoms were evident in participants with
5 higher PHQ-9 scores, with musculoskeletal, mood, and anxiety symptoms proving particularly
6 prominent.
7
8
9
10

11
12 **Table 3** demonstrates the relationship between measures of physical performance and
13 PHQ-9; differences in 6-minute walk distance, handgrip strength, leg balance, chair stand, and
14 mean steps are particularly associated with higher PHQ-9.
15
16
17

18
19 The interplay of higher PHQ-9 score predictors based on the LASSO regression is shown
20 in **Figure 1**. Model performance was similar between the training and test sets for each model
21 (Model 1: $R^2 = 0.032$ vs. 0.035 ; Model 2: $R^2 = 0.117$ vs. 0.112 ; Model 3: $R^2 = 0.167$ vs. 0.133 ;
22 Model 4: $R^2 = 0.247$ vs. 0.228 ; and Model 5: $R^2 = 0.270$ vs. 0.240 , respectively). Regardless of
23 adjustment factors, memory change, tension, shortness of breath, and indicators of
24 musculoskeletal symptoms are related to higher PHQ-9 scores (Models 1–3). Further details of
25 the LASSO analysis are included in the supplementary materials (**eTables 3–7**). Tension,
26 memory change, and back pain consistently remain in the models after adjustment. When
27 medical conditions, symptoms, and allergies are taken into account, indicators of obesity (body
28 mass index, waist circumference) and lack of physical fitness are the most significant predictors
29 of PHQ-9 score. When physical performance is also factored into the adjustment, laboratory
30 values are only weakly associated with PHQ-9 scores.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **eFigure 1** presents the distribution of PHQ-9 according to other health conditions. The
48 inter-relationships are clear across this spectrum of measures, emphasizing the importance of
49 understanding all 3 dimensions when designing interventions.
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Our study reinforces previous observations regarding the relationship between PHQ-9 and measures of chronic disease, psychological distress, and poor physical performance. While these findings are not surprising, they highlight how PHQ-9 is an entree into a variety of individual- and population-level concerns that demand more attention. Contextual awareness is critically important when the PHQ-9 is used in clinical practice¹³ as recommended by the U.S. Preventive Services Task Force¹⁴ for screening within a health system or for public health assessment.

This analysis cannot answer questions of cause and effect since it is cross-sectional. The PHQ-9 and detailed serial measures of biological, clinical, behavioral, and social function will be assessed in the ongoing BHS longitudinal study; the bi-directional relationship between the PHQ-9 and these multiple measures will be particularly interesting, as few studies have collected this amount of detail in a diverse population. This measurement depth of demographic, clinical, biological, and behavioral issues offers an opportunity to better understand how different aspects of distress track similarly or differently over time.

An important aspect of our examination is how the binary division of PHQ-9 into labels of depression or “not depression” leaves significant content unattended. While the division of PHQ-9 scores at 10 provides good discrimination with regard to a clinical diagnosis of Major Depressive Disorder,^{3,6,7} the gradient between a score of 0 and 10 contains relevant information about distress levels. Such a finding is not novel,¹⁵ but a reminder that singular focus on a binary classification tends to obscure important information. For example, demographic data demonstrate how females and younger participants had higher PHQ-9 scores, yet whether this

1
2
3 finding represents a different approach to revealing concerns or more significant distress is
4
5 unclear.

6
7
8 The higher scores associated with elevated heart rates, body mass index, and abdominal
9
10 girth were expected and consistent with previous literature. In general, PHQ-9 scores aligned
11
12 with musculoskeletal or central and peripheral nervous system disorders,^{16,17} but less with
13
14 cardiovascular disease, cancer, and other more organ-focused conditions. The previously widely-
15
16 reported association with obesity and diabetes was confirmed in our study.¹⁸⁻²¹ We found low
17
18 PHQ-9 scores in a small, but noticeable proportion of the population with a previous diagnosis of
19
20 depression, which could represent diagnostic errors, inaccurate reporting of medical history, or
21
22 recovery from a previous episode of depression.
23
24

25
26 The profound relationship between PHQ-9 score and a host of common symptoms²²⁻²⁶ is
27
28 also expected, but the continuous nature of the relationship with PHQ-9 score and the depth of
29
30 the relationships raise many issues that need further exploration. Significant predictors of PHQ-9
31
32 scores include a wide range of concerns encompassing neurological disease, musculoskeletal
33
34 disease,^{27,28} and psychological distress. A particularly notable finding is the progressive and
35
36 highly significant relationship between reported memory loss and PHQ-9 score. Among people
37
38 with PHQ-9 scores of 0, only 1.9% reported memory change, while among those with PHQ-9
39
40 scores >15, memory change was reported in 34%.
41
42
43

44
45 Finally, participants with higher PHQ-9 scores had impaired physical functioning, as
46
47 indicated by a host of measurements, including daily steps, 6-minute walk distance, ability to
48
49 balance on one leg, or propensity to exert a strong grip. Multiple previous studies have shown
50
51 that depression and physical functioning are inter-related²⁹⁻³⁴ and that interventions to increase
52
53 physical activity can improve depression status.^{35,36} Nevertheless, the overall picture of this study
54
55
56
57
58
59
60

1
2
3 highlights the need for multimodal intervention to enable people with social disadvantages and
4
5 physical comorbidities to improve physical function.
6
7
8
9

10 **Limitations**

11
12 This study has some limitations. First, the cross-sectional nature of the study limits our ability to
13
14 assess the time course of these findings; however, follow-up is currently accruing. The time
15
16 course of chronic disease and symptom progression in relation to the PHQ-9 will be of interest.
17
18 Second, people with significant depression are probably less likely to volunteer, thereby limiting
19
20 the breadth of depression observed in this study; BHS participants are volunteers from selected
21
22 sites who express willingness to share data. Finally, the population is generally representative of
23
24 adult age, sex, race, and ethnicity, but it is not a fully representative sample of the population; the
25
26 differences between those who volunteer for digital technology studies and the general
27
28 population are well-known.³⁷ We also lack detailed information on depression treatment, which
29
30 is a potentially modifying factor.
31
32
33
34
35
36
37

38 **Conclusions**

39
40 PHQ-9 scores are related to multiple demographic, vital sign, and clinical measures that indicate
41
42 poor physical status. BHS data provide a comprehensive picture of numerous interactive factors
43
44 influencing PHQ-9 scores, thereby demonstrating how focusing on one chief complaint in hopes
45
46 of improving depression status is likely futile, given that many common symptoms and physical
47
48 limitations are profoundly integrated with depression status. The close association with
49
50 symptoms often considered somatic raises a practical issue for clinical practice, and this is
51
52 evident across the entire spectrum of PHQ-9 scores. When a high PHQ-9 score or other indicator
53
54
55
56
57
58
59
60

1
2
3 of depression brings someone to the attention of a clinician, contextual awareness is critically
4
5 important to provide an effective clinical intervention. When someone has significant
6
7 neurological or musculoskeletal symptoms, assessment for depression should be a routine
8
9 consideration. The complex associations across biological, clinical, behavioral, and social factors
10
11 stress the need for holistic evaluation of depression for individuals, as well as patient
12
13
14
15 populations.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

Baseline Health Study Team

American Society of Clinical Oncology, Alexandria, VA, USA: Richard L. Schilsky. **Duke University, School of Medicine, Durham, NC, USA:** Jennifer Allen, MaryAnn Anderson, Kevin Anstrom, Lucus Araujo, Kristine Arges, Kaveh Ardalán, Bridget Baldwin, Suresh Balu, Mustafa R. Bashir, Manju Bhapkar, Robert Bigelow, Tanya Black, Rosalia Blanco, Gerald Bloomfield, Durga Borkar, Leah Bouk, Ebony Boulware, Nikki Brugnoli, Erin Campbell, Paul Campbell, Larry Carin, Tammy Jo Cassella, Tina Cates, Ranee Chatterjee Montgomery, Victoria Christian, John Choong, Michael Cohen-Wolkowicz, Elizabeth Cook, Scott Cousins, Ashley Crawford, Nisha Datta, Melissa Daubert, James Davis, Jillian Dirkes, Isabelle Doan, Marie Dockery, P. Murali Doraiswamy, Pamela S. Douglas, Shelly Duckworth, Ashley Dunham, Gary Dunn, Ryan Ebersohl, Julie Eckstrand, Vivienne Fang, April Flora, Emily Ford, Lucia Foster, Elizabeth Fraulo, John French, Geoffrey S. Ginsburg, Cindy Green, Latoya Greene, Jeffrey Guptill, Donna Hamel, Jennifer Hamill, Chris Harrington, Rob Harrison, Lauren Hedges, Brooke Heidenfelder, Adrian F. Hernandez, Cindy Heydary, Tim Hicks, Lina Hight, Deborah Hopkins, Erich S. Huang, Grace Huh, Jillian Hurst, Kelly Inman, Gemini Janas, Glenn Jaffee, Janace Johnson, Tiffanie Keaton, Michel Khouri, Daniel King, Jennifer Korzekwinski, Lynne H. Koweek, Anthony Kuo, Lydia Kwee, Dawn Landis, Rachele Lipsky, Desiree Lopez, Carolyn Lowry, Kelly Marcom, Keith Marsolo, Paige McAdams, Shannon McCall, , Robert McGarrah, John McGugan, Dani Mee, Sabrena Mervin-Blake, Prithu Mettu, Mathias Meyer, Justin Meyers, Calire N. Miller, Rebecca Moen, Lawrence H. Muhlbaier, Michael Murphy, Ben Neely, L. Kristin Newby, Jayne Nicoldson, Hoang Nguyen, Maggie Nguyen, Lori O'Brien, Sumru Onal, Jeremy O'Quinn, David Page, Neha J. Pagidipati, Kishan Parikh, Sarah R. Palmer, Bray

1
2
3 Patrick-Lake, Brenda Pattison, Michael Pencina, Eric D. Peterson, Jon Piccini, Terry Poole, Tom
4
5 Povsic, Alicia Provencher, Dawn Rabineau, Annette Rich, Susan Rimmer, Fides Schwartz,
6
7 Angela Serafin, Nishant Shah, Svati Shah, Kelly Shields, Steven Shipes, Peter Shrader, Jon
8
9 Stiber, Lynn Sutton, Geeta Swamy, Betsy Thomas, Sandra Torres, Debara Tucci, Anthony
10
11 Twisdale, Brooke Walker, Susan A. Whitney, Robin Williamson, Lauren Wilverding, Charlene
12
13 A. Wong, Lisa Wruck. **Ellen Young Gemini Group, USA: Jane Perlmutter. Health**
14
15 **Collaboratory and Cancer 101, New York, NY, USA: Sarah Krug. Rare Dots, Inc., USA: S.**
16
17 Whitney Bowman-Zatzkin. **Society of Participatory Medicine, USA: Sarah Krug. Stanford**
18
19 **University, School of Medicine, Stanford, CA, USA: Themistocles Assimes, Vikram Bajaj,**
20
21 Maxwell Cheong, Millie Das, Manisha Desai, Alice C. Fan, Dominik Fleischmann, Sanjiv S.
22
23 Gambhir, Garry Gold, Francois Haddad, David Hong, Curtis Langlotz, Yaping J. Liao, Rong Lu,
24
25 Kenneth W. Mahaffey, David Maron, Rebecca McCue, Rajan Munshi, Fatima Rodriguez,
26
27 Sumana Shashidhar, George Sledge, Susie Spielman, Ryan Spitler, Sue Swope, Donna Williams.
28
29 **University of Florida, College of Medicine, Gainesville, FL, USA: Carl J Pepine. University**
30
31 **of Missouri, Children's Mercy Hospital, Kansas City, MO, USA: John D Lantos. University**
32
33 **of Texas, Dell Medical School, Austin, TX, USA: Michael Pignone. University of**
34
35 **Washington, Department of Biostatistics, Seattle, WA, USA: Patrick Heagerty. Vanderbilt**
36
37 **University, School of Medicine, Nashville, TN, USA: Laura Beskow, Gordon Bernard. Verily**
38
39 **Inc., South San Francisco, CA, USA: Kelley Abad, Giulia Angi, Robert M. Califf, Lawrence**
40
41 Deang, Joy Huynh, Manway Liu, Cherry Mao, Michael Magdaleno, William J. Marks, Jr.,
42
43 Jessica Mega, David Miller, Nicole Ong, Darshita Patel, Vanessa Ridaura, Scarlet Shore, Sarah
44
45 Short, Michelle Tran, Veronica Vu, Celeste Wong. **Harvard University, School of Medicine,**
46
47 **Boston, MA, USA: Robert C. Green. Google Inc., Mountain View, CA, USA: John**
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Hernandez. **California Health and Longevity Institute, Westlake Village, CA, USA:** Jolene
4
5 Bengé, Gislia Negrete, Gelsey Sierra, Terry Schaack
6
7
8
9

10 **Sources of funding**

11
12 The Baseline Health Study and this analysis were funded by Verily Life Sciences, San Francisco,
13
14 CA. There is no associated award/grand number.
15
16
17
18

19 **Conflict of interest disclosures**

20
21 **Califf:** Employee of Verily Life Sciences and Google Health; Board member for Cytokinetics,
22
23 United Medicines, and Clinetic.
24
25

26 **Wong:** Employee of Verily Life Sciences.
27

28 **Doraiswamy:** Consulting fees from Verily Life Sciences, Neuronix, Apollo Health, VitaKey,
29
30 Neuroglee, Transposon, Otsuka; Research grants from Avanir, Lilly, Avid, Salix; Holds stock in
31
32 Evidation Health, Advera Health Analytics, Transposon Therapeutics, Marvel Biome; Board
33
34 membership in Apollo; Coinventor on patents for diagnosis or treatment of neuropsychiatric
35
36 disorders.
37
38

39
40 **Hong:** Research funding from NIMH; Consulting for Little Otter.
41

42 **Miller:** Employee of and holds stock in Verily Life Sciences.
43

44
45 **Mega:** Employee of Verily Life Sciences.
46
47
48

49 **Author contributions**

50
51 **Califf:** Dr. Califf had full access to all of the data in the study and takes responsibility for the
52
53 integrity of the data and the accuracy of the data analysis. Dr. Califf contributed to the
54
55
56
57
58
59

1
2
3 conception and design of the study, the data analysis, the data interpretation, the manuscript
4 drafting, and the critical revision of the manuscript.
5

6
7 **Wong:** Dr. Wong contributed to the conception and design of the study, data interpretation, the
8 manuscript drafting, and the critical revision of the manuscript.
9

10
11 **Doraiswamy:** Dr. Doraiswamy contributed to the data interpretation, the manuscript drafting,
12 and the critical revision of the manuscript.
13

14
15 **Hong:** Dr. Hong contributed to the data interpretation, the manuscript drafting, and the critical
16 revision of the manuscript.
17

18
19 **Miller:** Dr. Miller contributed to the conception and design of the study, data interpretation, the
20 manuscript drafting, and the critical revision of the manuscript.
21

22
23 **Mega:** Dr. Mega contributed to the conception and design of the study, the supervision, data
24 acquisition, data interpretation, the manuscript drafting, and the critical revision of the
25 manuscript.
26

27 28 29 30 31 32 33 34 35 **Data sharing statement**

36
37 The study is committed to access to the study data for qualified investigators from the global
38 community after testing the process within the diverse investigator communities of the
39 participating institutions. Please see the following article for more information: Arges K,
40 Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step towards a broader mission to
41 map human health. npj Digit Med. 3, 84 (2020). <https://doi.org/10.1038/s41746-020-0290-y>.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789–1858.
2. Perry PJ. *The Interaction of Major Depression and Medical Illness*. Medscape; 2005. Available at: <https://www.medscape.org/viewarticle/517033>.
3. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–613.
4. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. *J Gen Intern Med*. 2006;21(6):547–552.
5. Patel JS, Oh Y, Rand KL, et al. Measurement invariance of the patient health questionnaire-9 (PHQ-9) depression screener in U.S. adults across sex, race/ethnicity, and education level: NHANES 2005–2016. *Depress Anxiety*. 2019;36(9):813–823.
6. Levis B, Benedetti A, Thombs BD for the DEPRESSion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *BMJ*. 2019;365:1476.
7. Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. *JAMA*. 2020;323(22):2290–2300.
8. Arges K, Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step towards a broader mission to map human health. *NPJ Digit Med*. 2020;3:84.

- 1
2
3 9. Califf RM, Wong C, Doraiswamy PM, Hong DS, Miller DP, Mega JL. Importance of
4 social determinants in screening for depression. *J Gen Intern Med*. [In press].
5
6
- 7
8 10. Armitage P. Tests for linear trends in proportions and frequencies. *Biometrics*.
9
10 1955;11(3):375–386.
11
- 12 11. Liu L, Berger VW, Hershberger SL. Trend tests for counts and proportions. Wiley
13
14 *StatsRef: Statistics Reference Online*. 2014.
15
16 <https://doi.org/10.1002/9781118445112.stat06163>.
17
18
- 19 12. Mukaka MM. A guide to appropriate use of Correlation coefficient in medical research.
20
21 *Malawi Med J*. 2012;24(3):69–71.
22
- 23 13. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of
24
25 PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders*.
26
27 *Patient Health Questionnaire*. *JAMA*. 1999;282(18):1737–1744.
28
29
- 30 14. Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al.
31
32 *Screening for depression in adults: US Preventive Services Task Force Recommendation*
33
34 *Statement*. *JAMA*. 2016;315(4):380–387.
35
36
- 37 15. Thombs BD, Benedetti A, Kloda LA, et al. The diagnostic accuracy of the Patient Health
38
39 *Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health*
40
41 *Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic*
42
43 *review and individual patient data meta-analyses*. *Syst Rev*. 2014;3:124.
44
45
- 46 16. Hoshino E, Ohde S, Rahman M, Takahashi O, Fukui T, Deshpande GA. Variation in
47
48 *somatic symptoms by patient health questionnaire-9 depression scores in a representative*
49
50 *Japanese sample*. *BMC Public Health*. 2018;18(1):1406.
51
52
53
54
55
56
57
58
59
60

17. Leavens A, Patten SB, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research Group. Influence of somatic symptoms on Patient Health Questionnaire-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. *Arthritis Care Res (Hoboken)*. 2012;64(8):1195–1201.
18. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. *Lancet Diabetes Endocrinol*. 2015;3(6):450–460.
19. Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia*. 2010;53(12):2480–2486.
20. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. *Arch Intern Med*. 2000;160(21):3278–3285.
21. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care*. 2000;23(7):934–942.
22. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med*. 2002;64(2):258–266.
23. Kocalevent RD, Hinz A, Brähler E. Standardization of a screening instrument (PHQ-15) for somatization syndromes in the general population. *BMC Psychiatry*. 2013;13:91.
24. Löwe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. *Gen Hosp Psychiatry*. 2008;30(3):191–199.

- 1
2
3 25. Ziebold C, Goldberg DP, Reed GM, et al. Dimensional analysis of depressive, anxious
4 and somatic symptoms presented by primary care patients and their relationship with
5 ICD-11 PHC proposed diagnoses. *Psychol Med*. 2019;49(5):764–771.
6
7
8
9
10 26. Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire
11 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp*
12 *Psychiatry*. 2010;32(4):345–359.
13
14
15
16
17 27. Hartvigsen J, Christensen K. Pain in the back and neck are with us until the end: a
18 nationwide interview-based survey of Danish 100-year-olds. *Spine (Phila Pa 1976)*.
19 2008;33(8):909–913.
20
21
22
23
24 28. Reichborn-Kjennerud T, Stoltenberg C, Tambs K, et al. Back-neck pain and symptoms of
25 anxiety and depression: a population-based twin study. *Psychol Med*. 2002;32(6):1009–
26 1020.
27
28
29
30
31 29. Zhang J, Yen ST. Physical activity, gender difference, and depressive symptoms. *Health*
32 *Serv Res*. 2015 Oct;50(5):1550–173.
33
34
35
36 30. Farmer ME, Locke BZ, Mościcki EK, Dannenberg AL, Larson DB, Radloff LS. Physical
37 activity and depressive symptoms: the NHANES I Epidemiologic Follow-up Study. *Am J*
38 *Epidemiol*. 1988;128(6):1340–1351.
39
40
41
42 31. Helgadóttir B, Forsell Y, Ekblom Ö. Physical activity patterns of people affected by
43 depressive and anxiety disorders as measured by accelerometers: a cross-sectional study.
44 *PLoS One*. 2015;10(1):e0115894.
45
46
47
48
49 32. Sieverdes JC, Ray BM, Sui X, et al. Association between leisure time physical activity
50 and depressive symptoms in men. *Med Sci Sports Exerc*. 2012;44(2):260–265.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 33. Sun GZ, Ye N, Wu SJ, Zhou Y, Sun YX. 10-year ASCVD risk is positively correlated
4 with depressive symptoms in a large general population. *BMC Psychiatry*.
5
6 2019;19(1):125.
7
8
9
10 34. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrrough JW. Screening and
11 management of depression in patients with cardiovascular disease: JACC State-of-the-Art
12 Review. *J Am Coll Cardiol*. 2019;73(14):1827–1845.
13
14
15
16 35. Wegner M, Helmich I, Machado S, Nardi AE, Arias-Carrion O, Budde H. Effects of
17 exercise on anxiety and depression disorders: review of meta- analyses and
18 neurobiological mechanisms. *CNS Neurol Disord Drug Targets*. 2014;13(6):1002–1014.
19
20
21
22 36. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in
23 the treatment of major depressive disorder. *Psychosomatic Med*. 2007;69(7):587–596.
24
25
26
27 37. Fareed N, Swoboda CM, Jonnalagadda P, Huerta TR. Persistent digital divide in health-
28 related internet use among cancer survivors: findings from the Health Information
29 National Trends Survey, 2003–2018. *J Cancer Surviv*. 2021;15(1):87–98.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics: PHQ-9 score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
Age, median (25th, 75th)*	53.6 (36.7, 66.1)	51.7 (37.0, 66.5)	47.6 (32.7, 60.7)	42.8 (31.2, 55.1)	42.4 (32.1, 54.2)
Female sex*	227 (46.9)	622 (57.3)	299 (57.7)	108 (58.7)	62 (66.7)
Race					
Black	80 (16.5)	153 (14.1)	82 (15.8)	31 (16.8)	19 (20.4)
White	294 (60.7)	731 (67.3)	323 (62.4)	110 (59.8)	57 (61.3)
Asian†	64 (13.2)	113 (10.4)	47 (9.1)	15 (8.2)	5 (5.4)
NHOPI	7 (1.4)	11 (1)	7 (1.4)	2 (1.1)	0 (0.0)
American Indian or Alaska Native	4 (0.8)	8 (0.7)	11 (2.1)	3 (1.6)	1 (1.1)
Other†	35 (7.2)	70 (6.4)	48 (9.3)	23 (12.5)	11 (11.8)
Ethnicity					
Hispanic	54 (11.2)	108 (9.9)	69 (13.3)	26 (14.1)	13 (14.0)
Site					
Los Angeles	94 (19.4)	194 (17.9)	111 (21.4)	35 (19)	21 (22.6)
Durham	99 (20.5)	196 (18.0)	102 (19.7)	40 (21.7)	25 (26.9)
Kannapolis	100 (20.7)	226 (20.8)	105 (20.3)	41 (22.3)	28 (30.1)
Palo Alto †	191 (39.5)	470 (43.3)	200 (38.6)	68 (37.0)	19 (20.4)

Systolic BP, median (25th, 75th), mm Hg	123.0 (112.5, 133.1)	122.0 (112.0, 132.5)	123.0 (112.5, 133.5)	119.5 (109.9, 132.0)	122.5 (115.5, 130.5)
Diastolic BP, median (25th, 75th), mm Hg	75.5 (69.0, 82.0)	75.0 (68.0, 82.0)	76.0 (70.0, 83.5)	74.0 (68.9, 81.1)	77.5 (71.5, 84.0)
Body mass index, median (25th, 75th), kg/m ² *	26.5 (23.7, 29.9)	26.1 (22.9, 31.0)	28.0 (24.5, 33.2)	29.1 (25.1, 34.7)	30.0 (25.4, 38.8)
Waist circumference, median (25th, 75th), cm*	91.0 (81.0, 100.1)	88.9 (78.7, 101.6)	93.0 (81.3, 105.4)	96.5 (82.0, 111.8)	96.5 (81.6, 112.5)
Heart rate, median (25th, 75th), beats/min*	65.0 (58.0, 72.0)	66.0 (59.0, 73.0)	67.0 (60.0, 77.0)	70.0 (61.8, 80.0)	75.0 (65.0, 82.0)
Respiratory rate, median (25th, 75th), breaths/min*	16.0 (14.0, 16.0)	16.0 (14.0, 16.0)	16.0 (14.0, 17.0)	16.0 (14.0, 18.0)	16.0 (16.0, 18.0)
Oxygen saturation, median (25th, 75th), %†	99.0 (98.0, 100.0)	99.0 (98.0, 100.0)	99.0 (98.0, 100.0)	99.0 (97.0, 100.0)	98.0 (97.0, 100.0)
<p>Data shown are no. (%), unless otherwise indicated. BP, blood pressure; NHOPI, Native Hawaiians and other Pacific Islanders; PHQ-9, Patient Health Questionnaire-9. P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate. *P-value for trend <0.0001. †P-value for trend <0.01</p>					

Table 2. Medical history: PHQ-9 score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
Alcohol use disorder*	1 (0.2)	20 (1.8)	12 (2.3)	7 (3.8)	6 (6.5)
Fibromyalgia*	2 (0.4)	10 (0.9)	11 (2.1)	7 (3.8)	6 (6.5)
Gallbladder disorder†	18 (3.7)	57 (5.2)	32 (6.2)	14 (7.6)	8 (8.6)
Bipolar disorder*	3 (0.6)	9 (0.8)	12 (2.3)	9 (4.9)	8 (8.6)
PTSD*	8 (1.7)	14 (1.3)	15 (2.9)	21 (11.4)	9 (9.7)
Hypercholesterolemia	68 (14.0)	127 (11.7)	70 (13.5)	19 (10.3)	9 (9.7)
Irritable bowel disorder†	9 (1.9)	60 (5.5)	34 (6.6)	7 (3.8)	10 (10.8)
COPD with emphysema*	5 (1.0)	19 (1.7)	22 (4.2)	12 (6.5)	10 (10.8)
Sleep apnea	38 (7.9)	101 (9.3)	63 (12.2)	19 (10.3)	11 (11.8)
ADHD*	15 (3.1)	50 (4.6)	33 (6.4)	25 (13.6)	11 (11.8)
Diabetes type 2†	45 (9.3)	109 (10.0)	62 (12.0)	32 (17.4)	14 (15.1)
Pneumonia	30 (6.2)	85 (7.8)	40 (7.7)	12 (6.5)	15 (16.1)
Osteoarthritis	76 (15.7)	216 (19.9)	118 (22.8)	33 (17.9)	17 (18.3)
Asthma*	46 (9.5)	157 (14.5)	79 (15.3)	39 (21.2)	19 (20.4)
Migraine*	29 (6.0)	134 (12.3)	77 (14.9)	31 (16.8)	19 (20.4)
GERD*	64 (13.2)	176 (16.2)	106 (20.5)	40 (21.7)	23 (24.7)
Hypertension	122 (25.2)	297 (27.3)	144 (27.8)	51 (27.7)	26 (28.0)
Anxiety*	13 (2.7)	98 (9.0)	109 (21.0)	55 (29.9)	34 (36.6)
Depression*	16 (3.3)	93 (8.6)	110 (21.2)	63 (34.2)	55 (59.1)
Hay fever	26 (5.4)	78 (7.2)	36 (6.9)	19 (10.3)	3 (3.2)
Discharge†	19 (3.9)	64 (5.9)	44 (8.5)	18 (9.8)	8 (8.6)
Hemorrhoids†	22 (4.5)	69 (6.4)	40 (7.7)	17 (9.2)	9 (9.7)
Itching skin*	19 (3.9)	81 (7.5)	50 (9.7)	30 (16.3)	10 (10.8)
Sinus pain*	18 (3.7)	77 (7.1)	58 (11.2)	21 (11.4)	10 (10.8)
Urgency*	13 (2.7)	69 (6.4)	46 (8.9)	23 (12.5)	10 (10.8)
Excessive belching or passing of gas*	24 (5.0)	84 (7.7)	54 (10.4)	29 (15.8)	13 (14.0)
Ear ringing†	38 (7.9)	101 (9.3)	59 (11.4)	23 (12.5)	13 (14.0)
Dryness*	35 (7.2)	113 (10.4)	68 (13.1)	39 (21.2)	14 (15.1)
Heartburn*	27 (5.6)	94 (8.7)	70 (13.5)	42 (22.8)	15 (16.1)
Dry mouth*	27 (5.6)	84 (7.7)	64 (12.4)	28 (15.2)	16 (17.2)

Constipation *	22 (4.5)	98 (9.0)	64 (12.4)	48 (26.1)	17 (18.3)
Numbness or loss of sensation *	17 (3.5)	54 (5.0)	38 (7.3)	19 (10.3)	17 (18.3)
Easy bruising or bleeding [†]	39 (8.1)	130 (12.0)	68 (13.1)	22 (12.0)	18 (19.4)
Cramping*	14 (2.9)	62 (5.7)	45 (8.7)	18 (9.8)	18 (19.4)
Frequency of urination *	33 (6.8)	90 (8.3)	73 (14.1)	34 (18.5)	19 (20.4)
Runny nose [†]	70 (14.5)	210 (19.3)	116 (22.4)	44 (23.9)	20 (21.5)
Swelling in calves, legs, or feet *	15 (3.1)	62 (5.7)	49 (9.5)	31 (16.8)	20 (21.5)
Coughing up sputum *	12 (2.5)	62 (5.7)	56 (10.8)	27 (14.7)	20 (21.5)
Floater [†]	55 (11.4)	160 (14.7)	81 (15.6)	28 (15.2)	21 (22.6)
Pain or stiffness in neck *	32 (6.6)	128 (11.8)	72 (13.9)	49 (26.6)	22 (23.7)
Diarrhea *	24 (5.0)	99 (9.1)	70 (13.5)	31 (16.8)	22 (23.7)
Night sweats *	22 (4.5)	88 (8.1)	65 (12.5)	25 (13.6)	22 (23.7)
Lightheadedness *	11 (2.3)	62 (5.7)	53 (10.2)	37 (20.1)	22 (23.7)
Cough *	36 (7.4)	98 (9.0)	83 (16.0)	41 (22.3)	23 (24.7)
Tingling or numbness in extremities *	35 (7.2)	101 (9.3)	74 (14.3)	36 (19.6)	23 (24.7)
Leg cramps *	31 (6.4)	103 (9.5)	55 (10.6)	31 (16.8)	23 (24.7)
Shortness of breath with exercise *	11 (2.3)	59 (5.4)	68 (13.1)	37 (20.1)	23 (24.7)
Joint pain or swelling*	42 (8.7)	140 (12.9)	81 (15.6)	45 (24.5)	25 (26.9)
Sleeping pattern changes *	21 (4.3)	126 (11.6)	78 (15.1)	47 (25.5)	25 (26.9)
Tingling or pins and needles *	30 (6.2)	91 (8.4)	75 (14.5)	36 (19.6)	25 (26.9)
Appetite changes *	9 (1.9)	36 (3.3)	35 (6.8)	25 (13.6)	26 (28.0)
Heat or cold intolerance *	17 (3.5)	85 (7.8)	65 (12.5)	36 (19.6)	27 (29.0)
Shortness of breath *	8 (1.7)	51 (4.7)	57 (11.0)	34 (18.5)	27 (29.0)
Bloating *	26 (5.4)	104 (9.6)	61 (11.8)	41 (22.3)	29 (31.2)
Body image concerns *	9 (1.9)	40 (3.7)	46 (8.9)	33 (17.9)	29 (31.2)
Nasal stuffiness *	70 (14.5)	218 (20.1)	141 (27.2)	53 (28.8)	30 (32.3)
Urination at night *	69 (14.3)	172 (15.8)	105 (20.3)	43 (23.4)	30 (32.3)
Muscle or joint pain*	71 (14.7)	225 (20.7)	142 (27.4)	61 (33.2)	31 (33.3)
Memory change*	9 (1.9)	52 (4.8)	55 (10.6)	41 (22.3)	32 (34.4)
Headache*	28 (5.8)	151 (13.9)	104 (20.1)	44 (23.9)	38 (40.9)
Fatigue*	10 (2.1)	129 (11.9)	113 (21.8)	65 (35.3)	38 (40.9)

Stiffness*	76 (15.7)	267 (24.6)	121 (23.4)	63 (34.2)	39 (41.9)
Backache*	43 (8.9)	183 (16.9)	148 (28.6)	63 (34.2)	39 (41.9)
Nervousness*	4 (0.8)	46 (4.2)	51 (9.8)	39 (21.2)	43 (46.2)
Mood change*	6 (1.2)	36 (3.3)	60 (11.6)	42 (22.8)	44 (47.3)
Difficulty concentrating*	8 (1.7)	58 (5.3)	74 (14.3)	54 (29.3)	50 (53.8)
Neck or low back pain*	73 (15.1)	264 (24.3)	185 (35.7)	73 (39.7)	51 (54.8)
Tension*	10 (2.1)	84 (7.7)	86 (16.6)	44 (23.9)	51 (54.8)
Lack of energy*	6 (1.2)	92 (8.5)	115 (22.2)	74 (40.2)	53 (57.0)

Data presented as no. (%).

ADHD, attention deficit hyperactivity disorder; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; PHQ-9, Patient Health Questionnaire-9; PTSD, post-traumatic stress disorder.

P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate.

*P-value for trend <0.0001.

†P-value for trend <0.01.

Table 3. Physical Functioning: PHQ-9 Score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
6-minute walk*	485.5 (444.0, 543.2)	480.0 (431.7, 530.3)	465.0 (422.0, 517.6)	460.1 (403.8, 511.9)	443.0 (391.2, 492.4)
30-second chair stand*	15.0 (12.0, 18.0)	14.0 (12.0, 17.0)	13.0 (11.0, 16.0)	13.0 (10.0, 16.0)	12.0 (10.0, 15.0)
Mean leg balance time†	60.0 (23.5, 60.0)	55.0 (21.4, 60.0)	50.5 (14.0, 60.0)	49.5 (11.0, 60.0)	44.0 (12.5, 60.0)
10-meter walk speed*	2.0 (1.8, 2.2)	2.0 (1.8, 2.2)	2.0 (1.6, 2.1)	1.8 (1.5, 2.0)	1.8 (1.5, 2.0)
Handgrip†	35.8 (27.8, 44.4)	32.5 (26.3, 42.5)	32.3 (26.4, 42.8)	33.4 (25.6, 40.7)	30.0 (22.0, 39.7)
Sit-rise score	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	7.5 (5.0, 9.0)
EF at rest, %	59.0 (55.8, 60.5)	58.8 (55.9, 60.5)	59.2 (56.1, 60.5)	59.2 (56.0, 61.4)	58.9 (56.0, 60.9)
Mean steps in first 30 days*	8398.0 (6560.6, 10709.6)	8172.2 (6220.6, 10335.7)	7666.7 (5128.2, 9862.5)	7008.4 (4673.5, 9821.8)	6498.1 (4684.1, 9044.5)
Coronary calcium score†	0.0 (0.0, 33.9)	0.0 (0.0, 42.6)	0.0 (0.0, 8.8)	0.0 (0.0, 7.1)	0.0 (0.0, 1.9)
FEV1/FVC	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)
ABI†	1.1 (1.1, 1.2)	1.1 (1.1, 1.2)	1.1 (1.1, 1.2)	1.1 (1.0, 1.2)	1.1 (1.0, 1.2)
<p>Data presented as median (25th, 75th percentile). ABI, ankle brachial index; EF, ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PHQ-9, Patient Health Questionnaire. P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate. *P-value for trend <0.01. †P-value for trend <0.001</p>					

1
2
3 **FIGURE LEGENDS**
4


5 **Figure 1. Top 30 Regression Coefficients**
6

7 Top 30 regression coefficients for: A) model 1; B) model 2; C) model 3; D) model 4; E) model 5.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Top 30 Regression Coefficients for Model 1


Adjusted by Age and Sex



View Only

Top 30 Regression Coefficients for Model 2


Adjusted by Age, Sex, SES and Health Behavior



View only

Top 30 Regression Coefficients for Model 3

Adjusted by Age, Sex, SES, Health Behavior, and Medical Conditions




view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Top 30 Regression Coefficients for Model 4


Adjusted by Age, Sex, SES, Health Behavior, Medical Conditions, Symptoms and Allergies



new only

Top 30 Regression Coefficients for Model 5

Adjusted by Age, Sex, SES, Health Behavior, Medical Conditions, Symptoms, Allergies, and Physical Function



SUPPLEMENTAL MATERIAL

1		
2		
3		
4		
5		
6		
7	eTable 1. Key Variables Included in Each LASSO Covariate Model.....	2
8	eTable 2. Additional Medical History: PHQ-9 Scores	3
9	eTable 3. LASSO Regression Results: Model 1	5
10	eTable 4. LASSO Regression Results: Model 2.....	9
11	eTable 5. LASSO Regression Results: Model 3.....	13
12	eTable 6. LASSO Regression Results: Model 4.....	16
13	eTable 7. LASSO Regression Results: Model 5.....	18
14	eFigure 1A. Distribution of PHQ-9 Across Risk Groups by Asthma	20
15	eFigure 1B. Distribution of PHQ-9 Across Risk Groups by Backache	21
16	eFigure 1C. Distribution of PHQ-9 Across Risk Groups by Memory Change.....	22
17	eFigure 1D. Distribution of PHQ-9 Across Risk Groups by Body Image Concerns.....	23
18	eFigure 1E. Distribution of PHQ-9 Across Risk Groups by Sleep Apnea	24
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

eTable 1. Key Variables Included in Each LASSO Covariate Model

Variables	Model 1	Model 2	Model 3	Model 4	Model 5
Age, sex and age × sex interaction (Supplemental Table 1.1)	✓	✓	✓	✓	✓
Race and ethnicity (Supplemental Table 1.1)		✓	✓	✓	✓
Socioeconomic-related variables (Supplemental Table 1.6)		✓	✓	✓	✓
Behavioral-related behaviors (Supplemental Tables 1.1 and 1.6)		✓	✓	✓	✓
Medical conditions <i>not</i> related to mental health / depression (Supplemental Table 1.3)			✓	✓	✓
Symptoms and allergies <i>not</i> related to mental health / depression (Supplemental Table 1.3)				✓	✓
Physical health metrics (Table Supplemental Tables 1.2 and 1.7)					✓
Standard labs (Supplemental Table 1.5)					

eTable 2. Additional Medical History: PHQ-9 Scores

	0 (N=484)	1–4 (N=1086)	5–9 (N=518)	10–14 (N=184)	15+ (N=93)
Nonmelanoma skin cancer	12 (2.5)	42 (3.9)	18 (3.5)	3 (1.6)	0 (0.0)*
Osteoporosis	11 (2.3)	47 (4.3)	17 (3.3)	3 (1.6)	0 (0.0)*
Benign prostatic hyperplasia	22 (4.5)	44 (4.1)	17 (3.3)	3 (1.6)	0 (0.0)*
Melanoma skin cancer	11 (2.3)	23 (2.1)	5 (1.0)	0 (0.0)	0 (0.0)*
Prostate cancer	12 (2.5)	17 (1.6)	6 (1.2)	1 (0.5)	0 (0.0)*
Diabetes type 1	3 (0.6)	12 (1.1)	4 (0.8)	3 (1.6)	0 (0.0)
Macular degeneration	2 (0.4)	20 (1.8)	4 (0.8)	4 (2.2)	0 (0.0)
TIA	7 (1.4)	9 (0.8)	3 (0.6)	3 (1.6)	0 (0.0)
Hepatitis B	6 (1.2)	10 (0.9)	4 (0.8)	3 (1.6)	0 (0.0)
Coronary artery disease	11 (2.3)	44 (4.1)	13 (2.5)	6 (3.3)	1 (1.1)
Hashimoto's disease	8 (1.7)	22 (2.0)	11 (2.1)	3 (1.6)	1 (1.1)
Goiter	7 (1.4)	12 (1.1)	3 (0.6)	0 (0.0)	1 (1.1)
Hemorrhoids	11 (2.3)	44 (4.1)	18 (3.5)	4 (2.2)	1 (1.1)
Hypothyroidism	42 (8.7)	93 (8.6)	40 (7.7)	9 (4.9)	2 (2.2)
Glaucoma	14 (2.9)	29 (2.7)	10 (1.9)	6 (3.3)	2 (2.2)
Psoriasis	10 (2.1)	16 (1.5)	11 (2.1)	8 (4.3)	2 (2.2)
Peptic ulcer	5 (1.0)	22 (2.0)	13 (2.5)	4 (2.2)	2 (2.2)
Diverticulosis	8 (1.7)	29 (2.7)	10 (1.9)	5 (2.7)	2 (2.2)
Peripheral vascular disorder	1 (0.2)	15 (1.4)	8 (1.5)	2 (1.1)	2 (2.2)
Atrial fibrillation	4 (0.8)	17 (1.6)	1 (0.2)	1 (0.5)	2 (2.2)
Colon polyps	53 (11.0)	113 (10.4)	52 (10.0)	12 (6.5)	3 (3.2)
Arrhythmia	20 (4.1)	69 (6.4)	27 (5.2)	8 (4.3)	3 (3.2)
Tinnitus	31 (6.4)	52 (4.8)	35 (6.8)	6 (3.3)	3 (3.2)
Hearing Loss	29 (6.0)	75 (6.9)	26 (5.0)	12 (6.5)	3 (3.2)
Gout	14 (2.9)	29 (2.7)	14 (2.7)	5 (2.7)	3 (3.2)
Diverticulitis	3 (0.6)	20 (1.8)	17 (3.3)	3 (1.6)	3 (3.2)
Headaches	6 (1.2)	18 (1.7)	13 (2.5)	3 (1.6)	3 (3.2)
Epilepsy	5 (1.0)	19 (1.7)	12 (2.3)	5 (2.7)	3 (3.2)
Breast cancer	8 (1.7)	20 (1.8)	9 (1.7)	1 (0.5)	3 (3.2)
Myocardial infarction	6 (1.2)	19 (1.7)	11 (2.1)	1 (0.5)	3 (3.2)
Osteopenia	22 (4.5)	62 (5.7)	22 (4.2)	1 (0.5)	3 (3.2)
Stroke	5 (1.0)	12 (1.1)	9 (1.7)	1 (0.5)	3 (3.2)
Drug abuse*	5 (1.0)	14 (1.3)	5 (1.0)	13 (7.1)	4 (4.3)
Pulmonary embolism	4 (0.8)	17 (1.6)	7 (1.4)	3 (1.6)	4 (4.3)
Nonalcoholic fatty liver disease	5 (1.0)	17 (1.6)	16 (3.1)	3 (1.6)	4 (4.3)
Hepatitis C†	5 (1.0)	8 (0.7)	3 (0.6)	8 (4.3)	4 (4.3)
Cataracts	61 (12.6)	167 (15.4)	63 (12.2)	16 (8.7)	5 (5.4)
Kidney or bladder stones	36 (7.4)	66 (6.1)	18 (3.5)	13 (7.1)	5 (5.4)

1					
2					
3	Concussions	19 (3.9)	62 (5.7)	35 (6.8)	13 (7.1)
4					5 (5.4)
5	Rheumatoid arthritis†	4 (0.8)	13 (1.2)	12 (2.3)	4 (2.2)
6					6 (6.5)

P-values for trend were calculated with the use of Spearman Correlation or Cochrane-Armitage tests, where appropriate.

*P-value for trend <0.0001.

†P-value for trend <0.01.

For peer review only

eTable 3. LASSO Regression Results: Model 1

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.2344	< 0.0001	0.2026	0.2661
Memory change	0.2119	< 0.0001	0.1801	0.2437
Shortness of breath	0.2033	< 0.0001	0.1714	0.2352
Backache	0.1974	< 0.0001	0.1655	0.2293
Shortness of breath with exercise	0.1914	< 0.0001	0.1594	0.2233
Neck or low back pain	0.1869	< 0.0001	0.1549	0.2189
Waist circumference	0.1814	< 0.0001	0.1480	0.2149
Mean leg balance time	-0.1796	< 0.0001	-0.2172	-0.1420
Body image concerns	0.1726	< 0.0001	0.1403	0.2049
6-minute walk	-0.1608	< 0.0001	-0.1932	-0.1284
BMI	0.1604	< 0.0001	0.1282	0.1926
Number of pack-years smoked	0.1590	< 0.0001	0.1258	0.1922
Lightheadedness	0.1576	< 0.0001	0.1254	0.1899
Current smoker	0.1561	< 0.0001	0.1238	0.1884
Heat or cold intolerance	0.1560	< 0.0001	0.1238	0.1882
Headache	0.1532	< 0.0001	0.1205	0.1859
Not employed	0.1434	< 0.0001	0.1111	0.1757
Swelling in calves or feet	0.1421	< 0.0001	0.1098	0.1745
Coughing up sputum	0.1416	< 0.0001	0.1093	0.1739
30 second chair stand	-0.1407	< 0.0001	-0.1732	-0.1081
Tingling or pins and needles	0.1403	< 0.0001	0.1079	0.1727
Tingling or numbness in extremities	0.1373	< 0.0001	0.1049	0.1697
Sit-rise score	-0.1345	< 0.0001	-0.1714	-0.0975
Muscle or joint pain	0.1343	< 0.0001	0.1019	0.1668
Constipation	0.1334	< 0.0001	0.1010	0.1657
Income < \$25,000	0.1325	< 0.0001	0.1001	0.1650
WBC count	0.1322	< 0.0001	0.0998	0.1647
Bloating	0.1305	< 0.0001	0.0979	0.1631
Cough	0.1276	< 0.0001	0.0952	0.1601
Frequency of urination	0.1274	< 0.0001	0.0945	0.1603
Nasal stuffiness	0.1259	< 0.0001	0.0934	0.1583
COPD with emphysema	0.1228	< 0.0001	0.0901	0.1555
Joint pain swelling	0.1225	< 0.0001	0.0899	0.1550
Heartburn	0.1215	< 0.0001	0.0890	0.1540
Pain or stiffness in the neck	0.1206	< 0.0001	0.0881	0.1531
Stiffness	0.1194	< 0.0001	0.0868	0.1520
Mean daily steps in first 30 days	-0.1176	< 0.0001	-0.1503	-0.0848
Heart rate	0.1165	< 0.0001	0.0835	0.1495
Urination at night	0.1158	< 0.0001	0.0823	0.1492
HbA1c	0.1144	< 0.0001	0.0813	0.1476
Diarrhea	0.1138	< 0.0001	0.0812	0.1463
10-meter walk speed	-0.1137	< 0.0001	-0.1463	-0.0810
Blood glucose	0.1136	< 0.0001	0.0808	0.1463
Oxygen saturation	-0.1118	< 0.0001	-0.1458	-0.0777

1					
2					
3	Dry mouth	0.1117	< 0.0001	0.0791	0.1444
4	Night sweats	0.1110	< 0.0001	0.0784	0.1435
5	C-reactive protein	0.1084	< 0.0001	0.0759	0.1409
6	Urgency	0.1080	< 0.0001	0.0751	0.1410
7	Monocytes	0.1075	< 0.0001	0.0742	0.1408
8	Neutrophils	0.1072	< 0.0001	0.0747	0.1398
9	Numbness or loss of sensation	0.1055	< 0.0001	0.0729	0.1380
10	GERD	0.1004	< 0.0001	0.0675	0.1334
11	Itching skin	0.0971	< 0.0001	0.0645	0.1297
12	Excessive belching or passing of				
13	gas	0.0957	< 0.0001	0.0631	0.1283
14	Respiratory rate	0.0944	< 0.0001	0.0618	0.1270
15	Leg cramps	0.0933	< 0.0001	0.0606	0.1260
16	Urine specific gravity	0.0931	< 0.0001	0.0605	0.1257
17	Albumin in urine	-0.0928	< 0.0001	-0.1261	-0.0595
18	Dryness	0.0926	< 0.0001	0.0600	0.1252
19	Absolute basophils	0.0925	< 0.0001	0.0598	0.1251
20	Uninsured	0.0924	< 0.0001	0.0597	0.1250
21	Cramping	0.0920	< 0.0001	0.0592	0.1248
22	Osteoarthritis	0.0917	< 0.0001	0.0568	0.1267
23	Lymphocytes (total)	0.0883	< 0.0001	0.0554	0.1213
24	Sleep apnea	0.0877	< 0.0001	0.0541	0.1213
25	ALT	0.0848	< 0.0001	0.0522	0.1175
26	Married	-0.0848	< 0.0001	-0.1188	-0.0508
27	Sinus pain	0.0838	< 0.0001	0.0511	0.1164
28	HDL	-0.0835	< 0.0001	-0.1161	-0.0509
29	Creatinine (urine)	0.0811	< 0.0001	0.0484	0.1138
30	Reticulocytes (% RBC)	0.0803	< 0.0001	0.0475	0.1131
31	Triglycerides	0.0800	< 0.0001	0.0471	0.1128
32	Fibromyalgia	0.0798	< 0.0001	0.0472	0.1125
33	Asthma	0.0796	< 0.0001	0.0469	0.1123
34	Former smoker	0.0791	< 0.0001	0.0454	0.1127
35	Absolute reticulocytes	0.0786	< 0.0001	0.0458	0.1114
36	Diabetes type 2	0.0780	< 0.0001	0.0448	0.1111
37	Urine reaction pH	-0.0762	< 0.0001	-0.1095	-0.0430
38	Migraines	0.0753	< 0.0001	0.0425	0.1081
39	Hypertension	0.0749	< 0.0001	0.0397	0.1102
40	Runny nose	0.0738	< 0.0001	0.0411	0.1065
41	Vitamin D	-0.0732	< 0.0001	-0.1067	-0.0397
42	Easy bruising or bleeding	0.0719	< 0.0001	0.0390	0.1049
43	High school or less education	0.0706	< 0.0001	0.0379	0.1033
44	Floaters	0.0701	< 0.0001	0.0370	0.1033
45	Discharge	0.0698	< 0.0001	0.0372	0.1025
46	Ear ringing	0.0671	< 0.0001	0.0338	0.1003
47	Hemorrhoids (symptom)	0.0649	0.0001	0.0320	0.0977
48	Days watch worn 10+ hours in first				
49	30 days	-0.0639	0.0002	-0.0976	-0.0301
50	Asian race	-0.0636	0.0002	-0.0964	-0.0307
51	Absolute eosinophils	0.0632	0.0002	0.0304	0.0960
52	Seasonal allergies	0.0626	0.0002	0.0299	0.0954
53	Medication allergies	0.0612	0.0003	0.0283	0.0941
54	Irritable bowel disorder	0.0585	0.0005	0.0258	0.0912
55					
56					
57					
58					
59					
60					

1					
2					
3	Hepatitis C	0.0579	0.0005	0.0252	0.0907
4	Rheumatoid arthritis	0.0572	0.0006	0.0244	0.0900
5	Systolic blood pressure	0.0566	0.0017	0.0212	0.0920
6	Diverticulitis	0.0561	0.0008	0.0232	0.0890
7	Uric acid	0.0538	0.0019	0.0199	0.0876
8	Magnesium	-0.0537	0.0013	-0.0865	-0.0209
9	MCHC	-0.0533	0.0015	-0.0861	-0.0205
10	Handgrip	-0.0514	0.0021	-0.0842	-0.0187
11	Gallbladder disease	0.0488	0.0036	0.0160	0.0816
12	MCH	-0.0465	0.0065	-0.0799	-0.0130
13	AST	0.0443	0.0080	0.0116	0.0771
14	Epilepsy	0.0427	0.0106	0.0100	0.0755
15	Food allergies	0.0424	0.0112	0.0096	0.0752
16	Diastolic blood pressure	0.0420	0.0124	0.0091	0.0748
17	Pneumonia	0.0403	0.0163	0.0074	0.0732
18	Nonalcoholic fatty liver disease	0.0403	0.0159	0.0075	0.0731
19	Ejection fraction at rest	0.0403	0.0161	0.0075	0.0731
20	Non-seasonal allergies	0.0393	0.0189	0.0065	0.0722
21	Serum creatinine	0.0388	0.0239	0.0051	0.0725
22	Protein (serum)	-0.0381	0.0299	-0.0725	-0.0037
23	Cataracts	0.0368	0.0513	-0.0002	0.0737
24	Pulmonary embolism	0.0359	0.0321	0.0031	0.0688
25	Peripheral vascular disease	0.0344	0.0401	0.0016	0.0673
26	Hay fever	0.0342	0.0413	0.0014	0.0671
27	Stroke	0.0337	0.0450	0.0008	0.0667
28	MCV	-0.0331	0.0529	-0.0666	0.0004
29	Diverticulosis	0.0324	0.0541	-0.0006	0.0655
30	Arrhythmia	0.0324	0.0584	-0.0012	0.0659
31	Gout	0.0323	0.0570	-0.0010	0.0655
32	Myocardial infarction	0.0317	0.0606	-0.0014	0.0649
33	Cholesterol	-0.0305	0.0685	-0.0633	0.0023
34	Platelets	0.0303	0.0783	-0.0034	0.0640
35	LDL	-0.0301	0.0726	-0.0630	0.0028
36	Peptic ulcer	0.0300	0.0730	-0.0028	0.0628
37	Hypercholesterolemia	0.0297	0.0879	-0.0044	0.0638
38	Goiter	-0.0290	0.0836	-0.0618	0.0039
39	Coronary artery disease	0.0287	0.0959	-0.0051	0.0625
40	Chloride	-0.0268	0.1096	-0.0596	0.0060
41	Neutrophil lymphocyte ratio	0.0266	0.1156	-0.0065	0.0597
42	Basophils (% WBC)	0.0258	0.1242	-0.0071	0.0587
43	Chronic headaches	0.0258	0.1236	-0.0070	0.0586
44	Nonmelanoma skin cancer	0.0233	0.1738	-0.0103	0.0569
45	Hearing loss	0.0229	0.1869	-0.0111	0.0568
46	MPV	0.0224	0.1802	-0.0104	0.0552
47	AUDIT-C sum score	-0.0219	0.1897	-0.0547	0.0109
48	Benign prostatic hyperplasia	0.0218	0.2273	-0.0136	0.0571
49	Eosinophils (% WBC)	0.0216	0.2001	-0.0114	0.0545
50	Hypothyroidism	-0.0213	0.2064	-0.0544	0.0118
51	Macular degeneration	0.0209	0.2140	-0.0121	0.0540
52	Left ventricular mass index	0.0197	0.2623	-0.0147	0.0541
53	Hemoglobin	-0.0181	0.2868	-0.0515	0.0153
54					
55					
56					
57					
58					
59					
60					

1					
2					
3	RBC count	0.0180	0.2814	-0.0148	0.0508
4	Psoriasis	0.0170	0.3108	-0.0158	0.0497
5	Lymphocytes (% WBC)	-0.0166	0.3270	-0.0499	0.0166
6	Kidney or bladder stones	-0.0159	0.3448	-0.0490	0.0171
7	Glaucoma	0.0157	0.3547	-0.0175	0.0489
8	Hemorrhoids	0.0152	0.3649	-0.0177	0.0482
9	Coronary calcium score	0.0144	0.4287	-0.0213	0.0502
10	Other race	0.0131	0.4445	-0.0204	0.0466
11	Colon polyps	0.0120	0.4975	-0.0227	0.0467
12	Breast cancer	0.0118	0.4826	-0.0211	0.0446
13	Melanoma skin cancer	-0.0117	0.4889	-0.0450	0.0215
14	Sodium	-0.0117	0.4856	-0.0446	0.0212
15	Calcium	-0.0115	0.4909	-0.0443	0.0213
16	Hashimotos Disease	-0.0108	0.5175	-0.0436	0.0220
17	Transient ischemic attack	-0.0087	0.6029	-0.0417	0.0242
18	Osteopenia	-0.0076	0.6521	-0.0408	0.0256
19	Atrial fibrillation	0.0075	0.6601	-0.0258	0.0407
20	Neutrophil segments (% WBC)	0.0071	0.6714	-0.0257	0.0399
21	Total neutrophils (% WBC)	0.0071	0.6714	-0.0257	0.0399
22	TSH	0.0069	0.6786	-0.0259	0.0397
23	Potassium	-0.0060	0.7193	-0.0390	0.0269
24	Hematocrit	-0.0049	0.7722	-0.0383	0.0285
25	Monocytes (% WBC)	0.0041	0.8177	-0.0305	0.0386
26	Osteoporosis	-0.0039	0.8192	-0.0369	0.0292
27	GFR MDRD	0.0030	0.8737	-0.0343	0.0403
28	Tinnitus	0.0029	0.8627	-0.0304	0.0362
29	Diabetes type 1	-0.0027	0.8707	-0.0356	0.0301
30	Hispanic ethnicity	-0.0023	0.8914	-0.0360	0.0314
31	Hepatitis B	-0.0022	0.8963	-0.0351	0.0307
32	Prostate cancer	-0.0009	0.9575	-0.0348	0.0329
33	Black race	0.0004	0.9790	-0.0325	0.0334
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

eTable 4. LASSO Regression Results: Model 2

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.1970	< 0.0001	0.1659	0.2282
Memory change	0.1732	< 0.0001	0.1423	0.2040
Backache	0.1585	< 0.0001	0.1273	0.1898
Body image concerns	0.1527	< 0.0001	0.1216	0.1837
Neck or low back pain	0.1419	< 0.0001	0.1105	0.1733
Shortness of breath with exercise	0.1336	< 0.0001	0.1019	0.1652
Shortness of breath	0.1329	< 0.0001	0.1011	0.1646
BMI	0.1269	< 0.0001	0.0958	0.1581
Lightheadedness	0.1268	< 0.0001	0.0955	0.1581
Waist circumference	0.1235	< 0.0001	0.0925	0.1545
Headache	0.1188	< 0.0001	0.0871	0.1505
Heat or cold intolerance	0.1159	< 0.0001	0.0845	0.1472
6-minute walk	-0.1139	< 0.0001	-0.1451	-0.0827
Constipation	0.1078	< 0.0001	0.0766	0.1391
Muscle or joint pain	0.1044	< 0.0001	0.0732	0.1356
Swelling in calves or feet	0.1036	< 0.0001	0.0723	0.1349
Bloating	0.1036	< 0.0001	0.0721	0.1351
Nasal stuffiness	0.1014	< 0.0001	0.0702	0.1326
Coughing up sputum	0.0978	< 0.0001	0.0663	0.1293
Joint pain swelling	0.0971	< 0.0001	0.0659	0.1282
Pain or stiffness in the neck	0.0937	< 0.0001	0.0623	0.1250
Frequency of urination	0.0927	< 0.0001	0.0615	0.1238
Heartburn	0.0913	< 0.0001	0.0599	0.1227
Diarrhea	0.0903	< 0.0001	0.0589	0.1216
Tingling or numbness in extremities	0.0900	< 0.0001	0.0586	0.1214
30 second chair stand	-0.0893	< 0.0001	-0.1207	-0.0580
Tingling or pins and needles	0.0859	< 0.0001	0.0543	0.1176
Cough	0.0855	< 0.0001	0.0539	0.1170
C-reactive protein	0.0847	< 0.0001	0.0534	0.1161
Blood glucose	0.0819	< 0.0001	0.0506	0.1131
Night sweats	0.0811	< 0.0001	0.0497	0.1125
Stiffness	0.0806	< 0.0001	0.0492	0.1119
Mean leg balance time	-0.0777	< 0.0001	-0.1090	-0.0464
HbA1c	0.0772	< 0.0001	0.0460	0.1084
Heart rate	0.0771	< 0.0001	0.0450	0.1092
Urination at night	0.0770	< 0.0001	0.0458	0.1082
ALT	0.0751	< 0.0001	0.0439	0.1063
Mean daily steps in first 30 days	-0.0745	< 0.0001	-0.1058	-0.0432
Urgency	0.0743	< 0.0001	0.0430	0.1055
Excessive belching or passing of gas	0.0739	< 0.0001	0.0426	0.1052
GERD	0.0727	< 0.0001	0.0414	0.1039
10-meter walk speed	-0.0721	< 0.0001	-0.1035	-0.0407
Dry mouth	0.0718	< 0.0001	0.0404	0.1032

1					
2					
3	Asthma	0.0715	< 0.0001	0.0403	0.1028
4	Sleep apnea	0.0711	< 0.0001	0.0397	0.1024
5	Itching skin	0.0682	< 0.0001	0.0368	0.0997
6	Sit-rise score	-0.0663	< 0.0001	-0.0978	-0.0348
7	WBC count	0.0653	< 0.0001	0.0327	0.0979
8	MCH	-0.0653	< 0.0001	-0.0965	-0.0340
9	Sinus pain	0.0652	< 0.0001	0.0338	0.0966
10	Urine specific gravity	0.0651	< 0.0001	0.0338	0.0965
11	Respiratory rate	0.0646	< 0.0001	0.0332	0.0960
12	Absolute reticulocytes	0.0634	< 0.0001	0.0319	0.0948
13	Leg cramps	0.0632	< 0.0001	0.0319	0.0945
14	Dryness	0.0622	0.0001	0.0307	0.0937
15	Numbness or loss of sensation	0.0615	0.0001	0.0299	0.0930
16	Creatinine (urine)	0.0611	0.0001	0.0297	0.0925
17	Cramping	0.0602	0.0002	0.0284	0.0920
18	Reticulocytes (% RBC)	0.0601	0.0002	0.0286	0.0916
19	Oxygen saturation	-0.0597	0.0002	-0.0910	-0.0284
20	Albumin in urine	-0.0581	0.0003	-0.0894	-0.0268
21	Migraines	0.0581	0.0003	0.0266	0.0896
22	MCV	-0.0578	0.0003	-0.0891	-0.0266
23	Osteoarthritis	0.0561	0.0005	0.0247	0.0876
24	Seasonal allergies	0.0556	0.0005	0.0243	0.0868
25	HDL	-0.0534	0.0009	-0.0848	-0.0220
26	Hemorrhoids (symptom)	0.0528	0.0009	0.0215	0.0841
27	Fibromyalgia	0.0525	0.0011	0.0211	0.0840
28	Lymphocytes (total)	0.0518	0.0015	0.0198	0.0838
29	Runny nose	0.0515	0.0013	0.0201	0.0828
30	Irritable bowel disorder	0.0513	0.0013	0.0200	0.0826
31	Ear ringing	0.0498	0.0019	0.0184	0.0811
32	Vitamin D	-0.0497	0.0023	-0.0816	-0.0178
33	Days watch worn 10+ hours in first				
34	30 days	-0.0495	0.0023	-0.0813	-0.0177
35	COPD with emphysema	0.0488	0.0027	0.0170	0.0807
36	Food allergies	0.0483	0.0025	0.0170	0.0796
37	MCHC	-0.0483	0.0025	-0.0797	-0.0170
38	Hypertension	0.0479	0.0030	0.0162	0.0795
39	Urine reaction pH	-0.0473	0.0031	-0.0787	-0.0160
40	Triglycerides	0.0470	0.0033	0.0156	0.0783
41	Monocytes	0.0465	0.0037	0.0151	0.0779
42	Neutrophils	0.0462	0.0049	0.0140	0.0785
43	Serum creatinine	0.0460	0.0044	0.0143	0.0777
44	Uric acid	0.0460	0.0043	0.0144	0.0775
45	Diabetes type 2	0.0456	0.0044	0.0143	0.0769
46	AST	0.0447	0.0052	0.0134	0.0760
47	Discharge	0.0446	0.0054	0.0132	0.0760
48	Non-seasonal allergies	0.0445	0.0053	0.0132	0.0759
49	Diverticulitis	0.0432	0.0069	0.0119	0.0745
50	Floaters	0.0421	0.0084	0.0108	0.0734
51	Absolute basophils	0.0417	0.0098	0.0101	0.0734
52	Ejection fraction at rest	0.0415	0.0094	0.0102	0.0729
53	Easy bruising or bleeding	0.0354	0.0272	0.0040	0.0667
54	Medication allergies	0.0345	0.0311	0.0031	0.0658
55					
56					
57					
58					
59					
60					

1					
2					
3	Epilepsy	0.0318	0.0471	0.0004	0.0631
4	Systolic blood pressure	0.0316	0.0505	-0.0001	0.0632
5	Chloride	-0.0308	0.0544	-0.0621	0.0006
6	Nonalcoholic fatty liver disease	0.0303	0.0578	-0.0010	0.0617
7	Arrhythmia	0.0299	0.0629	-0.0016	0.0614
8	RBC count	0.0296	0.0641	-0.0017	0.0610
9	Kidney or bladder stones	-0.0288	0.0721	-0.0601	0.0026
10	Chronic headaches	0.0285	0.0746	-0.0028	0.0599
11	Rheumatoid arthritis	0.0280	0.0808	-0.0034	0.0594
12	Hay fever	0.0279	0.0815	-0.0035	0.0592
13	Benign prostatic hyperplasia	0.0274	0.0946	-0.0047	0.0596
14	Cholesterol	-0.0267	0.0947	-0.0581	0.0046
15	Absolute eosinophils	0.0265	0.0983	-0.0049	0.0580
16	Diverticulosis	0.0262	0.1013	-0.0051	0.0576
17	Goiter	-0.0261	0.1034	-0.0574	0.0053
18	Magnesium	-0.0258	0.1099	-0.0574	0.0058
19	Gout	0.0255	0.1116	-0.0059	0.0569
20	LDL	-0.0246	0.1238	-0.0560	0.0067
21	Hepatitis C	0.0239	0.1373	-0.0076	0.0554
22	Diastolic blood pressure	0.0232	0.1467	-0.0081	0.0546
23	Peripheral vascular disease	0.0230	0.1508	-0.0084	0.0543
24	Hypercholesterolemia	0.0227	0.1598	-0.0089	0.0543
25	Hemoglobin	-0.0225	0.1601	-0.0540	0.0089
26	Nonmelanoma skin cancer	0.0212	0.1869	-0.0103	0.0528
27	MPV	0.0211	0.1861	-0.0102	0.0525
28	Hearing loss	0.0210	0.1924	-0.0106	0.0527
29	Hypothyroidism	-0.0209	0.1930	-0.0523	0.0106
30	Handgrip	-0.0205	0.2025	-0.0522	0.0111
31	Pulmonary embolism	0.0194	0.2246	-0.0119	0.0508
32	Cataracts	0.0186	0.2549	-0.0134	0.0507
33	Glaucoma	0.0186	0.2477	-0.0129	0.0501
34	Sodium	-0.0167	0.2976	-0.0480	0.0147
35	Pneumonia	0.0166	0.3007	-0.0148	0.0479
36	Potassium	-0.0153	0.3403	-0.0466	0.0161
37	Macular degeneration	0.0140	0.3806	-0.0173	0.0454
38	Protein (serum)	-0.0139	0.3870	-0.0454	0.0176
39	Stroke	0.0133	0.4058	-0.0181	0.0447
40	Hemorrhoids	0.0132	0.4094	-0.0182	0.0446
41	Coronary artery disease	0.0123	0.4424	-0.0191	0.0438
42	Basophils (% WBC)	0.0118	0.4593	-0.0195	0.0432
43	Hematocrit	-0.0117	0.4667	-0.0431	0.0198
44	Psoriasis	0.0109	0.4946	-0.0204	0.0423
45	Myocardial infarction	0.0104	0.5153	-0.0210	0.0418
46	Eosinophils (% WBC)	0.0104	0.5158	-0.0210	0.0418
47	Peptic ulcer	0.0102	0.5244	-0.0212	0.0416
48	Breast cancer	0.0101	0.5287	-0.0213	0.0414
49	Neutrophil lymphocyte ratio	0.0100	0.5337	-0.0214	0.0413
50	Melanoma skin cancer	-0.0099	0.5384	-0.0414	0.0216
51	Calcium	-0.0098	0.5396	-0.0412	0.0215
52	Transient ischemic attack	-0.0090	0.5746	-0.0404	0.0224
53	Coronary calcium score	-0.0085	0.6007	-0.0401	0.0232
54					
55					
56					
57					
58					
59					
60					

1					
2					
3	Left ventricular mass index	0.0082	0.6113	-0.0234	0.0398
4	Gallbladder disease	0.0081	0.6131	-0.0234	0.0397
5	TSH	0.0081	0.6117	-0.0232	0.0395
6	Tinnitus	0.0081	0.6138	-0.0234	0.0397
7	Osteoporosis	-0.0081	0.6139	-0.0395	0.0233
8	GFR MDRD	0.0075	0.6465	-0.0247	0.0398
9	Colon polyps	0.0074	0.6490	-0.0244	0.0391
10	Hashimotos Disease	-0.0073	0.6467	-0.0387	0.0240
11	Neutrophil segments (% WBC)	-0.0072	0.6530	-0.0386	0.0242
12	Total neutrophils (% WBC)	-0.0072	0.6530	-0.0386	0.0242
13	Platelets	0.0059	0.7162	-0.0261	0.0380
14	Atrial fibrillation	0.0056	0.7273	-0.0259	0.0371
15	Osteopenia	-0.0046	0.7748	-0.0361	0.0269
16	Diabetes type 1	0.0039	0.8093	-0.0275	0.0352
17	Lymphocytes (% WBC)	0.0038	0.8133	-0.0276	0.0351
18	Hepatitis B	0.0030	0.8507	-0.0284	0.0344
19	Monocytes (% WBC)	0.0030	0.8543	-0.0288	0.0348
20	Prostate cancer	0.0030	0.8543	-0.0287	0.0347
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

eTable 5. LASSO Regression Results: Model 3

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.1847	< 0.0001	0.1543	0.2152
Memory change	0.1511	< 0.0001	0.1207	0.1816
Body image concerns	0.1457	< 0.0001	0.1154	0.1760
Backache	0.1336	< 0.0001	0.1026	0.1645
Neck or low back pain	0.1191	< 0.0001	0.0881	0.1501
Lightheadedness	0.1047	< 0.0001	0.0739	0.1355
Shortness of breath with exercise	0.1028	< 0.0001	0.0713	0.1343
Shortness of breath	0.0976	< 0.0001	0.0657	0.1294
Headache	0.0967	< 0.0001	0.0655	0.1280
Constipation	0.0932	< 0.0001	0.0627	0.1238
Heat or cold intolerance	0.0918	< 0.0001	0.0609	0.1227
Nasal stuffiness	0.0880	< 0.0001	0.0574	0.1185
Waist circumference	0.0834	< 0.0001	0.0528	0.1141
BMI	0.0829	< 0.0001	0.0517	0.1142
Swelling in calves or feet	0.0816	< 0.0001	0.0508	0.1124
6-minute walk	-0.0801	< 0.0001	-0.1111	-0.0491
Bloating	0.0795	< 0.0001	0.0484	0.1106
Muscle or joint pain	0.0791	< 0.0001	0.0484	0.1098
Frequency of urination	0.0786	< 0.0001	0.0482	0.1091
Coughing up sputum	0.0781	< 0.0001	0.0471	0.1090
30 second chair stand	-0.0762	< 0.0001	-0.1068	-0.0455
Pain or stiffness in the neck	0.0745	< 0.0001	0.0438	0.1053
Joint pain swelling	0.0735	< 0.0001	0.0428	0.1041
Tingling or numbness in extremities	0.0729	< 0.0001	0.0420	0.1037
Heartburn	0.0712	< 0.0001	0.0404	0.1021
Night sweats	0.0681	< 0.0001	0.0373	0.0988
Urination at night	0.0642	< 0.0001	0.0337	0.0946
Cough	0.0631	< 0.0001	0.0320	0.0941
Mean daily steps in first 30 days	-0.0620	< 0.0001	-0.0926	-0.0313
Tingling or pins and needles	0.0616	0.0001	0.0304	0.0928
Diarrhea	0.0609	0.0001	0.0298	0.0919
C-reactive protein	0.0604	0.0001	0.0296	0.0913
Urgency	0.0601	0.0001	0.0295	0.0906
Blood glucose	0.0594	0.0001	0.0288	0.0901
Stiffness	0.0591	0.0002	0.0284	0.0899
Leg cramps	0.0588	0.0002	0.0282	0.0893
Mean leg balance time	-0.0565	0.0003	-0.0870	-0.0260
ALT	0.0560	0.0003	0.0254	0.0865
Dryness	0.0556	0.0004	0.0250	0.0863
Heart rate	0.0550	0.0006	0.0234	0.0866
Itching skin	0.0548	0.0005	0.0240	0.0856
Excessive belching or passing of gas	0.0547	0.0005	0.0240	0.0854

1					
2					
3	Sit-rise score	-0.0526	0.0008	-0.0831	-0.0220
4	Sinus pain	0.0525	0.0008	0.0219	0.0832
5	10-meter walk speed	-0.0525	0.0008	-0.0833	-0.0217
6	Oxygen saturation	-0.0506	0.0012	-0.0811	-0.0201
7	HbA1c	0.0499	0.0014	0.0193	0.0805
8	Respiratory rate	0.0495	0.0016	0.0187	0.0802
9	Ejection fraction at rest	0.0465	0.0028	0.0160	0.0771
10	WBC count	0.0462	0.0045	0.0144	0.0781
11	Absolute reticulocytes	0.0462	0.0033	0.0154	0.0770
12	Reticulocytes (% RBC)	0.0461	0.0034	0.0153	0.0770
13	Dry mouth	0.0456	0.0038	0.0148	0.0765
14	Albumin in urine	-0.0456	0.0034	-0.0761	-0.0151
15	Numbness or loss of sensation	0.0441	0.0052	0.0132	0.0751
16	Ear ringing	0.0422	0.0068	0.0116	0.0727
17	Food allergies	0.0418	0.0072	0.0113	0.0724
18	MCH	-0.0413	0.0084	-0.0720	-0.0106
19	Runny nose	0.0389	0.0128	0.0083	0.0695
20	Cramping	0.0389	0.0147	0.0076	0.0701
21	Hemorrhoids (symptom)	0.0386	0.0134	0.0080	0.0691
22	Days watch worn 10+ hours in				
23	first 30 days	-0.0385	0.0149	-0.0696	-0.0075
24	Handgrip	-0.0379	0.0150	-0.0685	-0.0074
25	MCHC	-0.0378	0.0156	-0.0684	-0.0072
26	Urine specific gravity	0.0361	0.0222	0.0052	0.0669
27	Absolute basophils	0.0352	0.0255	0.0043	0.0660
28	Urine reaction pH	-0.0351	0.0243	-0.0657	-0.0046
29	Monocytes	0.0350	0.0253	0.0043	0.0657
30	Lymphocytes (total)	0.0350	0.0283	0.0037	0.0663
31	Triglycerides	0.0347	0.0262	0.0041	0.0654
32	Discharge	0.0345	0.0273	0.0039	0.0652
33	MCV	-0.0338	0.0306	-0.0645	-0.0032
34	Neutrophils	0.0331	0.0390	0.0017	0.0645
35	Floaters	0.0330	0.0342	0.0025	0.0636
36	Creatinine (urine)	0.0325	0.0397	0.0015	0.0635
37	AST	0.0319	0.0404	0.0014	0.0625
38	Serum creatinine	0.0311	0.0465	0.0005	0.0618
39	Seasonal allergies	0.0288	0.0650	-0.0018	0.0595
40	Easy bruising or bleeding	0.0272	0.0821	-0.0035	0.0578
41	Vitamin D	-0.0269	0.0928	-0.0583	0.0045
42	Medication allergies	0.0258	0.0977	-0.0047	0.0564
43	Uric acid	0.0247	0.1137	-0.0059	0.0552
44	Non-seasonal allergies	0.0237	0.1300	-0.0070	0.0543
45	HDL	-0.0229	0.1470	-0.0540	0.0081
46	Hemoglobin	-0.0229	0.1427	-0.0535	0.0077
47	Chloride	-0.0219	0.1590	-0.0525	0.0086
48	Protein (serum)	-0.0213	0.1737	-0.0520	0.0094
49	Systolic blood pressure	0.0186	0.2348	-0.0121	0.0492
50	Hay fever	0.0173	0.2677	-0.0133	0.0478
51	MPV	0.0154	0.3227	-0.0152	0.0460
52	Absolute eosinophils	0.0147	0.3473	-0.0160	0.0455
53	Hematocrit	-0.0147	0.3474	-0.0453	0.0159
54	Basophils (% WBC)	0.0140	0.3691	-0.0166	0.0446
55					
56					
57					
58					
59					
60					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Coronary calcium score	-0.0118	0.4500	-0.0426	0.0189
RBC count	0.0109	0.4830	-0.0196	0.0415
LDL	-0.0105	0.5007	-0.0411	0.0201
GFR MDRD	-0.0087	0.5884	-0.0402	0.0228
Diastolic blood pressure	0.0087	0.5775	-0.0219	0.0393
Neutrophil lymphocyte ratio	0.0079	0.6135	-0.0227	0.0384
Sodium	-0.0077	0.6218	-0.0383	0.0229
Calcium	-0.0056	0.7179	-0.0362	0.0249
Cholesterol	-0.0054	0.7296	-0.0360	0.0252
Monocytes (% WBC)	0.0038	0.8106	-0.0271	0.0346
Neutrophil segments (% WBC)	-0.0035	0.8244	-0.0340	0.0271
Total neutrophils (% WBC)	-0.0035	0.8244	-0.0340	0.0271
Platelets	0.0031	0.8456	-0.0280	0.0342
Left ventricular mass index	-0.0026	0.8673	-0.0333	0.0280
TSH	0.0025	0.8751	-0.0281	0.0330
Eosinophils (% WBC)	0.0023	0.8824	-0.0283	0.0329
Lymphocytes (% WBC)	0.0014	0.9280	-0.0292	0.0320
Potassium	-0.0008	0.9588	-0.0314	0.0298
Magnesium	-0.0005	0.9745	-0.0316	0.0306

eTable 6. LASSO Regression Results: Model 4

Variable	Estimate	P-value	CI 25%	CI 75%
BMI	0.0664	< 0.0001	0.0369	0.0960
6-minute walk	-0.0661	< 0.0001	-0.0955	-0.0368
Waist circumference	0.0618	< 0.0001	0.0326	0.0910
Mean daily steps in first 30 days	-0.0522	0.0004	-0.0813	-0.0232
ALT	0.0520	0.0004	0.0230	0.0809
Heart rate	0.0491	0.0012	0.0195	0.0787
30 second chair stand	-0.0458	0.0023	-0.0752	-0.0164
Blood glucose	0.0454	0.0022	0.0164	0.0745
WBC count	0.0454	0.0028	0.0157	0.0751
C-reactive protein	0.0431	0.0040	0.0137	0.0724
Absolute reticulocytes	0.0413	0.0054	0.0122	0.0705
Sit-rise score	-0.0408	0.0058	-0.0697	-0.0118
Reticulocytes (% RBC)	0.0401	0.0071	0.0109	0.0692
Handgrip	-0.0399	0.0070	-0.0688	-0.0109
Mean leg balance time	-0.0390	0.0083	-0.0679	-0.0100
Oxygen saturation	-0.0385	0.0091	-0.0675	-0.0096
AST	0.0374	0.0112	0.0085	0.0663
Respiratory rate	0.0367	0.0138	0.0075	0.0659
10-meter walk speed	-0.0362	0.0154	-0.0654	-0.0069
Albumin in urine	-0.0361	0.0146	-0.0651	-0.0071
Days watch worn 10+ hours in first 30 days	-0.0360	0.0157	-0.0653	-0.0068
Lymphocytes (total)	0.0354	0.0181	0.0060	0.0648
HbA1c	0.0352	0.0177	0.0061	0.0643
Ejection fraction at rest	0.0351	0.0173	0.0062	0.0641
Neutrophils	0.0350	0.0200	0.0055	0.0644
MCHC	-0.0341	0.0212	-0.0631	-0.0051
MCH	-0.0301	0.0428	-0.0592	-0.0010
Monocytes	0.0282	0.0577	-0.0009	0.0572
Absolute basophils	0.0270	0.0702	-0.0022	0.0562
Triglycerides	0.0267	0.0716	-0.0023	0.0557
Urine reaction pH	-0.0265	0.0734	-0.0554	0.0025
MCV	-0.0223	0.1333	-0.0513	0.0068
Sodium	-0.0220	0.1359	-0.0510	0.0069
Chloride	-0.0211	0.1537	-0.0500	0.0079
Serum creatinine	0.0203	0.1701	-0.0087	0.0492
MPV	0.0189	0.2015	-0.0101	0.0478
Potassium	-0.0185	0.2097	-0.0475	0.0104
Urine specific gravity	0.0179	0.2308	-0.0114	0.0473
Vitamin D	-0.0166	0.2713	-0.0462	0.0130
Systolic blood pressure	0.0165	0.2654	-0.0125	0.0455
LDL	-0.0158	0.2837	-0.0448	0.0131
Protein (serum)	-0.0145	0.3256	-0.0435	0.0145
RBC count	0.0144	0.3285	-0.0145	0.0434

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Creatinine (urine)	0.0140	0.3518	-0.0154	0.0434
Basophils (% WBC)	0.0119	0.4208	-0.0171	0.0408
Left ventricular mass index	-0.0114	0.4391	-0.0404	0.0175
Uric acid	0.0111	0.4506	-0.0178	0.0401
Coronary calcium score	-0.0108	0.4681	-0.0398	0.0183
TSH	0.0102	0.4912	-0.0188	0.0391
Hemoglobin	-0.0095	0.5236	-0.0385	0.0196
Magnesium	-0.0074	0.6195	-0.0366	0.0218
Diastolic blood pressure	0.0064	0.6651	-0.0226	0.0354
Eosinophils (% WBC)	-0.0057	0.7011	-0.0346	0.0233
GFR MDRD	-0.0054	0.7173	-0.0349	0.0241
Neutrophil lymphocyte ratio	0.0053	0.7185	-0.0236	0.0343
Calcium	-0.0049	0.7398	-0.0339	0.0240
Platelets	0.0039	0.7947	-0.0254	0.0331
Cholesterol	-0.0034	0.8172	-0.0324	0.0256
HDL	-0.0027	0.8565	-0.0322	0.0267
Monocytes (% WBC)	0.0025	0.8652	-0.0266	0.0317
Absolute eosinophils	0.0017	0.9082	-0.0274	0.0309
Lymphocytes (% WBC)	0.0015	0.9192	-0.0275	0.0305
Neutrophil segments (% WBC)	-0.0013	0.9307	-0.0302	0.0277
Total neutrophils (% WBC)	-0.0013	0.9307	-0.0302	0.0277
Hematocrit	-0.0011	0.9413	-0.0301	0.0279


eTable 7. LASSO Regression Results: Model 5

Variable	Estimate	P-value	CI 25%	CI 75%
AST	0.0382	0.0087	0.0096	0.0667
ALT	0.0352	0.0162	0.0065	0.0638
HDL	0.0312	0.0383	0.0017	0.0607
Serum creatinine	0.0220	0.1313	-0.0066	0.0506
LDL	-0.0212	0.1460	-0.0497	0.0074
Blood glucose	0.0207	0.1606	-0.0082	0.0497
MCHC	-0.0199	0.1747	-0.0486	0.0088
Basophils (% WBC)	0.0183	0.2085	-0.0102	0.0469
Chloride	-0.0183	0.2099	-0.0468	0.0103
MPV	0.0181	0.2145	-0.0105	0.0467
Sodium	-0.0179	0.2203	-0.0464	0.0107
Absolute basophils	0.0170	0.2479	-0.0119	0.0460
Protein (serum)	-0.0169	0.2471	-0.0455	0.0117
MCH	-0.0148	0.3137	-0.0437	0.0140
Potassium	-0.0143	0.3259	-0.0429	0.0143
GFR MDRD	-0.0138	0.3535	-0.0430	0.0154
Lymphocytes (total)	0.0133	0.3748	-0.0160	0.0425
Platelets	-0.0127	0.3923	-0.0417	0.0164
WBC count	0.0125	0.4143	-0.0175	0.0424
Monocytes	0.0121	0.4122	-0.0168	0.0409
C-reactive protein	0.0104	0.4880	-0.0190	0.0398
Monocytes (% WBC)	0.0103	0.4818	-0.0185	0.0391
HbA1c	0.0101	0.4930	-0.0188	0.0391
MCV	-0.0101	0.4933	-0.0388	0.0187
TSH	0.0100	0.4930	-0.0186	0.0386
Albumin in urine	-0.0096	0.5130	-0.0383	0.0192
Magnesium	0.0095	0.5205	-0.0195	0.0385
Uric acid	-0.0080	0.5827	-0.0366	0.0206
RBC count	0.0073	0.6161	-0.0213	0.0359
Urine reaction pH	-0.0073	0.6185	-0.0360	0.0214
Neutrophil segments (% WBC)	-0.0072	0.6205	-0.0358	0.0214
Total neutrophils (% WBC)	-0.0072	0.6205	-0.0358	0.0214
Absolute reticulocytes	0.0069	0.6408	-0.0222	0.0361
Neutrophils	0.0068	0.6483	-0.0226	0.0363
Absolute eosinophils	-0.0064	0.6635	-0.0352	0.0224
Calcium	0.0062	0.6691	-0.0224	0.0348
Vitamin D	0.0057	0.7024	-0.0237	0.0352
Lymphocytes (% WBC)	0.0057	0.6944	-0.0229	0.0343
Reticulocytes (% RBC)	0.0057	0.7017	-0.0235	0.0349
Triglycerides	0.0055	0.7075	-0.0233	0.0343
Eosinophils (% WBC)	-0.0047	0.7449	-0.0333	0.0238
Hemoglobin	-0.0047	0.7481	-0.0334	0.0240

1					
2					
3	Cholesterol	-0.0033	0.8231	-0.0319	0.0254
4	Urine specific gravity	-0.0029	0.8465	-0.0321	0.0263
5	Neutrophil lymphocyte				
6	ratio	-0.0009	0.9488	-0.0295	0.0276
7	Creatinine (urine)	0.0006	0.9663	-0.0285	0.0298
8	Hematocrit	0.0000	0.9974	-0.0286	0.0287
9					
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					
29					
30					
31					
32					
33					
34					
35					
36					
37					
38					
39					
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50					
51					
52					
53					
54					
55					
56					
57					
58					
59					
60					

eFigure 1A. Distribution of PHQ-9 Across Risk Groups by Asthma


Distribution of PHQ-9 across Risk Group by Asthma



Peer review only

eFigure 1B. Distribution of PHQ-9 Across Risk Groups by Backache


Distribution of PHQ-9 across Risk Group by Backache



Peer review only

eFigure 1C. Distribution of PHQ-9 Across Risk Groups by Memory Change


Distribution of PHQ-9 across Risk Group by Memory Change



Peer review only


eFigure 1D. Distribution of PHQ-9 Across Risk Groups by Body Image Concerns

Distribution of PHQ-9 across Risk Group by Body Image Concerns



eFigure 1E. Distribution of PHQ-9 Across Risk Groups by Sleep Apnea

Distribution of PHQ-9 across Risk Group by Sleep Apnea



For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2,3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	7-9
		(c) Explain how missing data were addressed	7-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7-9
		(e) Describe any sensitivity analyses	n/a

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9,10
		(b) Give reasons for non-participation at each stage	9,10
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,10
		(b) Indicate number of participants with missing data for each variable of interest	9,10
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	9,10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	9,10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10
		(b) Report category boundaries when continuous variables were categorized	9,10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9,10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13,14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13,14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Biological and Clinical Correlates of the Patient Health Questionnaire-9: Exploratory Cross-Sectional Analyses of the Baseline Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054741.R1
Article Type:	Original research
Date Submitted by the Author:	26-Oct-2021
Complete List of Authors:	Califf, Robert; Verily Life Sciences LLC Wong, Celeste; Verily Life Sciences LLC Doraiswamy, Murali; Duke University Medical Center, Psychiatry; Duke University Medical Center, Brain Sciences Hong, David ; Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences Miller, David; Verily Life Sciences LLC Mega, Jessica; Verily Life Sciences LLC
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Public health
Keywords:	MENTAL HEALTH, PUBLIC HEALTH, Depression & mood disorders < PSYCHIATRY, Anxiety disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

ORIGINAL RESEARCH**Biological and Clinical Correlates of the Patient Health Questionnaire-9: Exploratory Cross-Sectional Analyses of the Baseline Health Study****Running title:** Biological and Clinical Correlates of PHQ-9Robert M. Califf, MD¹; Celeste Wong, MPH¹; P. Murali Doraiswamy, MBBS²;David S. Hong, MD³; David P. Miller, MS¹; Jessica L. Mega, MD, MPH¹; for the Baseline Study Group¹Verily Life Sciences, San Francisco, CA; ²Department of Psychiatry and Behavioral Sciences and the Duke Institute for Brain Sciences, Duke University School of Medicine, Durham, NC;³Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA.**Address for correspondence:** Robert M. Califf, MD; Verily Life Sciences, 269 E Grand Ave., South San Francisco, CA 94080; Email: robert.califf@duke.edu**Number of references:** 41**Number of tables:** 3**Number of figures:** 5**Number of appendices:** 1 (12 eTables, 1 eFigure w/5 parts)**Text word count:** 2827**Abstract word count:** 300

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: Patient Health Questionnaire-9; measures of health and disease; effective clinical intervention

For peer review only

ABSTRACT

Objectives: We assessed the relationship between the Patient Health Questionnaire-9 (PHQ-9) at intake and other measurements intended to assess biological factors, markers of disease, and health status.

Design, setting, and participants: We performed a cross-sectional analysis of 2365 participants from the Baseline Health Study (BHS), a prospective cohort of adults selected to represent major demographic groups in the United States. Participants underwent deep phenotyping on demographic, clinical, laboratory, functional, and imaging findings.

Importance: Despite extensive research on the clinical implications of the PHQ-9, data are limited on the relationship between PHQ-9 scores and other measures of health and disease; we sought to better understand this relationship.

Interventions: None.

Main outcomes and measures: Cross-sectional measures of medical illnesses, gait, balance strength, activities of daily living, imaging, and laboratory tests.

Results: Compared with lower PHQ-9 scores, higher scores were associated with female sex (46.9 to 66.7%), younger participants (53.6 to 42.4 years), and compromised physical status (higher resting heart rates [65 vs. 75 bpm], larger body mass index [26.5 to 30 kg/m²], greater waist circumference [91 to 96.5 cm]) and chronic conditions, including gastroesophageal reflux disease (13.2 to 24.7%) and asthma (9.5 to 20.4%) ($p < 0.0001$). Increasing PHQ-9 score was associated with a higher frequency of comorbidities (migraines [6 to 20.4%]) and active symptoms (leg cramps [6.4 to 24.7%], mood change [1.2 to 47.3%], lack of energy [1.2 to 57%]) ($p < 0.0001$). After adjustment for relevant demographic, socioeconomic, behavioral, and medical characteristics, we found that memory change, tension, shortness of breath, and indicators of

1
2
3
4 musculoskeletal symptoms (backache and neck pain) are related to higher PHQ-9 scores
5
6 (p<0.0001).
7

8 **Conclusions:** Our study highlights how: 1) even subthreshold depressive symptoms (measured
9
10 by PHQ-9) may be indicative of several individual- and population-level concerns that demand
11
12 more attention; and 2) depression should be considered a comorbidity in common disease.
13
14

15 **Clinical trial registration:** <https://clinicaltrials.gov/ct2/show/NCT03154346>
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations of this study

- This study included deep phenotyping on demographic, clinical, laboratory, functional, and imaging findings of 2365 participants from the Baseline Health Study (BHS).
- This study provides important data on the relationship between PHQ-9 scores and other measures of health and disease.
- The cross-sectional nature of this study limits our ability to assess the time course of these findings; however, follow-up is currently accruing.
- People with significant depression are less likely to volunteer, thereby limiting the breadth of depression observed in this study.
- The study population is generally representative of adult age, sex, race, and ethnicity, but it is not a fully representative sample of the population.

INTRODUCTION

Depression is a complex, chronic condition that affects hundreds of millions of people worldwide.¹ Bidirectional relationships have been reported between depression and many chronic illnesses²; however, most studies have focused on specific conditions, such as diabetes, stroke, or congestive heart failure, as opposed to a multidimensional deep phenotyping approach. Findings from previous studies highlight the need to more fully characterize the relationship between depression and physical health.³⁻⁵ Furthermore, it would be helpful to better understand whether these relationships exist only above a certain threshold or across the entire continuum.

The most common screening tool for depression is the Patient Health Questionnaire-9 (PHQ-9), whose operating characteristics are well known⁶ and have been validated in a variety of contexts.^{7,8} Despite extensive research on the clinical and behavioral implications of PHQ-9,^{9,10} the results of this questionnaire are often used in a dichotomous manner (e.g., cut-off of 10) without evaluating the full relationship between PHQ-9 scores and measures of health and disease.

The Baseline Health Study (BHS)¹¹ is a prospective cohort study of an adult population selected to represent major demographic groups in the U.S. In BHS, deep phenotyping of numerous demographic, clinical, laboratory, functional, and imaging findings is coupled with ongoing longitudinal follow-up. The purpose of our study was to assess the relationship between the entire spectrum of depression, measured by PHQ-9, and a broad array of measurements intended to assess health status.

METHODS

The Baseline Health Study

1
2
3
4 BHS methods have been previously described,¹¹⁻¹³ including entry and exclusion criteria, the
5
6 institutional review board and participant consent procedures, the data collection scheme, and
7
8 key components of study procedures. Briefly, BHS (ClinicalTrials.gov Identifier:
9
10 NCT03154346) was approved by the Western Institutional Review Board, Inc. (Puyallup, WA;
11
12 protocol number is 2017-BL-001). All research participants gave written, informed consent prior
13
14 to participation.
15

16
17 Additional details of the effects of social determinants on health in the BHS study have
18
19 been previously reported.¹² BHS is enrolling a large number of participants, beginning with
20
21 intensive measurement of the first 2502 people (the deeply phenotyped cohort) in whom a large
22
23 volume of multimodal data are collected. Four clinical BHS sites in the U.S. have begun
24
25 enrollment.
26
27

28
29 The participants were enrolled through a virtual online registry with selection of
30
31 participants for the deep phenotyping cohort included in this report using an algorithm intended
32
33 to produce a representative sample of U.S. adult age, race, and ethnicity. People in good health
34
35 and with medical conditions were included and the sampling method was designed to over-
36
37 represent people at risk of heart disease or cancer. The PHQ-9 in this report was collected at the
38
39 initial study visit in person or online.
40
41

42
43 A pre-BHS pilot study, which tested clinical assessment workflows, was conducted in
44
45 200 healthy participants prior to initiation of the primary study. BHS is funded by Verily (San
46
47 Francisco, CA) and is managed in collaboration with Stanford University (Stanford, CA), Duke
48
49 University (Durham, NC), and the California Health and Longevity Institute (Westlake Village,
50
51 CA) with enrolling sites in Durham, NC; Kannapolis, NC; Los Angeles, CA; and Palo Alto, CA.
52
53
54
55
56
57
58
59
60

1
2
3
4 The extended studies have governance approaches specific to the needs of each study. Herein,
5
6 we examine a cross-sectional analysis of the first BHS time point PHQ-9 scores.
7
8
9

10 **Statistical methods**

11
12 The statistical methods used in this manuscript have been described previously.¹² Distributional
13
14 measures; medians and 25th, 75th percentiles for continuous variables; and counts and
15
16 percentages for categorical variables were computed and summarized across each of 5 PHQ-9
17
18 severity groups⁶ (0, 1–4, 5–9, 10–14, >14), divided by convention to be consistent with prior
19
20 studies. The Cochran-Armitage trend test for binomial variables,^{13,14} and the Spearman rank
21
22 correlation test for continuous variables¹⁵ or categorical variables that are ordinal in nature (e.g.,
23
24 education and income), were used to test for linear trend across severity group. Multiple tests
25
26 were not adjusted for, given the exploratory nature of this study. Subsequent studies with pre-
27
28 planned hypotheses are needed to confirm results.
29
30
31
32

33
34 Penalized regression using the least absolute shrinkage and selection operator (LASSO)
35
36 was conducted to model physical, phenotypic, and symptom factors that could predict the PHQ-9
37
38 score (logarithm of PHQ-9 + 1). Data were randomly split into a training set (approximately 70%
39
40 of the data), which was used to build the models, and an independent test set, which was used to
41
42 evaluate model performance. The final linear model was trained on the full training set, retaining
43
44 all predictors with coefficients not equal to zero, and was evaluated on the held-aside test set.
45
46

47
48 Since inference rather than prediction is the goal of this analysis, we considered 5 sets of
49
50 sequential “adjustment” models, consisting of smaller-to-larger covariate lists that were entered
51
52 into a LASSO regression model. The LASSO-predicted values resulting from each of the 5
53
54 models were used to estimate a covariate-adjusted effect for all other candidate variables.
55
56
57
58
59
60

1
2
3
4 Separate regressions for *each* of the candidate variables that are not included in a given model
5
6 were performed to obtain coefficients and confidence intervals (i.e., only the LASSO-predicted
7
8 value and the candidate variable to be evaluated were included in each model).
9

10 The LASSO adjustment models comprise the following covariates: 1) Model 1: age, sex,
11 and age \times sex interaction; 2) Model 2: variables from Model 1, plus race and ethnicity,
12 socioeconomic-related variables (highest education completed, household income, marital status,
13 employment status, and health insurance), and behavioral-related variables (smoking status,
14 pack-years smoked, and the Alcohol Use Disorders Identification Test-Consumption [AUDIT-C]
15 sum score); 3) Model 3: variables from Model 2 plus medical conditions except mental health
16 disorder diagnoses or disorders directly related to mental health or depression (major depressive
17 disorder, generalized anxiety disorder, attention deficit hyperactivity disorder, post-traumatic
18 stress disorder, bipolar disorder, alcohol abuse, drug abuse, and concussion or loss of
19 consciousness); 4) Model 4: variables from Model 3, plus symptoms and allergies, except those
20 symptoms that are directly related to mental health or depression (i.e., nervousness, mood
21 changes, fatigue, lack of energy, change in sleep patterns, change in appetite, and difficulty
22 concentrating); and 5) Model 5: variables from Model 4, plus all physical health metrics. Patient-
23 reported outcomes, including measures of anxiety, psychological and social well-being (e.g.,
24 General Anxiety Disorder-7, World Health Organization Disability Assessment Schedule, and
25 Satisfaction with Life), and self-reported medical conditions and symptoms related to mental
26 health or depression, have been reported⁶ and were excluded from these analyses to enable a
27 focus on physical and medical findings. In preliminary analyses, higher PHQ-9 score was
28 associated with female sex, age, and the age by sex interaction, confirming the well-established
29 relationship between depression, sex, and age,¹⁶ thereby informing our decision to include age
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and sex in all models. The key variables included in each covariate model can be found in

4
5
6 **eTable 1.**
7

8 Since LASSO regression techniques require an input dataset with complete data, missing
9 data were addressed using iterative regression-based imputation, where predictors were first
10 grouped by data type, then the groups were rank-ordered by the most missing to the least missing
11 data. The rank of the whole group was based on the amount of missingness of the majority
12 ($\geq 50\%$) of the fields within that group), and then at each imputation step, the grouped predictors
13 were used in a regression model to predict the missing data. The PHQ-9 score was imputed in the
14 last step along with other patient-reported outcome scores and, therefore, all 2502 participants
15 were included in the LASSO models.
16
17
18
19
20
21
22
23
24
25

26 To summarize key model findings adjusted for known demographic and socioeconomic-
27 related risk factors of PHQ-9, 4 groups were created based on the LASSO-predicted value using
28 Model 1 (age, sex, and age \times sex interaction) and Model 2 (race, ethnicity, socioeconomic-
29 related variables and health behaviors). For both models, “high risk” was defined as the top 50%
30 of the predicted value, while “low risk” was defined as the bottom 50% of the predicted value.
31
32 The 2 risk groups from each model were combined to create the following 4 groups: 1) high risk
33 Model 1 + high risk Model 2; 2) high risk Model 1 + low risk Model 2; 3) low risk Model 1 +
34 high risk Model 2; and 4) low risk Model 1 + low risk Model 2.
35
36
37
38
39
40
41
42
43
44
45
46

47 **Patient and public involvement statement**
48

49 From the beginning, BHS has used participant and community engagement methods. Participants
50 have been involved in feedback sessions, and return of results is a commitment of the project.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Community meetings have also been held to assure broad feedback on the goals and conduct of
5
6 the project.
7
8
9

10 RESULTS

11
12 The relationship between the PHQ-9 score and key demographic characteristics and vital signs is
13 shown in **Table 1**. Younger participants, women, people of color, and those of Hispanic ethnicity
14 had higher PHQ-9 scores. While no difference was observed in blood pressure or temperature,
15 higher PHQ-9 scores were found in participants with higher resting heart rates, larger body mass
16 index, greater waist circumference, and higher respiratory rates.
17
18
19
20
21
22
23

24 PHQ-9 scores as a function of medical history and symptoms are shown in **Table 2** and
25 **eTable 2**. As expected, participants with other chronic conditions, particularly gastroesophageal
26 reflux disease, anxiety, and asthma, had higher PHQ-9 scores. A history of diagnosed depression
27 was highly correlated with elevated PHQ-9. Various symptoms were evident in participants with
28 higher PHQ-9 scores, with musculoskeletal, mood, and anxiety symptoms proving particularly
29 prominent.
30
31
32
33
34
35
36
37

38 **Table 3** demonstrates the relationship between measures of physical performance and
39 PHQ-9; differences in 6-minute walk distance, handgrip strength, leg balance, chair stand, and
40 mean steps are particularly associated with higher PHQ-9.
41
42
43
44

45 The covariates resulting from each LASSO model are shown in **eTables 3–7**. All other
46 variables that are not presented in those tables are set to zero by the LASSO regression and
47 thereby excluded from the final adjustment models. Age remained a top predictor in all models.
48 Where health behaviors and measures of socioeconomic status were included (i.e., Models 2–5),
49 smoking status and employment, insurance, and marital status also remained in the models as
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 significant predictors. When medical conditions were added (i.e., Models 3–5), respiratory-
5
6 related conditions such as asthma remained in the models, and when symptoms were added (i.e.,
7
8 Models 4 and 5), tension, body image concerns, and memory change remained in the models as
9
10 top predictors. Model performance was similar between the training and test sets for each model
11
12 (Model 1: $R^2 = 0.032$ vs. 0.035 ; Model 2: $R^2 = 0.117$ vs. 0.112 ; Model 3: $R^2 = 0.167$ vs. 0.133 ;
13
14 Model 4: $R^2 = 0.247$ vs. 0.228 ; and Model 5: $R^2 = 0.270$ vs. 0.240 , respectively).

17 The interplay of higher PHQ-9 score predictors based on the LASSO regression
18
19 adjustment models is shown in **Figures 1–5**. Regardless of adjustment factors included in the
20
21 models, memory change, tension, shortness of breath, and indicators of musculoskeletal
22
23 symptoms are significantly related to higher PHQ-9 scores (Models 1–3). Further details of the
24
25 LASSO analysis are included in the supplementary materials (**eTables 8–12**). Tension, memory
26
27 change, and back pain consistently remain in the models after adjustment. When medical
28
29 conditions, symptoms, and allergies are taken into account, indicators of obesity (body mass
30
31 index, waist circumference) and lack of physical fitness are the most significant predictors of
32
33 PHQ-9 score. When physical performance is also factored into the adjustment, laboratory values
34
35
36
37
38 are only weakly associated with PHQ-9 scores.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **eFigures 1–5** present the distribution of PHQ-9 according to a sample of other health
5 conditions, such as asthma, sleep apnea and body image concerns, after adjustment for known
6 demographic and socioeconomic-related risk factors of PHQ-9. The inter-relationships are clear
7 across this spectrum of measures, emphasizing the importance of understanding all 3 dimensions
8 when designing interventions.
9
10
11
12
13
14
15
16

17 **DISCUSSION**

19 Our study reinforces previous observations regarding the relationship between PHQ-9 and
20 measures of chronic disease and poor physical performance in addition to the critical importance
21 of social factors and psychological distress, previously published.¹² While these findings are not
22 surprising, they highlight how PHQ-9 is an entree into a variety of individual- and population-
23 level concerns that demand more attention. Contextual awareness is critically important when the
24 PHQ-9 is used in clinical practice¹⁷ as recommended by the U.S. Preventive Services Task
25 Force¹⁸ for screening within a health system or for public health assessment.
26
27
28
29
30
31
32
33
34
35

36 This analysis cannot answer questions of cause and effect since it is cross-sectional. The
37 PHQ-9 and detailed serial measures of biological, clinical, behavioral, and social function will be
38 assessed in the ongoing BHS longitudinal study; the bi-directional relationship between the
39 PHQ-9 and these multiple measures will be particularly interesting, as few studies have collected
40 this amount of detail in a diverse population. This measurement depth of demographic, clinical,
41 biological, and behavioral issues offers an opportunity to better understand how different aspects
42 of distress track similarly or differently over time.
43
44
45
46
47
48
49
50
51

52 An important aspect of our examination is how the binary division of PHQ-9 into labels
53 of depression or “not depression” leaves significant content unattended. While the division of
54
55
56
57
58
59
60

1
2
3
4 PHQ-9 scores at 10 provides good discrimination with regard to a clinical diagnosis of Major
5
6 Depressive Disorder,^{6,9,10} the gradient between a score of 0 and 10 contains relevant information
7
8 about distress levels. Such a finding is not novel,¹⁹ but a reminder that singular focus on a binary
9
10 classification tends to obscure important information. For example, demographic data
11
12 demonstrate how females and younger participants had higher PHQ-9 scores, yet whether this
13
14 finding represents a different approach to revealing concerns or more significant distress is
15
16 unclear.
17
18

19
20 The higher scores associated with elevated heart rates, body mass index, and abdominal
21
22 girth were expected and consistent with previous literature. In general, PHQ-9 scores aligned
23
24 with musculoskeletal or central and peripheral nervous system disorders,^{20,21} but less with
25
26 cardiovascular disease, cancer, and other more organ-focused conditions. The previously widely-
27
28 reported association with obesity and diabetes was confirmed in our study.²²⁻²⁵ We found low
29
30 PHQ-9 scores in a small, but noticeable proportion of the population with a previous diagnosis of
31
32 depression, which could represent diagnostic errors, inaccurate reporting of medical history, or
33
34 recovery from a previous episode of depression.
35
36

37
38 The profound relationship between PHQ-9 score and a host of common symptoms²⁶⁻³⁰ is
39
40 also expected, but the continuous nature of the relationship with PHQ-9 score and the depth of
41
42 the relationships raise many issues that need further exploration. Significant predictors of PHQ-9
43
44 scores include a wide range of concerns encompassing neurological disease, musculoskeletal
45
46 disease,^{31,32} and psychological distress. A particularly notable finding is the progressive and
47
48 highly significant relationship between reported memory loss and PHQ-9 score. Among people
49
50 with PHQ-9 scores of 0, only 1.9% reported memory change, while among those with PHQ-9
51
52 scores >15, memory change was reported in 34%.
53
54
55
56
57
58
59
60

1
2
3
4 Finally, participants with higher PHQ-9 scores had impaired physical functioning, as
5
6 indicated by a host of measurements, including daily steps, 6-minute walk distance, ability to
7
8 balance on one leg, or propensity to exert a strong grip. Multiple previous studies have shown
9
10 that depression and physical functioning are inter-related³³⁻³⁸ and that interventions to increase
11
12 physical activity can improve depression status.^{39,40} Nevertheless, the overall picture of this study
13
14 highlights the need for multimodal intervention to enable people with social disadvantages and
15
16 physical comorbidities to improve physical and psychological function.
17
18
19
20
21

22 **Limitations**

23
24 This study has some limitations. First, the cross-sectional nature of the study limits our ability to
25
26 assess the time course of these findings; however, follow-up is currently accruing. The time
27
28 course of chronic disease and symptom progression in relation to the PHQ-9 will be of interest.
29
30 Second, people with significant depression are probably less likely to volunteer, thereby limiting
31
32 the breadth of depression observed in this study; BHS participants are volunteers from selected
33
34 sites who express willingness to share data. Third, the population is generally representative of
35
36 adult age, sex, race, and ethnicity, but it is not a fully representative sample of the population; the
37
38 differences between those who volunteer for digital technology studies and the general
39
40 population are well-known.⁴¹ Fourth, we acknowledge the high comorbidity of depression and
41
42 anxiety, which is a potential bias; psychological comorbidities are important contextual factors to
43
44 consider when assessing depression. We also lack detailed information on depression treatment,
45
46 which is a potentially modifying factor. Finally, even though the PHQ-9 is a validated screening
47
48 instrument, our study did not include psychiatric interviews.
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

PHQ-9 scores are related to multiple demographic, vital sign, and clinical measures that indicate poor physical status. BHS data provide a comprehensive picture of numerous interactive factors influencing PHQ-9 scores, thereby demonstrating how focusing on one chief complaint in hopes of improving depression status is likely futile, given that many common symptoms and physical limitations are profoundly integrated with depression status. The close association with symptoms often considered somatic raises a practical issue for clinical practice, and this is evident across the entire spectrum of PHQ-9 scores. When a high PHQ-9 score or other indicator of depression brings someone to the attention of a clinician, contextual awareness is critically important to provide an effective clinical intervention. When someone has significant neurological or musculoskeletal symptoms, assessment for depression should be a routine consideration. The complex associations across biological, clinical, behavioral, and social factors stress the need for holistic evaluation of depression for individuals, as well as patient populations.

ACKNOWLEDGMENTS

Baseline Health Study Team

American Society of Clinical Oncology, Alexandria, VA, USA: Richard L. Schilsky. **Duke University, School of Medicine, Durham, NC, USA:** Jennifer Allen, MaryAnn Anderson, Kevin Anstrom, Lucus Araujo, Kristine Arges, Kaveh Ardalán, Bridget Baldwin, Suresh Balu, Mustafa R. Bashir, Manju Bhapkar, Robert Bigelow, Tanya Black, Rosalia Blanco, Gerald Bloomfield, Durga Borkar, Leah Bouk, Ebony Boulware, Nikki Brugnoli, Erin Campbell, Paul Campbell, Larry Carin, Tammy Jo Cassella, Tina Cates, Ranee Chatterjee Montgomery, Victoria Christian, John Choong, Michael Cohen-Wolkowicz, Elizabeth Cook, Scott Cousins, Ashley Crawford, Nisha Datta, Melissa Daubert, James Davis, Jillian Dirkes, Isabelle Doan, Marie Dockery, P. Murali Doraiswamy, Pamela S. Douglas, Shelly Duckworth, Ashley Dunham, Gary Dunn, Ryan Ebersohl, Julie Eckstrand, Vivienne Fang, April Flora, Emily Ford, Lucia Foster, Elizabeth Fraulo, John French, Geoffrey S. Ginsburg, Cindy Green, Latoya Greene, Jeffrey Guptill, Donna Hamel, Jennifer Hamill, Chris Harrington, Rob Harrison, Lauren Hedges, Brooke Heidenfelder, Adrian F. Hernandez, Cindy Heydary, Tim Hicks, Lina Hight, Deborah Hopkins, Erich S. Huang, Grace Huh, Jillian Hurst, Kelly Inman, Gemini Janas, Glenn Jaffee, Janace Johnson, Tiffanie Keaton, Michel Khouri, Daniel King, Jennifer Korzekwinski, Lynne H. Koweeck, Anthony Kuo, Lydia Kwee, Dawn Landis, Rachele Lipsky, Desiree Lopez, Carolyn Lowry, Kelly Marcom, Keith Marsolo, Paige McAdams, Shannon McCall, Robert McGarrah, John McGugan, Dani Mee, Sabrena Mervin-Blake, Prithu Mettu, Mathias Meyer, Justin Meyers, Calire N. Miller, Rebecca Moen, Lawrence H. Muhlbaier, Michael Murphy, Ben Neely, L. Kristin Newby, Jayne Nicoldson, Hoang Nguyen, Maggie Nguyen, Lori O'Brien, Sumru Onal, Jeremey O'Quinn, David Page, Neha J. Pagidipati, Kishan Parikh, Sarah R. Palmer, Bray

1
2
3
4 Patrick-Lake, Brenda Pattison, Michael Pencina, Eric D. Peterson, Jon Piccini, Terry Poole, Tom
5
6 Povsic, Alicia Provencher, Dawn Rabineau, Annette Rich, Susan Rimmer, Fides Schwartz,
7
8 Angela Serafin, Nishant Shah, Svati Shah, Kelly Shields, Steven Shipes, Peter Shrader, Jon
9
10 Stiber, Lynn Sutton, Geeta Swamy, Betsy Thomas, Sandra Torres, Debara Tucci, Anthony
11
12 Twisdale, Brooke Walker, Susan A. Whitney, Robin Williamson, Lauren Wilverding, Charlene
13
14 A. Wong, Lisa Wruck. **Ellen Young Gemini Group, USA:** Jane Perlmutter. **Health**
15
16 **Collaboratory and Cancer 101, New York, NY, USA:** Sarah Krug. **Rare Dots, Inc., USA:** S.
17
18 Whitney Bowman-Zatzkin. **Society of Participatory Medicine, USA:** Sarah Krug. **Stanford**
19
20 **University, School of Medicine, Stanford, CA, USA:** Themistocles Assimes, Vikram Bajaj,
21
22 Maxwell Cheong, Millie Das, Manisha Desai, Alice C. Fan, Dominik Fleischmann, Sanjiv S.
23
24 Gambhir, Garry Gold, Francois Haddad, David Hong, Curtis Langlotz, Yaping J. Liao, Rong Lu,
25
26 Kenneth W. Mahaffey, David Maron, Rebecca McCue, Rajan Munshi, Fatima Rodriguez,
27
28 Sumana Shashidhar, George Sledge, Susie Spielman, Ryan Spitler, Sue Swope, Donna Williams.
29
30 **University of Florida, College of Medicine, Gainesville, FL, USA:** Carl J Pepine. **University**
31
32 **of Missouri, Children's Mercy Hospital, Kansas City, MO, USA:** John D Lantos. **University**
33
34 **of Texas, Dell Medical School, Austin, TX, USA:** Michael Pignone. **University of**
35
36 **Washington, Department of Biostatistics, Seattle, WA, USA:** Patrick Heagerty. **Vanderbilt**
37
38 **University, School of Medicine, Nashville, TN, USA:** Laura Beskow, Gordon Bernard. **Verily**
39
40 **Inc., South San Francisco, CA, USA:** Kelley Abad, Giulia Angi, Robert M. Califf, Lawrence
41
42 Deang, Joy Huynh, Manway Liu, Cherry Mao, Michael Magdaleno, William J. Marks, Jr.,
43
44 Jessica Mega, David Miller, Nicole Ong, Darshita Patel, Vanessa Ridaura, Scarlet Shore, Sarah
45
46 Short, Michelle Tran, Veronica Vu, Celeste Wong. **Harvard University, School of Medicine,**
47
48 **Boston, MA, USA:** Robert C. Green. **Google Inc., Mountain View, CA, USA:** John
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Hernandez. **California Health and Longevity Institute, Westlake Village, CA, USA:** Jolene
4
5
6 Benge, Gislia Negrete, Gelsey Sierra, Terry Schaack
7
8
9

10 **Sources of funding**

11
12 The Baseline Health Study and this analysis were funded by Verily Life Sciences, San Francisco,
13
14 CA.
15
16
17
18

19 **Conflict of interest disclosures**

20
21
22 **Califf:** Employee of Verily Life Sciences and Google Health; Board member for Cytokinetics,
23
24 United Medicines, and Clinetic.
25

26
27 **Wong:** Employee of Verily Life Sciences.
28

29
30 **Doraiswamy:** Consulting fees from Verily Life Sciences, Neuronix, Apollo Health, VitaKey,
31
32 Neuroglee, Transposon, Otsuka; Research grants from Avanir, Lilly, Avid, Salix; Holds stock in
33
34 Evidation Health, Advera Health Analytics, Transposon Therapeutics, Marvel Biome; Board
35
36 membership in Apollo; Coinventor on patents for diagnosis or treatment of neuropsychiatric
37
38 disorders.
39

40
41 **Hong:** Research funding from NIMH; Consulting for Little Otter.
42

43
44 **Miller:** Employee of and holds stock in Verily Life Sciences.
45

46
47
48
49 **Mega:** Employee of Verily Life Sciences.
50

51 **Author contributions**

52
53 **Califf:** Dr. Califf had full access to all of the data in the study and takes responsibility for the
54
55 integrity of the data and the accuracy of the data analysis. Dr. Califf contributed to the
56
57
58
59

1
2
3
4 conception and design of the study, the data analysis, the data interpretation, the manuscript
5
6 drafting, and the critical revision of the manuscript.
7

8 **Wong:** Dr. Wong contributed to the conception and design of the study, data interpretation, the
9
10 manuscript drafting, and the critical revision of the manuscript.
11

12 **Doraiswamy:** Dr. Doraiswamy contributed to the data interpretation, the manuscript drafting,
13
14 and the critical revision of the manuscript.
15

16 **Hong:** Dr. Hong contributed to the data interpretation, the manuscript drafting, and the critical
17
18 revision of the manuscript.
19

20 **Miller:** Dr. Miller contributed to the conception and design of the study, data interpretation, the
21
22 manuscript drafting, and the critical revision of the manuscript.
23

24 **Mega:** Dr. Mega contributed to the conception and design of the study, the supervision, data
25
26 acquisition, data interpretation, the manuscript drafting, and the critical revision of the
27
28 manuscript.
29
30
31
32

33 34 35 **Data Sharing Statement**

36
37
38 The Baseline Study data will be available to qualified researchers for exploratory analysis after
39
40 the data are adequately curated and initial planned primary manuscripts are written. Qualified
41
42 external researchers will be able to apply through applications reviewed by the Proposal Review
43
44 and Publications Committee and Scientific Executive Committee.
45
46
47
48

49 **Ethics Statement**

50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This study involves human participants and was approved by an Ethics Committee(s) or

5
6 Institutional Board(s):

7
8 Approved by: wcg IRB

9
10 Work order #: 1-1379515-1

11
12 IRB tracking #: 20170163

13
14 Approval expires: 02/27/2022

15
16 Continuing review frequency: annual
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789–1858.
2. Perry PJ. *The Interaction of Major Depression and Medical Illness*. Medscape; 2005. Available at: <https://www.medscape.org/viewarticle/517033>.
3. Kampling H, Baumeister H, Bengel J, et al. Prevention of depression in adults with long-term physical conditions, *Cochrane Database Syst Rev*. 2021;3(3):CD011246.
4. Zhdanova M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured U.S. patients with physical conditions. *J Manag Care Spec Pharm*. 2020;26(8):996–1007.
5. Rosenblat JD, Kurdyak P, Cosci F, et al. Depression in the medically ill. *Aust N Z J Psychiatry*. 2020;54(4):346–366.
6. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–613.
7. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. *J Gen Intern Med*. 2006;21(6):547–552.
8. Patel JS, Oh Y, Rand KL, et al. Measurement invariance of the patient health questionnaire-9 (PHQ-9) depression screener in U.S. adults across sex, race/ethnicity, and education level: NHANES 2005–2016. *Depress Anxiety*. 2019;36(9):813–823.

- 1
2
3
4 9. Levis B, Benedetti A, Thombs BD for the DEPRESSion Screening Data (DEPRESSD)
5
6 Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to
7
8 detect major depression: individual participant data meta-analysis. *BMJ*. 2019;365:1476.
9
- 10
11 10. Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 alone and in combination with the
12
13 PHQ-9 for screening to detect major depression: systematic review and meta-analysis.
14
15 *JAMA*. 2020;323(22):2290–2300.
16
- 17
18 11. Arges K, Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step towards a
19
20 broader mission to map human health. *NPJ Digit Med*. 2020;3:84.
21
- 22
23 12. Califf RM, Wong C, Doraiswamy PM, Hong DS, Miller DP, Mega JL; Baseline Study
24
25 Group. Importance of social determinants in screening for depression. *J Gen Intern Med*.
26
27 2021. doi: 10.1007/s11606-021-06957-5. [Online ahead of print].
28
- 29
30 13. Armitage P. Tests for linear trends in proportions and frequencies. *Biometrics*.
31
32 1955;11(3):375–386.
33
- 34
35 14. Liu L, Berger VW, Hershberger SL. Trend tests for counts and proportions. Wiley
36
37 *StatsRef: Statistics Reference Online*. 2014.
38
39 <https://doi.org/10.1002/9781118445112.stat06163>.
40
- 41
42 15. Mukaka MM. A guide to appropriate use of Correlation coefficient in medical research.
43
44 *Malawi Med J*. 2012;24(3):69–71.
45
- 46
47 16. CDC
48
49 17. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of
50
51 PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders*.
52
53 Patient Health Questionnaire. *JAMA*. 1999;282(18):1737–1744.
54
55
56
57
58
59
60

- 1
2
3
4 18. Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al.
5
6 Screening for depression in adults: US Preventive Services Task Force Recommendation
7
8 Statement. *JAMA*. 2016;315(4):380–387.
9
- 10
11 19. Thombs BD, Benedetti A, Kloda LA, et al. The diagnostic accuracy of the Patient Health
12
13 Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health
14
15 Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic
16
17 review and individual patient data meta-analyses. *Syst Rev*. 2014;3:124.
18
- 19
20 20. Hoshino E, Ohde S, Rahman M, Takahashi O, Fukui T, Deshpande GA. Variation in
21
22 somatic symptoms by patient health questionnaire-9 depression scores in a representative
23
24 Japanese sample. *BMC Public Health*. 2018;18(1):1406.
25
- 26
27 21. Leavens A, Patten SB, Hudson M, Baron M, Thombs BD; Canadian Scleroderma
28
29 Research Group. Influence of somatic symptoms on Patient Health Questionnaire-9
30
31 depression scores among patients with systemic sclerosis compared to a healthy general
32
33 population sample. *Arthritis Care Res (Hoboken)*. 2012;64(8):1195–1201.
34
- 35
36 22. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes:
37
38 time for an appraisal. *Lancet Diabetes Endocrinol*. 2015;3(6):450–460.
39
- 40
41 23. Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the
42
43 onset of depression: a systematic review and meta-analysis. *Diabetologia*.
44
45 2010;53(12):2480–2486.
46
- 47
48 24. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive
49
50 symptoms on adherence, function, and costs. *Arch Intern Med*. 2000;160(21):3278–3285.
51
52
53
54
55
56
57
58
59

- 1
2
3
4 25. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE.
5
6 Depression and poor glyceimic control: a meta-analytic review of the literature. *Diabetes*
7
8 *Care*. 2000;23(7):934–942.
9
- 10 26. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for
11
12 evaluating the severity of somatic symptoms. *Psychosom Med*. 2002;64(2):258–266.
13
14
- 15 27. Kocalevent RD, Hinz A, Brähler E. Standardization of a screening instrument (PHQ-15)
16
17 for somatization syndromes in the general population. *BMC Psychiatry*. 2013;13:91.
18
19
- 20 28. Löwe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression,
21
22 anxiety and somatization in primary care: syndrome overlap and functional impairment.
23
24 *Gen Hosp Psychiatry*. 2008;30(3):191–199.
25
- 26 29. Ziebold C, Goldberg DP, Reed GM, et al. Dimensional analysis of depressive, anxious
27
28 and somatic symptoms presented by primary care patients and their relationship with
29
30 ICD-11 PHC proposed diagnoses. *Psychol Med*. 2019;49(5):764–771.
31
32
- 33 30. Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire
34
35 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *Gen Hosp*
36
37 *Psychiatry*. 2010;32(4):345–359.
38
39
- 40 31. Hartvigsen J, Christensen K. Pain in the back and neck are with us until the end: a
41
42 nationwide interview-based survey of Danish 100-year-olds. *Spine (Phila Pa 1976)*.
43
44 2008;33(8):909–913.
45
46
- 47 32. Reichborn-Kjennerud T, Stoltenberg C, Tambs K, et al. Back-neck pain and symptoms of
48
49 anxiety and depression: a population-based twin study. *Psychol Med*. 2002;32(6):1009–
50
51 1020.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 33. Zhang J, Yen ST. Physical activity, gender difference, and depressive symptoms. *Health*
5 *Serv Res*. 2015 Oct;50(5):1550–173.
6
7
8 34. Farmer ME, Locke BZ, Mościcki EK, Dannenberg AL, Larson DB, Radloff LS. Physical
9 activity and depressive symptoms: the NHANES I Epidemiologic Follow-up Study. *Am J*
10 *Epidemiol*. 1988;128(6):1340–1351.
11
12
13
14
15 35. Helgadóttir B, Forsell Y, Ekblom Ö. Physical activity patterns of people affected by
16 depressive and anxiety disorders as measured by accelerometers: a cross-sectional study.
17 *PLoS One*. 2015;10(1):e0115894.
18
19
20
21
22 36. Sieverdes JC, Ray BM, Sui X, et al. Association between leisure time physical activity
23 and depressive symptoms in men. *Med Sci Sports Exerc*. 2012;44(2):260–265.
24
25
26
27 37. Sun GZ, Ye N, Wu SJ, Zhou Y, Sun YX. 10-year ASCVD risk is positively correlated
28 with depressive symptoms in a large general population. *BMC Psychiatry*.
29 2019;19(1):125.
30
31
32
33 38. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and
34 management of depression in patients with cardiovascular disease: JACC State-of-the-Art
35 Review. *J Am Coll Cardiol*. 2019;73(14):1827–1845.
36
37
38
39
40 39. Wegner M, Helmich I, Machado S, Nardi AE, Arias-Carrion O, Budde H. Effects of
41 exercise on anxiety and depression disorders: review of meta- analyses and
42 neurobiological mechanisms. *CNS Neurol Disord Drug Targets*. 2014;13(6):1002–1014.
43
44
45
46
47 40. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in
48 the treatment of major depressive disorder. *Psychosomatic Med*. 2007;69(7):587–596.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 41. Fareed N, Swoboda CM, Jonnalagadda P, Huerta TR. Persistent digital divide in health-
5 related internet use among cancer survivors: findings from the Health Information
6 National Trends Survey, 2003–2018. J Cancer Surviv. 2021;15(1):87–98.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics: PHQ-9 score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
Age, median (25th, 75th)*	53.6 (36.7, 66.1)	51.7 (37.0, 66.5)	47.6 (32.7, 60.7)	42.8 (31.2, 55.1)	42.4 (32.1, 54.2)
Female sex*	227 (46.9)	622 (57.3)	299 (57.7)	108 (58.7)	62 (66.7)
Race					
Black	80 (16.5)	153 (14.1)	82 (15.8)	31 (16.8)	19 (20.4)
White	294 (60.7)	731 (67.3)	323 (62.4)	110 (59.8)	57 (61.3)
Asian†	64 (13.2)	113 (10.4)	47 (9.1)	15 (8.2)	5 (5.4)
NHOPI	7 (1.4)	11 (1)	7 (1.4)	2 (1.1)	0 (0.0)
American Indian or Alaska Native	4 (0.8)	8 (0.7)	11 (2.1)	3 (1.6)	1 (1.1)
Other†	35 (7.2)	70 (6.4)	48 (9.3)	23 (12.5)	11 (11.8)
Ethnicity					
Hispanic	54 (11.2)	108 (9.9)	69 (13.3)	26 (14.1)	13 (14.0)
Site					
Los Angeles	94 (19.4)	194 (17.9)	111 (21.4)	35 (19)	21 (22.6)
Durham	99 (20.5)	196 (18.0)	102 (19.7)	40 (21.7)	25 (26.9)
Kannapolis	100 (20.7)	226 (20.8)	105 (20.3)	41 (22.3)	28 (30.1)
Palo Alto †	191 (39.5)	470 (43.3)	200 (38.6)	68 (37.0)	19 (20.4)

Systolic BP, median (25th, 75th), mm Hg	123.0 (112.5, 133.1)	122.0 (112.0, 132.5)	123.0 (112.5, 133.5)	119.5 (109.9, 132.0)	122.5 (115.5, 130.5)
Diastolic BP, median (25th, 75th), mm Hg	75.5 (69.0, 82.0)	75.0 (68.0, 82.0)	76.0 (70.0, 83.5)	74.0 (68.9, 81.1)	77.5 (71.5, 84.0)
Body mass index, median (25th, 75th), kg/m ² *	26.5 (23.7, 29.9)	26.1 (22.9, 31.0)	28.0 (24.5, 33.2)	29.1 (25.1, 34.7)	30.0 (25.4, 38.8)
Waist circumference, median (25th, 75th), cm*	91.0 (81.0, 100.1)	88.9 (78.7, 101.6)	93.0 (81.3, 105.4)	96.5 (82.0, 111.8)	96.5 (81.6, 112.5)
Heart rate, median (25th, 75th), beats/min*	65.0 (58.0, 72.0)	66.0 (59.0, 73.0)	67.0 (60.0, 77.0)	70.0 (61.8, 80.0)	75.0 (65.0, 82.0)
Respiratory rate, median (25th, 75th), breaths/min*	16.0 (14.0, 16.0)	16.0 (14.0, 16.0)	16.0 (14.0, 17.0)	16.0 (14.0, 18.0)	16.0 (16.0, 18.0)
Oxygen saturation, median (25th, 75th), %†	99.0 (98.0, 100.0)	99.0 (98.0, 100.0)	99.0 (98.0, 100.0)	99.0 (97.0, 100.0)	98.0 (97.0, 100.0)
<p>Data shown are no. (%), unless otherwise indicated. BP, blood pressure; NHOPI, Native Hawaiians and other Pacific Islanders; PHQ-9, Patient Health Questionnaire-9. P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate. *P-value for trend <0.0001. †P-value for trend <0.01</p>					

Table 2. Medical history: PHQ-9 score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
Alcohol use disorder*	1 (0.2)	20 (1.8)	12 (2.3)	7 (3.8)	6 (6.5)
Fibromyalgia*	2 (0.4)	10 (0.9)	11 (2.1)	7 (3.8)	6 (6.5)
Bipolar disorder*	3 (0.6)	9 (0.8)	12 (2.3)	9 (4.9)	8 (8.6)
PTSD*	8 (1.7)	14 (1.3)	15 (2.9)	21 (11.4)	9 (9.7)
COPD with emphysema*	5 (1.0)	19 (1.7)	22 (4.2)	12 (6.5)	10 (10.8)
ADHD*	15 (3.1)	50 (4.6)	33 (6.4)	25 (13.6)	11 (11.8)
Asthma*	46 (9.5)	157 (14.5)	79 (15.3)	39 (21.2)	19 (20.4)
Migraine*	29 (6.0)	134 (12.3)	77 (14.9)	31 (16.8)	19 (20.4)
GERD*	64 (13.2)	176 (16.2)	106 (20.5)	40 (21.7)	23 (24.7)
Anxiety*	13 (2.7)	98 (9.0)	109 (21.0)	55 (29.9)	34 (36.6)
Depression*	16 (3.3)	93 (8.6)	110 (21.2)	63 (34.2)	55 (59.1)
Itching skin*	19 (3.9)	81 (7.5)	50 (9.7)	30 (16.3)	10 (10.8)
Sinus pain*	18 (3.7)	77 (7.1)	58 (11.2)	21 (11.4)	10 (10.8)
Urgency*	13 (2.7)	69 (6.4)	46 (8.9)	23 (12.5)	10 (10.8)
Excessive belching or passing of gas*	24 (5.0)	84 (7.7)	54 (10.4)	29 (15.8)	13 (14.0)
Dryness*	35 (7.2)	113 (10.4)	68 (13.1)	39 (21.2)	14 (15.1)
Heartburn*	27 (5.6)	94 (8.7)	70 (13.5)	42 (22.8)	15 (16.1)
Dry mouth*	27 (5.6)	84 (7.7)	64 (12.4)	28 (15.2)	16 (17.2)
Constipation*	22 (4.5)	98 (9.0)	64 (12.4)	48 (26.1)	17 (18.3)
Numbness or loss of sensation*	17 (3.5)	54 (5.0)	38 (7.3)	19 (10.3)	17 (18.3)
Cramping*	14 (2.9)	62 (5.7)	45 (8.7)	18 (9.8)	18 (19.4)
Frequency of urination*	33 (6.8)	90 (8.3)	73 (14.1)	34 (18.5)	19 (20.4)
Swelling in calves, legs, or feet*	15 (3.1)	62 (5.7)	49 (9.5)	31 (16.8)	20 (21.5)
Coughing up sputum*	12 (2.5)	62 (5.7)	56 (10.8)	27 (14.7)	20 (21.5)
Pain or stiffness in neck*	32 (6.6)	128 (11.8)	72 (13.9)	49 (26.6)	22 (23.7)
Diarrhea*	24 (5.0)	99 (9.1)	70 (13.5)	31 (16.8)	22 (23.7)
Night sweats*	22 (4.5)	88 (8.1)	65 (12.5)	25 (13.6)	22 (23.7)
Lightheadedness*	11 (2.3)	62 (5.7)	53 (10.2)	37 (20.1)	22 (23.7)

Cough *	36 (7.4)	98 (9.0)	83 (16.0)	41 (22.3)	23 (24.7)
Tingling or numbness in extremities *	35 (7.2)	101 (9.3)	74 (14.3)	36 (19.6)	23 (24.7)
Leg cramps *	31 (6.4)	103 (9.5)	55 (10.6)	31 (16.8)	23 (24.7)
Shortness of breath with exercise *	11 (2.3)	59 (5.4)	68 (13.1)	37 (20.1)	23 (24.7)
Joint pain or swelling*	42 (8.7)	140 (12.9)	81 (15.6)	45 (24.5)	25 (26.9)
Sleeping pattern changes *	21 (4.3)	126 (11.6)	78 (15.1)	47 (25.5)	25 (26.9)
Tingling or pins and needles *	30 (6.2)	91 (8.4)	75 (14.5)	36 (19.6)	25 (26.9)
Appetite changes *	9 (1.9)	36 (3.3)	35 (6.8)	25 (13.6)	26 (28.0)
Heat or cold intolerance *	17 (3.5)	85 (7.8)	65 (12.5)	36 (19.6)	27 (29.0)
Shortness of breath *	8 (1.7)	51 (4.7)	57 (11.0)	34 (18.5)	27 (29.0)
Bloating *	26 (5.4)	104 (9.6)	61 (11.8)	41 (22.3)	29 (31.2)
Body image concerns *	9 (1.9)	40 (3.7)	46 (8.9)	33 (17.9)	29 (31.2)
Nasal stuffiness *	70 (14.5)	218 (20.1)	141 (27.2)	53 (28.8)	30 (32.3)
Urination at night *	69 (14.3)	172 (15.8)	105 (20.3)	43 (23.4)	30 (32.3)
Muscle or joint pain*	71 (14.7)	225 (20.7)	142 (27.4)	61 (33.2)	31 (33.3)
Memory change*	9 (1.9)	52 (4.8)	55 (10.6)	41 (22.3)	32 (34.4)
Headache*	28 (5.8)	151 (13.9)	104 (20.1)	44 (23.9)	38 (40.9)
Fatigue*	10 (2.1)	129 (11.9)	113 (21.8)	65 (35.3)	38 (40.9)
Stiffness*	76 (15.7)	267 (24.6)	121 (23.4)	63 (34.2)	39 (41.9)
Backache*	43 (8.9)	183 (16.9)	148 (28.6)	63 (34.2)	39 (41.9)
Nervousness*	4 (0.8)	46 (4.2)	51 (9.8)	39 (21.2)	43 (46.2)
Mood change*	6 (1.2)	36 (3.3)	60 (11.6)	42 (22.8)	44 (47.3)
Difficulty concentrating*	8 (1.7)	58 (5.3)	74 (14.3)	54 (29.3)	50 (53.8)
Neck or low back pain*	73 (15.1)	264 (24.3)	185 (35.7)	73 (39.7)	51 (54.8)
Tension*	10 (2.1)	84 (7.7)	86 (16.6)	44 (23.9)	51 (54.8)
Lack of energy*	6 (1.2)	92 (8.5)	115 (22.2)	74 (40.2)	53 (57.0)

Data presented as no. (%).

ADHD, attention deficit hyperactivity disorder; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; PHQ-9, Patient Health Questionnaire-9; PTSD, post-traumatic stress disorder.

P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate.

*P-value for trend <0.0001.

Table 3. Physical Functioning: PHQ-9 Score

	PHQ-9 0 (N=484)	PHQ-9 1-4 (N=1086)	PHQ-9 5-9 (N=518)	PHQ-9 10-14 (N=184)	PHQ-9 15+ (N=93)
6-minute walk*	485.5 (444.0, 543.2)	480.0 (431.7, 530.3)	465.0 (422.0, 517.6)	460.1 (403.8, 511.9)	443.0 (391.2, 492.4)
30-second chair stand*	15.0 (12.0, 18.0)	14.0 (12.0, 17.0)	13.0 (11.0, 16.0)	13.0 (10.0, 16.0)	12.0 (10.0, 15.0)
Mean leg balance time†	60.0 (23.5, 60.0)	55.0 (21.4, 60.0)	50.5 (14.0, 60.0)	49.5 (11.0, 60.0)	44.0 (12.5, 60.0)
10-meter walk speed*	2.0 (1.8, 2.2)	2.0 (1.8, 2.2)	2.0 (1.6, 2.1)	1.8 (1.5, 2.0)	1.8 (1.5, 2.0)
Handgrip†	35.8 (27.8, 44.4)	32.5 (26.3, 42.5)	32.3 (26.4, 42.8)	33.4 (25.6, 40.7)	30.0 (22.0, 39.7)
Sit-rise score	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	8.0 (6.0, 9.0)	7.5 (5.0, 9.0)
EF at rest, %	59.0 (55.8, 60.5)	58.8 (55.9, 60.5)	59.2 (56.1, 60.5)	59.2 (56.0, 61.4)	58.9 (56.0, 60.9)
Mean steps in first 30 days*	8398.0 (6560.6, 10709.6)	8172.2 (6220.6, 10335.7)	7666.7 (5128.2, 9862.5)	7008.4 (4673.5, 9821.8)	6498.1 (4684.1, 9044.5)
Coronary calcium score†	0.0 (0.0, 33.9)	0.0 (0.0, 42.6)	0.0 (0.0, 8.8)	0.0 (0.0, 7.1)	0.0 (0.0, 1.9)
FEV1/FVC	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)
ABI †	1.1 (1.1, 1.2)	1.1 (1.1, 1.2)	1.1 (1.1, 1.2)	1.1 (1.0, 1.2)	1.1 (1.0, 1.2)
<p>Data presented as median (25th, 75th percentile). ABI, ankle brachial index; EF, ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PHQ-9, Patient Health Questionnaire. P-values for trend were calculated with the use of Spearman Correlation or Cochran-Armitage tests, where appropriate. *P-value for trend <0.01. †P-value for trend <0.001</p>					

FIGURE LEGENDS

Figure 1. Top 30 Factors Associated with PHQ-9 Score Adjusted by Age, Sex, and Age by Sex Interaction

LASSO regression model 1 comprised age, sex, and age by sex interaction. The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables.

BMI, body mass index; LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9; WBC, white blood cell

Figure 2. Top 30 Factors Associated with PHQ-9 Score Adjusted by Age, Sex, Age by Sex Interaction, Race, Ethnicity, Socioeconomic Status and Health Behaviors

LASSO regression model 2 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status and health behaviors. The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables.

BMI, body mass index; LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9

Figure 3. Top 30 Factors Associated with PHQ-9 Score Adjusted by Age, Sex, Age by Sex Interaction, Race, Ethnicity, Socioeconomic Status, Health Behaviors, and Medical Conditions

LASSO regression model 3 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, and medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression). The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables.

1
2
3
4 BMI, body mass index; LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient
5
6 Health Questionnaire-9
7
8
9

10 **Figure 4. Top 30 Factors Associated with PHQ-9 Score Adjusted by Age, Sex, Age by Sex**
11 **Interaction, Race, Ethnicity, Socioeconomic Status, Health Behaviors, Medical Conditions,**
12 **Symptoms, and Allergies**
13
14

15
16 LASSO regression model 4 comprised age, sex, age by sex interaction, race, ethnicity,
17
18 socioeconomic status, health behaviors, medical conditions (except mental health disorder
19
20 diagnoses or disorders directly related to mental health or depression), symptoms (except those
21
22 that are directly related to mental health or depression), and allergies. The LASSO-predicted
23
24 value was used to estimate a covariate-adjusted effect for all other candidate variables.
25
26

27
28 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
29
30 HbA1c, hemoglobin A1c; LASSO, least absolute shrinkage and selection operator; MCH, mean
31
32 corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PHQ-9, Patient
33
34 Health Questionnaire-9; RBC, red blood cell; WBC, white blood cell
35
36
37
38
39


40 **Figure 5. Top 30 Factors Associated with PHQ-9 Score Adjusted by Age, Sex, Age by Sex**
41 **Interaction, Race, Ethnicity, Socioeconomic Status, Health Behaviors, Medical Conditions,**
42 **Symptoms, Allergies, and Physical Function**
43
44

45
46 LASSO regression model 5 comprised age, sex, age by sex interaction, race, ethnicity,
47
48 socioeconomic status, health behaviors, medical conditions (except mental health disorder
49
50 diagnoses or disorders directly related to mental health or depression), symptoms (except those
51
52 that are directly related to mental health or depression), allergies, and physical function. The
53
54
55
56
57
58
59


1
2
3
4 LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate
5
6 variables.

7
8 ALT, alanine aminotransferase; AST, aspartate aminotransferase; GFR, glomerular filtration
9
10 rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LASSO, least absolute shrinkage
11
12 and selection operator; LDL, low density lipoprotein; MCH, mean corpuscular hemoglobin;
13
14 MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MDRD,
15
16 modification of diet in renal disease; MPV, mean platelet volume; pH, potential hydrogen; PHQ-
17
18 9, Patient Health Questionnaire-9; RBC, red blood cell; TSH, thyroid-stimulating hormone;
19
20
21
22 WBC, white blood cell
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




535x336mm (177 x 177 DPI)




535x336mm (177 x 177 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




535x336mm (177 x 177 DPI)



578x336mm (177 x 177 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



450x336mm (177 x 177 DPI)

SUPPLEMENTAL MATERIAL

1		
2		
3		
4		
5		
6	eTable 1. Key Variables Included in Each LASSO Covariate Model	2
7	eTable 2. Additional Medical History: PHQ-9 Scores	3
8	eTable 3. Estimates of the Non-Zero Coefficients from LASSO Model 1	5
9	eTable 4. Estimates of the Non-Zero Coefficients from LASSO Model 2	6
10	eTable 5. Estimates of the Non-Zero Coefficients from LASSO Model 3	7
11	eTable 6. Estimates of the Non-Zero Coefficients from LASSO Model 4	9
12	eTable 7. Estimates of the Non-Zero Coefficients from LASSO Model 5	11
13	eTable 8. LASSO Regression Results: Model 1	13
14	eTable 9. LASSO Regression Results: Model 2	20
15	eTable 10. LASSO Regression Results: Model 3	26
16	eTable 11. LASSO Regression Results: Model 4	31
17	eTable 12. LASSO Regression Results: Model 5	34
18	eFigure 1. Distribution of PHQ-9 Score across Risk Groups by Asthma	36
19	eFigure 2. Distribution of PHQ-9 Score across Risk Groups by Backache	37
20	eFigure 3. Distribution of PHQ-9 Score across Risk Groups by Memory Change	38
21	eFigure 4. Distribution of PHQ-9 Score across Risk Groups by Body Image Concerns	39
22	eFigure 5. Distribution of PHQ-9 Score across Risk Groups by Sleep Apnea	40
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

eTable 1. Key Variables Included in Each LASSO Covariate Model

Variables	Model 1	Model 2	Model 3	Model 4	Model 5
Age, sex and age x sex interaction	✓	✓	✓	✓	✓
Race and ethnicity		✓	✓	✓	✓
Socioeconomic-related variables		✓	✓	✓	✓
Behavioral-related behaviors		✓	✓	✓	✓
Medical conditions <i>not</i> related to mental health / depression			✓	✓	✓
Symptoms and allergies <i>not</i> related to mental health / depression				✓	✓
Physical health metrics					✓
Standard labs					

eTable 2. Additional Medical History: PHQ-9 Scores

	0 (N=484)	1–4 (N=1086)	5–9 (N=518)	10–14 (N=184)	15+ (N=93)
Nonmelanoma skin cancer	12 (2.5)	42 (3.9)	18 (3.5)	3 (1.6)	0 (0.0)*
Osteoporosis	11 (2.3)	47 (4.3)	17 (3.3)	3 (1.6)	0 (0.0)*
Benign prostatic hyperplasia	22 (4.5)	44 (4.1)	17 (3.3)	3 (1.6)	0 (0.0)*
Melanoma skin cancer	11 (2.3)	23 (2.1)	5 (1.0)	0 (0.0)	0 (0.0)*
Prostate cancer	12 (2.5)	17 (1.6)	6 (1.2)	1 (0.5)	0 (0.0)*
Diabetes type 1	3 (0.6)	12 (1.1)	4 (0.8)	3 (1.6)	0 (0.0)
Macular degeneration	2 (0.4)	20 (1.8)	4 (0.8)	4 (2.2)	0 (0.0)
TIA	7 (1.4)	9 (0.8)	3 (0.6)	3 (1.6)	0 (0.0)
Hepatitis B	6 (1.2)	10 (0.9)	4 (0.8)	3 (1.6)	0 (0.0)
Coronary artery disease	11 (2.3)	44 (4.1)	13 (2.5)	6 (3.3)	1 (1.1)
Hashimoto's disease	8 (1.7)	22 (2.0)	11 (2.1)	3 (1.6)	1 (1.1)
Goiter	7 (1.4)	12 (1.1)	3 (0.6)	0 (0.0)	1 (1.1)
Hemorrhoids	11 (2.3)	44 (4.1)	18 (3.5)	4 (2.2)	1 (1.1)
Hypothyroidism	42 (8.7)	93 (8.6)	40 (7.7)	9 (4.9)	2 (2.2)
Glaucoma	14 (2.9)	29 (2.7)	10 (1.9)	6 (3.3)	2 (2.2)
Psoriasis	10 (2.1)	16 (1.5)	11 (2.1)	8 (4.3)	2 (2.2)
Peptic ulcer	5 (1.0)	22 (2.0)	13 (2.5)	4 (2.2)	2 (2.2)
Diverticulosis	8 (1.7)	29 (2.7)	10 (1.9)	5 (2.7)	2 (2.2)
Peripheral vascular disorder	1 (0.2)	15 (1.4)	8 (1.5)	2 (1.1)	2 (2.2)
Atrial fibrillation	4 (0.8)	17 (1.6)	1 (0.2)	1 (0.5)	2 (2.2)
Colon polyps	53 (11.0)	113 (10.4)	52 (10.0)	12 (6.5)	3 (3.2)
Arrhythmia	20 (4.1)	69 (6.4)	27 (5.2)	8 (4.3)	3 (3.2)
Tinnitus	31 (6.4)	52 (4.8)	35 (6.8)	6 (3.3)	3 (3.2)
Hearing Loss	29 (6.0)	75 (6.9)	26 (5.0)	12 (6.5)	3 (3.2)
Gout	14 (2.9)	29 (2.7)	14 (2.7)	5 (2.7)	3 (3.2)
Diverticulitis	3 (0.6)	20 (1.8)	17 (3.3)	3 (1.6)	3 (3.2)
Headaches	6 (1.2)	18 (1.7)	13 (2.5)	3 (1.6)	3 (3.2)
Epilepsy	5 (1.0)	19 (1.7)	12 (2.3)	5 (2.7)	3 (3.2)
Breast cancer	8 (1.7)	20 (1.8)	9 (1.7)	1 (0.5)	3 (3.2)
Myocardial infarction	6 (1.2)	19 (1.7)	11 (2.1)	1 (0.5)	3 (3.2)
Osteopenia	22 (4.5)	62 (5.7)	22 (4.2)	1 (0.5)	3 (3.2)
Stroke	5 (1.0)	12 (1.1)	9 (1.7)	1 (0.5)	3 (3.2)
Drug abuse*	5 (1.0)	14 (1.3)	5 (1.0)	13 (7.1)	4 (4.3)
Pulmonary embolism	4 (0.8)	17 (1.6)	7 (1.4)	3 (1.6)	4 (4.3)
Nonalcoholic fatty liver disease	5 (1.0)	17 (1.6)	16 (3.1)	3 (1.6)	4 (4.3)
Hepatitis C†	5 (1.0)	8 (0.7)	3 (0.6)	8 (4.3)	4 (4.3)
Cataracts	61 (12.6)	167 (15.4)	63 (12.2)	16 (8.7)	5 (5.4)
Kidney or bladder stones	36 (7.4)	66 (6.1)	18 (3.5)	13 (7.1)	5 (5.4)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Concussions	19 (3.9)	62 (5.7)	35 (6.8)	13 (7.1)	5 (5.4)
Rheumatoid arthritis†	4 (0.8)	13 (1.2)	12 (2.3)	4 (2.2)	6 (6.5)
Gallbladder disorder†	18 (3.7)	57 (5.2)	32 (6.2)	14 (7.6)	8 (8.6)
Hypercholesterolemia	68 (14.0)	127 (11.7)	70 (13.5)	19 (10.3)	9 (9.7)
Irritable bowel disorder†	9 (1.9)	60 (5.5)	34 (6.6)	7 (3.8)	10 (10.8)
Sleep apnea	38 (7.9)	101 (9.3)	63 (12.2)	19 (10.3)	11 (11.8)
Diabetes type 2†	45 (9.3)	109 (10.0)	62 (12.0)	32 (17.4)	14 (15.1)
Pneumonia	30 (6.2)	85 (7.8)	40 (7.7)	12 (6.5)	15 (16.1)
Osteoarthritis	76 (15.7)	216 (19.9)	118 (22.8)	33 (17.9)	17 (18.3)
Hypertension	122 (25.2)	297 (27.3)	144 (27.8)	51 (27.7)	26 (28.0)
Hay fever	26 (5.4)	78 (7.2)	36 (6.9)	19 (10.3)	3 (3.2)
Discharge†	19 (3.9)	64 (5.9)	44 (8.5)	18 (9.8)	8 (8.6)
Hemorrhoids†	22 (4.5)	69 (6.4)	40 (7.7)	17 (9.2)	9 (9.7)
Ear ringing†	38 (7.9)	101 (9.3)	59 (11.4)	23 (12.5)	13 (14.0)
Easy bruising or bleeding†	39 (8.1)	130 (12.0)	68 (13.1)	22 (12.0)	18 (19.4)
Runny nose†	70 (14.5)	210 (19.3)	116 (22.4)	44 (23.9)	20 (21.5)
Floater†	55 (11.4)	160 (14.7)	81 (15.6)	28 (15.2)	21 (22.6)

Data shown are no. (%), unless otherwise indicated.

P-values for trend were calculated with the use of Spearman Correlation or Cochrane-Armitage tests, where appropriate.

*P-value for trend <0.0001.

†P-value for trend <0.01.

eTable 3. Estimates of the Non-Zero Coefficients from LASSO Model 1

Variable	Estimate
Age	-0.152
Age x sex	0.063

LASSO regression model 1 comprised age, sex, and age by sex interaction. Variables with zero estimates are not shown.

For peer review only

eTable 4. Estimates of the Non-Zero Coefficients from LASSO Model 2

Variable	Estimate
Age	-0.167
Current smoker	0.103
Not employed	0.096
Black race	-0.076
Age x sex	0.074
Former smoker	0.061
Number of pack-years smoked	0.058
Income < \$25,000	0.057
Asian race	-0.042
Uninsured	0.032
Married	-0.025
AUDIT-C score	-0.012
High school or less education	0.009
Other race	0.005
Hispanic ethnicity	0.003

LASSO regression model 2 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status and health behaviors.

Variables with zero estimates are not shown.

AUDIT-C, Alcohol Use Disorders Identification Test-Concise; LASSO, least absolute shrinkage and selection operator.

eTable 5. Estimates of the Non-Zero Coefficients from LASSO Model 3

Variable	Estimate
Age	-0.194
Current smoker	0.106
Not employed	0.065
Former smoker	0.054
Uninsured	0.049
COPD with emphysema	0.048
Asthma	0.048
Sleep apnea	0.048
Fibromyalgia	0.038
Married	-0.037
GERD	0.036
Age x sex	0.035
Kidney or bladder stones	-0.032
Osteoarthritis	0.03
Asian race	-0.029
Hypertension	0.028
Epilepsy	0.027
Irritable bowel disorder	0.025
Diverticulitis	0.024
Pulmonary embolism	0.023
Migraines	0.023
Black race	-0.02
Chronic headaches	0.017
Hepatitis C	0.017
Income < \$25,000	0.016
Diabetes type 2	0.015
Cataracts	0.011
Osteoporosis	-0.011
Goiter	-0.011
Rheumatoid arthritis	0.01
Psoriasis	0.01
Nonmelanoma skin cancer	0.009
Number of pack-years smoked	0.009
Hypothyroidism	-0.009
Arrhythmia	0.008
Glaucoma	0.008
Female	0.006
Nonalcoholic fatty liver disease	0.006
Prostate cancer	-0.003

Hypercholesterolemia

0.002

LASSO regression model 3 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, and medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression). Variables with zero estimates are not shown.

COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; LASSO, least absolute shrinkage and selection operator.

For peer review only

eTable 6. Estimates of the Non-Zero Coefficients from LASSO Model 4

Variable	Estimate
Age	-0.14
Tension	0.095
Body image concerns	0.085
Current smoker	0.071
Not employed	0.06
Memory change	0.059
Uninsured	0.042
Asthma	0.041
Shortness of breath	0.039
Backache	0.037
Sleep apnea	0.037
Former smoker	0.035
Lightheadedness	0.034
Kidney or bladder stones	-0.026
Married	-0.025
Neck or low back pain	0.022
Black race	-0.021
Coughing up sputum	0.019
Osteoarthritis	0.019
Headache	0.017
Food allergies	0.016
Diverticulitis	0.015
Cataracts	0.014
Constipation	0.014
Asian race	-0.014
Shortness of breath with exercise	0.012
Hypothyroidism	-0.012
Fibromyalgia	0.011
Epilepsy	0.011
GERD	0.011
Migraines	0.011
Joint pain swelling	0.009
COPD with emphysema	0.009
Heat or cold intolerance	0.009
Pulmonary embolism	0.009
Bloating	0.009
Diabetes type 2	0.007
Swelling in calves or feet	0.007
Irritable bowel disorder	0.007

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Nasal stuffiness	0.007
Pneumonia	0.004
Nonmelanoma skin cancer	0.004
Hypertension	0.004
Psoriasis	0.002
Cough	0.002
Chronic headaches	0.002
Hepatitis C	0.001
Prostate cancer	-0.001

LASSO regression model 4 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression), symptoms (except those that are directly related to mental health or depression), and allergies. Variables with zero estimates are not shown. COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; LASSO, least absolute shrinkage and selection operator.

eTable 7. Estimates of the Non-Zero Coefficients from LASSO Model 5

Variable	Estimate
Age	-0.148
Tension	0.094
Body image concerns	0.077
Current smoker	0.068
Memory change	0.062
Not employed	0.051
Waist circumference	0.049
Black race	-0.042
Asthma	0.038
6-minute walk	-0.037
Uninsured	0.036
Backache	0.035
Days watch worn 10+ hours in first 30 days	-0.032
Lightheadedness	0.031
BMI	0.031
Former smoker	0.031
Shortness of breath	0.029
Kidney or bladder stones	-0.026
Sleep apnea	0.025
Neck or low back pain	0.022
Coughing up sputum	0.021
Cataracts	0.02
Mean daily steps in first 30 days	-0.019
Constipation	0.018
Married	-0.017
Ejection fraction at rest	0.016
Food allergies	0.016
Osteoarthritis	0.015
Heart rate	0.015
Hypothyroidism	-0.015
Coronary calcium score	-0.015
Heat or cold intolerance	0.013
Headache	0.013
Irritable bowel disorder	0.013
Diverticulitis	0.012
Handgrip	-0.012
Bloating	0.011
Nonmelanoma skin cancer	0.01
Migraines	0.01

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Asian race	-0.01
AUDIT-C	0.009
Joint pain swelling	0.009
Epilepsy	0.009
Pneumonia	0.008
COPD with emphysema	0.007
Pulmonary embolism	0.007
Respiratory rate	0.007
Gallbladder disease	-0.007
Nasal stuffiness	0.006
30 second chair stand	-0.005
GERD	0.004
Discharge	-0.004
Shortness of breath with exercise	0.002
Fibromyalgia	0.002
Colon polyps	0.002
Arrhythmia	0.001
Goiter	-0.001

LASSO regression model 5 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression), symptoms (except those that are directly related to mental health or depression), allergies, and physical function. Variables with zero estimates are not shown.

AUDIT-C, Alcohol Use Disorders Identification Test-Concise; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; LASSO, least absolute shrinkage and selection operator.

eTable 8. LASSO Regression Results: Model 1

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.2344	< 0.0001	0.2026	0.2661
Memory change	0.2119	< 0.0001	0.1801	0.2437
Shortness of breath	0.2033	< 0.0001	0.1714	0.2352
Backache	0.1974	< 0.0001	0.1655	0.2293
Shortness of breath with exercise	0.1914	< 0.0001	0.1594	0.2233
Neck or low back pain	0.1869	< 0.0001	0.1549	0.2189
Waist circumference	0.1814	< 0.0001	0.1480	0.2149
Mean leg balance time	-0.1796	< 0.0001	-0.2172	-0.1420
Body image concerns	0.1726	< 0.0001	0.1403	0.2049
6-minute walk	-0.1608	< 0.0001	-0.1932	-0.1284
BMI	0.1604	< 0.0001	0.1282	0.1926
Number of pack-years smoked	0.1590	< 0.0001	0.1258	0.1922
Lightheadedness	0.1576	< 0.0001	0.1254	0.1899
Current smoker	0.1561	< 0.0001	0.1238	0.1884
Heat or cold intolerance	0.1560	< 0.0001	0.1238	0.1882
Headache	0.1532	< 0.0001	0.1205	0.1859
Not employed	0.1434	< 0.0001	0.1111	0.1757
Swelling in calves or feet	0.1421	< 0.0001	0.1098	0.1745
Coughing up sputum	0.1416	< 0.0001	0.1093	0.1739
30 second chair stand	-0.1407	< 0.0001	-0.1732	-0.1081
Tingling or pins and needles	0.1403	< 0.0001	0.1079	0.1727
Tingling or numbness in extremities	0.1373	< 0.0001	0.1049	0.1697
Sit-rise score	-0.1345	< 0.0001	-0.1714	-0.0975
Muscle or joint pain	0.1343	< 0.0001	0.1019	0.1668
Constipation	0.1334	< 0.0001	0.1010	0.1657
Income < \$25,000	0.1325	< 0.0001	0.1001	0.1650
WBC count	0.1322	< 0.0001	0.0998	0.1647
Bloating	0.1305	< 0.0001	0.0979	0.1631
Cough	0.1276	< 0.0001	0.0952	0.1601
Frequency of urination	0.1274	< 0.0001	0.0945	0.1603
Nasal stuffiness	0.1259	< 0.0001	0.0934	0.1583
COPD with emphysema	0.1228	< 0.0001	0.0901	0.1555
Joint pain swelling	0.1225	< 0.0001	0.0899	0.1550
Heartburn	0.1215	< 0.0001	0.0890	0.1540
Pain or stiffness in the neck	0.1206	< 0.0001	0.0881	0.1531
Stiffness	0.1194	< 0.0001	0.0868	0.1520
Mean daily steps in first 30 days	-0.1176	< 0.0001	-0.1503	-0.0848
Heart rate	0.1165	< 0.0001	0.0835	0.1495
Urination at night	0.1158	< 0.0001	0.0823	0.1492
HbA1c	0.1144	< 0.0001	0.0813	0.1476
Diarrhea	0.1138	< 0.0001	0.0812	0.1463
10-meter walk speed	-0.1137	< 0.0001	-0.1463	-0.0810
Blood glucose	0.1136	< 0.0001	0.0808	0.1463
Oxygen saturation	-0.1118	< 0.0001	-0.1458	-0.0777
Dry mouth	0.1117	< 0.0001	0.0791	0.1444
Night sweats	0.1110	< 0.0001	0.0784	0.1435
C-reactive protein	0.1084	< 0.0001	0.0759	0.1409
Urgency	0.1080	< 0.0001	0.0751	0.1410
Monocytes	0.1075	< 0.0001	0.0742	0.1408
Neutrophils	0.1072	< 0.0001	0.0747	0.1398
Numbness or loss of sensation	0.1055	< 0.0001	0.0729	0.1380
GERD	0.1004	< 0.0001	0.0675	0.1334

1					
2					
3	Itching skin	0.0971	< 0.0001	0.0645	0.1297
4	Excessive belching or passing of				
5	gas	0.0957	< 0.0001	0.0631	0.1283
6	Respiratory rate	0.0944	< 0.0001	0.0618	0.1270
7	Leg cramps	0.0933	< 0.0001	0.0606	0.1260
8	Urine specific gravity	0.0931	< 0.0001	0.0605	0.1257
9	Albumin in urine	-0.0928	< 0.0001	-0.1261	-0.0595
10	Dryness	0.0926	< 0.0001	0.0600	0.1252
11	Absolute basophils	0.0925	< 0.0001	0.0598	0.1251
12	Uninsured	0.0924	< 0.0001	0.0597	0.1250
13	Cramping	0.0920	< 0.0001	0.0592	0.1248
14	Osteoarthritis	0.0917	< 0.0001	0.0568	0.1267
15	Lymphocytes (total)	0.0883	< 0.0001	0.0554	0.1213
16	Sleep apnea	0.0877	< 0.0001	0.0541	0.1213
17	ALT	0.0848	< 0.0001	0.0522	0.1175
18	Married	-0.0848	< 0.0001	-0.1188	-0.0508
19	Sinus pain	0.0838	< 0.0001	0.0511	0.1164
20	HDL	-0.0835	< 0.0001	-0.1161	-0.0509
21	Creatinine (urine)	0.0811	< 0.0001	0.0484	0.1138
22	Reticulocytes (% RBC)	0.0803	< 0.0001	0.0475	0.1131
23	Triglycerides	0.0800	< 0.0001	0.0471	0.1128
24	Fibromyalgia	0.0798	< 0.0001	0.0472	0.1125
25	Asthma	0.0796	< 0.0001	0.0469	0.1123
26	Former smoker	0.0791	< 0.0001	0.0454	0.1127
27	Absolute reticulocytes	0.0786	< 0.0001	0.0458	0.1114
28	Diabetes type 2	0.0780	< 0.0001	0.0448	0.1111
29	Urine reaction pH	-0.0762	< 0.0001	-0.1095	-0.0430
30	Migraines	0.0753	< 0.0001	0.0425	0.1081
31	Hypertension	0.0749	< 0.0001	0.0397	0.1102
32	Runny nose	0.0738	< 0.0001	0.0411	0.1065
33	Vitamin D	-0.0732	< 0.0001	-0.1067	-0.0397
34	Easy bruising or bleeding	0.0719	< 0.0001	0.0390	0.1049
35	High school or less education	0.0706	< 0.0001	0.0379	0.1033
36	Floater	0.0701	< 0.0001	0.0370	0.1033
37	Discharge	0.0698	< 0.0001	0.0372	0.1025
38	Ear ringing	0.0671	< 0.0001	0.0338	0.1003
39	Hemorrhoids (symptom)	0.0649	0.0001	0.0320	0.0977
40	Days watch worn 10+ hours in first				
41	30 days	-0.0639	0.0002	-0.0976	-0.0301
42	Asian race	-0.0636	0.0002	-0.0964	-0.0307
43	Absolute eosinophils	0.0632	0.0002	0.0304	0.0960
44	Seasonal allergies	0.0626	0.0002	0.0299	0.0954
45	Medication allergies	0.0612	0.0003	0.0283	0.0941
46	Irritable bowel disorder	0.0585	0.0005	0.0258	0.0912
47	Hepatitis C	0.0579	0.0005	0.0252	0.0907
48	Rheumatoid arthritis	0.0572	0.0006	0.0244	0.0900
49	Systolic blood pressure	0.0566	0.0017	0.0212	0.0920
50	Diverticulitis	0.0561	0.0008	0.0232	0.0890
51	Uric acid	0.0538	0.0019	0.0199	0.0876
52	Magnesium	-0.0537	0.0013	-0.0865	-0.0209
53	MCHC	-0.0533	0.0015	-0.0861	-0.0205
54	Handgrip	-0.0514	0.0021	-0.0842	-0.0187
55	Gallbladder disease	0.0488	0.0036	0.0160	0.0816
56	MCH	-0.0465	0.0065	-0.0799	-0.0130
57	AST	0.0443	0.0080	0.0116	0.0771
58	Epilepsy	0.0427	0.0106	0.0100	0.0755
59					
60					

1					
2					
3	Food allergies	0.0424	0.0112	0.0096	0.0752
4	Diastolic blood pressure	0.0420	0.0124	0.0091	0.0748
5	Pneumonia	0.0403	0.0163	0.0074	0.0732
6	Nonalcoholic fatty liver disease	0.0403	0.0159	0.0075	0.0731
7	Ejection fraction at rest	0.0403	0.0161	0.0075	0.0731
8	Non-seasonal allergies	0.0393	0.0189	0.0065	0.0722
9	Serum creatinine	0.0388	0.0239	0.0051	0.0725
10	Protein (serum)	-0.0381	0.0299	-0.0725	-0.0037
11	Cataracts	0.0368	0.0513	-0.0002	0.0737
12	Pulmonary embolism	0.0359	0.0321	0.0031	0.0688
13	Peripheral vascular disease	0.0344	0.0401	0.0016	0.0673
14	Hay fever	0.0342	0.0413	0.0014	0.0671
15	Stroke	0.0337	0.0450	0.0008	0.0667
16	MCV	-0.0331	0.0529	-0.0666	0.0004
17	Diverticulosis	0.0324	0.0541	-0.0006	0.0655
18	Arrhythmia	0.0324	0.0584	-0.0012	0.0659
19	Gout	0.0323	0.0570	-0.0010	0.0655
20	Myocardial infarction	0.0317	0.0606	-0.0014	0.0649
21	Cholesterol	-0.0305	0.0685	-0.0633	0.0023
22	Platelets	0.0303	0.0783	-0.0034	0.0640
23	LDL	-0.0301	0.0726	-0.0630	0.0028
24	Peptic ulcer	0.0300	0.0730	-0.0028	0.0628
25	Hypercholesterolemia	0.0297	0.0879	-0.0044	0.0638
26	Goiter	-0.0290	0.0836	-0.0618	0.0039
27	Coronary artery disease	0.0287	0.0959	-0.0051	0.0625
28	Chloride	-0.0268	0.1096	-0.0596	0.0060
29	Neutrophil lymphocyte ratio	0.0266	0.1156	-0.0065	0.0597
30	Basophils (% WBC)	0.0258	0.1242	-0.0071	0.0587
31	Chronic headaches	0.0258	0.1236	-0.0070	0.0586
32	Nonmelanoma skin cancer	0.0233	0.1738	-0.0103	0.0569
33	Hearing loss	0.0229	0.1869	-0.0111	0.0568
34	MPV	0.0224	0.1802	-0.0104	0.0552
35	AUDIT-C sum score	-0.0219	0.1897	-0.0547	0.0109
36	Benign prostatic hyperplasia	0.0218	0.2273	-0.0136	0.0571
37	Eosinophils (% WBC)	0.0216	0.2001	-0.0114	0.0545
38	Hypothyroidism	-0.0213	0.2064	-0.0544	0.0118
39	Macular degeneration	0.0209	0.2140	-0.0121	0.0540
40	Left ventricular mass index	0.0197	0.2623	-0.0147	0.0541
41	Hemoglobin	-0.0181	0.2868	-0.0515	0.0153
42	RBC count	0.0180	0.2814	-0.0148	0.0508
43	Psoriasis	0.0170	0.3108	-0.0158	0.0497
44	Lymphocytes (% WBC)	-0.0166	0.3270	-0.0499	0.0166
45	Kidney or bladder stones	-0.0159	0.3448	-0.0490	0.0171
46	Glaucoma	0.0157	0.3547	-0.0175	0.0489
47	Hemorrhoids	0.0152	0.3649	-0.0177	0.0482
48	Coronary calcium score	0.0144	0.4287	-0.0213	0.0502
49	Other race	0.0131	0.4445	-0.0204	0.0466
50	Colon polyps	0.0120	0.4975	-0.0227	0.0467
51	Breast cancer	0.0118	0.4826	-0.0211	0.0446
52	Melanoma skin cancer	-0.0117	0.4889	-0.0450	0.0215
53	Sodium	-0.0117	0.4856	-0.0446	0.0212
54	Calcium	-0.0115	0.4909	-0.0443	0.0213
55	Hashimotos Disease	-0.0108	0.5175	-0.0436	0.0220
56	Transient ischemic attack	-0.0087	0.6029	-0.0417	0.0242
57	Osteopenia	-0.0076	0.6521	-0.0408	0.0256
58	Atrial fibrillation	0.0075	0.6601	-0.0258	0.0407
59					
60					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Neutrophil segments (% WBC)	0.0071	0.6714	-0.0257	0.0399
Total neutrophils (% WBC)	0.0071	0.6714	-0.0257	0.0399
TSH	0.0069	0.6786	-0.0259	0.0397
Potassium	-0.0060	0.7193	-0.0390	0.0269
Hematocrit	-0.0049	0.7722	-0.0383	0.0285
Monocytes (% WBC)	0.0041	0.8177	-0.0305	0.0386
Osteoporosis	-0.0039	0.8192	-0.0369	0.0292
GFR MDRD	0.0030	0.8737	-0.0343	0.0403
Tinnitus	0.0029	0.8627	-0.0304	0.0362
Diabetes type 1	-0.0027	0.8707	-0.0356	0.0301
Hispanic ethnicity	-0.0023	0.8914	-0.0360	0.0314
Hepatitis B	-0.0022	0.8963	-0.0351	0.0307
Prostate cancer	-0.0009	0.9575	-0.0348	0.0329
Black race	0.0004	0.9790	-0.0325	0.0334

LASSO regression model 1 comprised age, sex, and age by sex interaction. The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables shown.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUDIT-C, Alcohol Use Disorders Identification Test-Concise; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; GERD, gastroesophageal reflux disease; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LASSO, least absolute shrinkage and selection operator; LDL, low density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MDRD, modification of diet in renal disease; RBC, red blood cells; TSH, thyroid-stimulating hormone; WBC, white blood cells.

eTable 9. LASSO Regression Results: Model 2

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.1970	< 0.0001	0.1659	0.2282
Memory change	0.1732	< 0.0001	0.1423	0.2040
Backache	0.1585	< 0.0001	0.1273	0.1898
Body image concerns	0.1527	< 0.0001	0.1216	0.1837
Neck or low back pain	0.1419	< 0.0001	0.1105	0.1733
Shortness of breath with exercise	0.1336	< 0.0001	0.1019	0.1652
Shortness of breath	0.1329	< 0.0001	0.1011	0.1646
BMI	0.1269	< 0.0001	0.0958	0.1581
Lightheadedness	0.1268	< 0.0001	0.0955	0.1581
Waist circumference	0.1235	< 0.0001	0.0925	0.1545
Headache	0.1188	< 0.0001	0.0871	0.1505
Heat or cold intolerance	0.1159	< 0.0001	0.0845	0.1472
6-minute walk	-0.1139	< 0.0001	-0.1451	-0.0827
Constipation	0.1078	< 0.0001	0.0766	0.1391
Muscle or joint pain	0.1044	< 0.0001	0.0732	0.1356
Swelling in calves or feet	0.1036	< 0.0001	0.0723	0.1349
Bloating	0.1036	< 0.0001	0.0721	0.1351
Nasal stuffiness	0.1014	< 0.0001	0.0702	0.1326
Coughing up sputum	0.0978	< 0.0001	0.0663	0.1293
Joint pain swelling	0.0971	< 0.0001	0.0659	0.1282
Pain or stiffness in the neck	0.0937	< 0.0001	0.0623	0.1250
Frequency of urination	0.0927	< 0.0001	0.0615	0.1238
Heartburn	0.0913	< 0.0001	0.0599	0.1227
Diarrhea	0.0903	< 0.0001	0.0589	0.1216
Tingling or numbness in extremities	0.0900	< 0.0001	0.0586	0.1214
30 second chair stand	-0.0893	< 0.0001	-0.1207	-0.0580
Tingling or pins and needles	0.0859	< 0.0001	0.0543	0.1176
Cough	0.0855	< 0.0001	0.0539	0.1170
C-reactive protein	0.0847	< 0.0001	0.0534	0.1161
Blood glucose	0.0819	< 0.0001	0.0506	0.1131
Night sweats	0.0811	< 0.0001	0.0497	0.1125
Stiffness	0.0806	< 0.0001	0.0492	0.1119
Mean leg balance time	-0.0777	< 0.0001	-0.1090	-0.0464
HbA1c	0.0772	< 0.0001	0.0460	0.1084
Heart rate	0.0771	< 0.0001	0.0450	0.1092
Urination at night	0.0770	< 0.0001	0.0458	0.1082
ALT	0.0751	< 0.0001	0.0439	0.1063
Mean daily steps in first 30 days	-0.0745	< 0.0001	-0.1058	-0.0432
Urgency	0.0743	< 0.0001	0.0430	0.1055
Excessive belching or passing of gas	0.0739	< 0.0001	0.0426	0.1052
GERD	0.0727	< 0.0001	0.0414	0.1039
10-meter walk speed	-0.0721	< 0.0001	-0.1035	-0.0407
Dry mouth	0.0718	< 0.0001	0.0404	0.1032
Asthma	0.0715	< 0.0001	0.0403	0.1028
Sleep apnea	0.0711	< 0.0001	0.0397	0.1024
Itching skin	0.0682	< 0.0001	0.0368	0.0997
Sit-rise score	-0.0663	< 0.0001	-0.0978	-0.0348
WBC count	0.0653	< 0.0001	0.0327	0.0979
MCH	-0.0653	< 0.0001	-0.0965	-0.0340
Sinus pain	0.0652	< 0.0001	0.0338	0.0966
Urine specific gravity	0.0651	< 0.0001	0.0338	0.0965

1					
2					
3	Respiratory rate	0.0646	< 0.0001	0.0332	0.0960
4	Absolute reticulocytes	0.0634	< 0.0001	0.0319	0.0948
5	Leg cramps	0.0632	< 0.0001	0.0319	0.0945
6	Dryness	0.0622	0.0001	0.0307	0.0937
7	Numbness or loss of sensation	0.0615	0.0001	0.0299	0.0930
8	Creatinine (urine)	0.0611	0.0001	0.0297	0.0925
9	Cramping	0.0602	0.0002	0.0284	0.0920
10	Reticulocytes (% RBC)	0.0601	0.0002	0.0286	0.0916
11	Oxygen saturation	-0.0597	0.0002	-0.0910	-0.0284
12	Albumin in urine	-0.0581	0.0003	-0.0894	-0.0268
13	Migraines	0.0581	0.0003	0.0266	0.0896
14	MCV	-0.0578	0.0003	-0.0891	-0.0266
15	Osteoarthritis	0.0561	0.0005	0.0247	0.0876
16	Seasonal allergies	0.0556	0.0005	0.0243	0.0868
17	HDL	-0.0534	0.0009	-0.0848	-0.0220
18	Hemorrhoids (symptom)	0.0528	0.0009	0.0215	0.0841
19	Fibromyalgia	0.0525	0.0011	0.0211	0.0840
20	Lymphocytes (total)	0.0518	0.0015	0.0198	0.0838
21	Runny nose	0.0515	0.0013	0.0201	0.0828
22	Irritable bowel disorder	0.0513	0.0013	0.0200	0.0826
23	Ear ringing	0.0498	0.0019	0.0184	0.0811
24	Vitamin D	-0.0497	0.0023	-0.0816	-0.0178
25	Days watch worn 10+ hours in first 30 days	-0.0495	0.0023	-0.0813	-0.0177
26	COPD with emphysema	0.0488	0.0027	0.0170	0.0807
27	Food allergies	0.0483	0.0025	0.0170	0.0796
28	MCHC	-0.0483	0.0025	-0.0797	-0.0170
29	Hypertension	0.0479	0.0030	0.0162	0.0795
30	Urine reaction pH	-0.0473	0.0031	-0.0787	-0.0160
31	Triglycerides	0.0470	0.0033	0.0156	0.0783
32	Monocytes	0.0465	0.0037	0.0151	0.0779
33	Neutrophils	0.0462	0.0049	0.0140	0.0785
34	Serum creatinine	0.0460	0.0044	0.0143	0.0777
35	Uric acid	0.0460	0.0043	0.0144	0.0775
36	Diabetes type 2	0.0456	0.0044	0.0143	0.0769
37	AST	0.0447	0.0052	0.0134	0.0760
38	Discharge	0.0446	0.0054	0.0132	0.0760
39	Non-seasonal allergies	0.0445	0.0053	0.0132	0.0759
40	Diverticulitis	0.0432	0.0069	0.0119	0.0745
41	Floater	0.0421	0.0084	0.0108	0.0734
42	Absolute basophils	0.0417	0.0098	0.0101	0.0734
43	Ejection fraction at rest	0.0415	0.0094	0.0102	0.0729
44	Easy bruising or bleeding	0.0354	0.0272	0.0040	0.0667
45	Medication allergies	0.0345	0.0311	0.0031	0.0658
46	Epilepsy	0.0318	0.0471	0.0004	0.0631
47	Systolic blood pressure	0.0316	0.0505	-0.0001	0.0632
48	Chloride	-0.0308	0.0544	-0.0621	0.0006
49	Nonalcoholic fatty liver disease	0.0303	0.0578	-0.0010	0.0617
50	Arrhythmia	0.0299	0.0629	-0.0016	0.0614
51	RBC count	0.0296	0.0641	-0.0017	0.0610
52	Kidney or bladder stones	-0.0288	0.0721	-0.0601	0.0026
53	Chronic headaches	0.0285	0.0746	-0.0028	0.0599
54	Rheumatoid arthritis	0.0280	0.0808	-0.0034	0.0594
55	Hay fever	0.0279	0.0815	-0.0035	0.0592
56	Benign prostatic hyperplasia	0.0274	0.0946	-0.0047	0.0596
57	Cholesterol	-0.0267	0.0947	-0.0581	0.0046
58					
59					
60					

1					
2					
3	Absolute eosinophils	0.0265	0.0983	-0.0049	0.0580
4	Diverticulosis	0.0262	0.1013	-0.0051	0.0576
5	Goiter	-0.0261	0.1034	-0.0574	0.0053
6	Magnesium	-0.0258	0.1099	-0.0574	0.0058
7	Gout	0.0255	0.1116	-0.0059	0.0569
8	LDL	-0.0246	0.1238	-0.0560	0.0067
9	Hepatitis C	0.0239	0.1373	-0.0076	0.0554
10	Diastolic blood pressure	0.0232	0.1467	-0.0081	0.0546
11	Peripheral vascular disease	0.0230	0.1508	-0.0084	0.0543
12	Hypercholesterolemia	0.0227	0.1598	-0.0089	0.0543
13	Hemoglobin	-0.0225	0.1601	-0.0540	0.0089
14	Nonmelanoma skin cancer	0.0212	0.1869	-0.0103	0.0528
15	MPV	0.0211	0.1861	-0.0102	0.0525
16	Hearing loss	0.0210	0.1924	-0.0106	0.0527
17	Hypothyroidism	-0.0209	0.1930	-0.0523	0.0106
18	Handgrip	-0.0205	0.2025	-0.0522	0.0111
19	Pulmonary embolism	0.0194	0.2246	-0.0119	0.0508
20	Cataracts	0.0186	0.2549	-0.0134	0.0507
21	Glaucoma	0.0186	0.2477	-0.0129	0.0501
22	Sodium	-0.0167	0.2976	-0.0480	0.0147
23	Pneumonia	0.0166	0.3007	-0.0148	0.0479
24	Potassium	-0.0153	0.3403	-0.0466	0.0161
25	Macular degeneration	0.0140	0.3806	-0.0173	0.0454
26	Protein (serum)	-0.0139	0.3870	-0.0454	0.0176
27	Stroke	0.0133	0.4058	-0.0181	0.0447
28	Hemorrhoids	0.0132	0.4094	-0.0182	0.0446
29	Coronary artery disease	0.0123	0.4424	-0.0191	0.0438
30	Basophils (% WBC)	0.0118	0.4593	-0.0195	0.0432
31	Hematocrit	-0.0117	0.4667	-0.0431	0.0198
32	Psoriasis	0.0109	0.4946	-0.0204	0.0423
33	Myocardial infarction	0.0104	0.5153	-0.0210	0.0418
34	Eosinophils (% WBC)	0.0104	0.5158	-0.0210	0.0418
35	Peptic ulcer	0.0102	0.5244	-0.0212	0.0416
36	Breast cancer	0.0101	0.5287	-0.0213	0.0414
37	Neutrophil lymphocyte ratio	0.0100	0.5337	-0.0214	0.0413
38	Melanoma skin cancer	-0.0099	0.5384	-0.0414	0.0216
39	Calcium	-0.0098	0.5396	-0.0412	0.0215
40	Transient ischemic attack	-0.0090	0.5746	-0.0404	0.0224
41	Coronary calcium score	-0.0085	0.6007	-0.0401	0.0232
42	Left ventricular mass index	0.0082	0.6113	-0.0234	0.0398
43	Gallbladder disease	0.0081	0.6131	-0.0234	0.0397
44	TSH	0.0081	0.6117	-0.0232	0.0395
45	Tinnitus	0.0081	0.6138	-0.0234	0.0397
46	Osteoporosis	-0.0081	0.6139	-0.0395	0.0233
47	GFR MDRD	0.0075	0.6465	-0.0247	0.0398
48	Colon polyps	0.0074	0.6490	-0.0244	0.0391
49	Hashimotos Disease	-0.0073	0.6467	-0.0387	0.0240
50	Neutrophil segments (% WBC)	-0.0072	0.6530	-0.0386	0.0242
51	Total neutrophils (% WBC)	-0.0072	0.6530	-0.0386	0.0242
52	Platelets	0.0059	0.7162	-0.0261	0.0380
53	Atrial fibrillation	0.0056	0.7273	-0.0259	0.0371
54	Osteopenia	-0.0046	0.7748	-0.0361	0.0269
55	Diabetes type 1	0.0039	0.8093	-0.0275	0.0352
56	Lymphocytes (% WBC)	0.0038	0.8133	-0.0276	0.0351
57	Hepatitis B	0.0030	0.8507	-0.0284	0.0344
58	Monocytes (% WBC)	0.0030	0.8543	-0.0288	0.0348
59					
60					

1
2
3 Prostate cancer 0.0030 0.8543 -0.0287 0.0347

4 LASSO regression model 2 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status and health behaviors.
5 The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables shown.

6 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; COPD, chronic obstructive pulmonary
7 disease; GFR, glomerular filtration rate; GERD, gastroesophageal reflux disease; HbA1c, hemoglobin A1c; HDL, high density
8 lipoprotein; LASSO, least absolute shrinkage and selection operator; LDL, low density lipoprotein; MCH, mean corpuscular
9 hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MDRD, modification of diet in
renal disease; RBC, red blood cells; TSH, thyroid-stimulating hormone; WBC, white blood cells.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

eTable 10. LASSO Regression Results: Model 3

Variable	Estimate	P-value	CI 25%	CI 75%
Tension	0.1847	< 0.0001	0.1543	0.2152
Memory change	0.1511	< 0.0001	0.1207	0.1816
Body image concerns	0.1457	< 0.0001	0.1154	0.1760
Backache	0.1336	< 0.0001	0.1026	0.1645
Neck or low back pain	0.1191	< 0.0001	0.0881	0.1501
Lightheadedness	0.1047	< 0.0001	0.0739	0.1355
Shortness of breath with exercise	0.1028	< 0.0001	0.0713	0.1343
Shortness of breath	0.0976	< 0.0001	0.0657	0.1294
Headache	0.0967	< 0.0001	0.0655	0.1280
Constipation	0.0932	< 0.0001	0.0627	0.1238
Heat or cold intolerance	0.0918	< 0.0001	0.0609	0.1227
Nasal stuffiness	0.0880	< 0.0001	0.0574	0.1185
Waist circumference	0.0834	< 0.0001	0.0528	0.1141
BMI	0.0829	< 0.0001	0.0517	0.1142
Swelling in calves or feet	0.0816	< 0.0001	0.0508	0.1124
6-minute walk	-0.0801	< 0.0001	-0.1111	-0.0491
Bloating	0.0795	< 0.0001	0.0484	0.1106
Muscle or joint pain	0.0791	< 0.0001	0.0484	0.1098
Frequency of urination	0.0786	< 0.0001	0.0482	0.1091
Coughing up sputum	0.0781	< 0.0001	0.0471	0.1090
30 second chair stand	-0.0762	< 0.0001	-0.1068	-0.0455
Pain or stiffness in the neck	0.0745	< 0.0001	0.0438	0.1053
Joint pain swelling	0.0735	< 0.0001	0.0428	0.1041
Tingling or numbness in extremities	0.0729	< 0.0001	0.0420	0.1037
Heartburn	0.0712	< 0.0001	0.0404	0.1021
Night sweats	0.0681	< 0.0001	0.0373	0.0988
Urination at night	0.0642	< 0.0001	0.0337	0.0946
Cough	0.0631	< 0.0001	0.0320	0.0941
Mean daily steps in first 30 days	-0.0620	< 0.0001	-0.0926	-0.0313
Tingling or pins and needles	0.0616	0.0001	0.0304	0.0928
Diarrhea	0.0609	0.0001	0.0298	0.0919
C-reactive protein	0.0604	0.0001	0.0296	0.0913
Urgency	0.0601	0.0001	0.0295	0.0906
Blood glucose	0.0594	0.0001	0.0288	0.0901
Stiffness	0.0591	0.0002	0.0284	0.0899
Leg cramps	0.0588	0.0002	0.0282	0.0893
Mean leg balance time	-0.0565	0.0003	-0.0870	-0.0260
ALT	0.0560	0.0003	0.0254	0.0865
Dryness	0.0556	0.0004	0.0250	0.0863
Heart rate	0.0550	0.0006	0.0234	0.0866
Itching skin	0.0548	0.0005	0.0240	0.0856
Excessive belching or passing of gas	0.0547	0.0005	0.0240	0.0854
Sit-rise score	-0.0526	0.0008	-0.0831	-0.0220
Sinus pain	0.0525	0.0008	0.0219	0.0832
10-meter walk speed	-0.0525	0.0008	-0.0833	-0.0217
Oxygen saturation	-0.0506	0.0012	-0.0811	-0.0201
HbA1c	0.0499	0.0014	0.0193	0.0805
Respiratory rate	0.0495	0.0016	0.0187	0.0802
Ejection fraction at rest	0.0465	0.0028	0.0160	0.0771
WBC count	0.0462	0.0045	0.0144	0.0781

1					
2					
3	Absolute reticulocytes	0.0462	0.0033	0.0154	0.0770
4	Reticulocytes (% RBC)	0.0461	0.0034	0.0153	0.0770
5	Dry mouth	0.0456	0.0038	0.0148	0.0765
6	Albumin in urine	-0.0456	0.0034	-0.0761	-0.0151
7	Numbness or loss of sensation	0.0441	0.0052	0.0132	0.0751
8	Ear ringing	0.0422	0.0068	0.0116	0.0727
9	Food allergies	0.0418	0.0072	0.0113	0.0724
10	MCH	-0.0413	0.0084	-0.0720	-0.0106
11	Runny nose	0.0389	0.0128	0.0083	0.0695
12	Cramping	0.0389	0.0147	0.0076	0.0701
13	Hemorrhoids (symptom)	0.0386	0.0134	0.0080	0.0691
14	Days watch worn 10+ hours in				
15	first 30 days	-0.0385	0.0149	-0.0696	-0.0075
16	Handgrip	-0.0379	0.0150	-0.0685	-0.0074
17	MCHC	-0.0378	0.0156	-0.0684	-0.0072
18	Urine specific gravity	0.0361	0.0222	0.0052	0.0669
19	Absolute basophils	0.0352	0.0255	0.0043	0.0660
20	Urine reaction pH	-0.0351	0.0243	-0.0657	-0.0046
21	Monocytes	0.0350	0.0253	0.0043	0.0657
22	Lymphocytes (total)	0.0350	0.0283	0.0037	0.0663
23	Triglycerides	0.0347	0.0262	0.0041	0.0654
24	Discharge	0.0345	0.0273	0.0039	0.0652
25	MCV	-0.0338	0.0306	-0.0645	-0.0032
26	Neutrophils	0.0331	0.0390	0.0017	0.0645
27	Floater	0.0330	0.0342	0.0025	0.0636
28	Creatinine (urine)	0.0325	0.0397	0.0015	0.0635
29	AST	0.0319	0.0404	0.0014	0.0625
30	Serum creatinine	0.0311	0.0465	0.0005	0.0618
31	Seasonal allergies	0.0288	0.0650	-0.0018	0.0595
32	Easy bruising or bleeding	0.0272	0.0821	-0.0035	0.0578
33	Vitamin D	-0.0269	0.0928	-0.0583	0.0045
34	Medication allergies	0.0258	0.0977	-0.0047	0.0564
35	Uric acid	0.0247	0.1137	-0.0059	0.0552
36	Non-seasonal allergies	0.0237	0.1300	-0.0070	0.0543
37	HDL	-0.0229	0.1470	-0.0540	0.0081
38	Hemoglobin	-0.0229	0.1427	-0.0535	0.0077
39	Chloride	-0.0219	0.1590	-0.0525	0.0086
40	Protein (serum)	-0.0213	0.1737	-0.0520	0.0094
41	Systolic blood pressure	0.0186	0.2348	-0.0121	0.0492
42	Hay fever	0.0173	0.2677	-0.0133	0.0478
43	MPV	0.0154	0.3227	-0.0152	0.0460
44	Absolute eosinophils	0.0147	0.3473	-0.0160	0.0455
45	Hematocrit	-0.0147	0.3474	-0.0453	0.0159
46	Basophils (% WBC)	0.0140	0.3691	-0.0166	0.0446
47	Coronary calcium score	-0.0118	0.4500	-0.0426	0.0189
48	RBC count	0.0109	0.4830	-0.0196	0.0415
49	LDL	-0.0105	0.5007	-0.0411	0.0201
50	GFR MDRD	-0.0087	0.5884	-0.0402	0.0228
51	Diastolic blood pressure	0.0087	0.5775	-0.0219	0.0393
52	Neutrophil lymphocyte ratio	0.0079	0.6135	-0.0227	0.0384
53	Sodium	-0.0077	0.6218	-0.0383	0.0229
54	Calcium	-0.0056	0.7179	-0.0362	0.0249
55	Cholesterol	-0.0054	0.7296	-0.0360	0.0252
56	Monocytes (% WBC)	0.0038	0.8106	-0.0271	0.0346
57	Neutrophil segments (% WBC)	-0.0035	0.8244	-0.0340	0.0271
58	Total neutrophils (% WBC)	-0.0035	0.8244	-0.0340	0.0271
59					
60					

1				
2				
3	Platelets	0.0031	0.8456	-0.0280
4	Left ventricular mass index	-0.0026	0.8673	-0.0333
5	TSH	0.0025	0.8751	-0.0281
6	Eosinophils (% WBC)	0.0023	0.8824	-0.0283
7	Lymphocytes (% WBC)	0.0014	0.9280	-0.0292
8	Potassium	-0.0008	0.9588	-0.0314
9	Magnesium	-0.0005	0.9745	-0.0316

LASSO regression model 3 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, and medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression). The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables shown. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GFR, glomerular filtration rate; GERD, gastroesophageal reflux disease; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LASSO, least absolute shrinkage and selection operator; LDL, low density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MDRD, modification of diet in renal disease; RBC, red blood cells; TSH, thyroid-stimulating hormone; WBC, white blood cells.

For peer review only

eTable 11. LASSO Regression Results: Model 4

Variable	Estimate	P-value	CI 25%	CI 75%
BMI	0.0664	< 0.0001	0.0369	0.0960
6-minute walk	-0.0661	< 0.0001	-0.0955	-0.0368
Waist circumference	0.0618	< 0.0001	0.0326	0.0910
Mean daily steps in first 30 days	-0.0522	0.0004	-0.0813	-0.0232
ALT	0.0520	0.0004	0.0230	0.0809
Heart rate	0.0491	0.0012	0.0195	0.0787
30 second chair stand	-0.0458	0.0023	-0.0752	-0.0164
Blood glucose	0.0454	0.0022	0.0164	0.0745
WBC count	0.0454	0.0028	0.0157	0.0751
C-reactive protein	0.0431	0.0040	0.0137	0.0724
Absolute reticulocytes	0.0413	0.0054	0.0122	0.0705
Sit-rise score	-0.0408	0.0058	-0.0697	-0.0118
Reticulocytes (% RBC)	0.0401	0.0071	0.0109	0.0692
Handgrip	-0.0399	0.0070	-0.0688	-0.0109
Mean leg balance time	-0.0390	0.0083	-0.0679	-0.0100
Oxygen saturation	-0.0385	0.0091	-0.0675	-0.0096
AST	0.0374	0.0112	0.0085	0.0663
Respiratory rate	0.0367	0.0138	0.0075	0.0659
10-meter walk speed	-0.0362	0.0154	-0.0654	-0.0069
Albumin in urine	-0.0361	0.0146	-0.0651	-0.0071
Days watch worn 10+ hours in first 30 days	-0.0360	0.0157	-0.0653	-0.0068
Lymphocytes (total)	0.0354	0.0181	0.0060	0.0648
HbA1c	0.0352	0.0177	0.0061	0.0643
Ejection fraction at rest	0.0351	0.0173	0.0062	0.0641
Neutrophils	0.0350	0.0200	0.0055	0.0644
MCHC	-0.0341	0.0212	-0.0631	-0.0051
MCH	-0.0301	0.0428	-0.0592	-0.0010
Monocytes	0.0282	0.0577	-0.0009	0.0572
Absolute basophils	0.0270	0.0702	-0.0022	0.0562
Triglycerides	0.0267	0.0716	-0.0023	0.0557
Urine reaction pH	-0.0265	0.0734	-0.0554	0.0025
MCV	-0.0223	0.1333	-0.0513	0.0068
Sodium	-0.0220	0.1359	-0.0510	0.0069
Chloride	-0.0211	0.1537	-0.0500	0.0079
Serum creatinine	0.0203	0.1701	-0.0087	0.0492
MPV	0.0189	0.2015	-0.0101	0.0478
Potassium	-0.0185	0.2097	-0.0475	0.0104
Urine specific gravity	0.0179	0.2308	-0.0114	0.0473
Vitamin D	-0.0166	0.2713	-0.0462	0.0130
Systolic blood pressure	0.0165	0.2654	-0.0125	0.0455
LDL	-0.0158	0.2837	-0.0448	0.0131
Protein (serum)	-0.0145	0.3256	-0.0435	0.0145
RBC count	0.0144	0.3285	-0.0145	0.0434
Creatinine (urine)	0.0140	0.3518	-0.0154	0.0434
Basophils (% WBC)	0.0119	0.4208	-0.0171	0.0408
Left ventricular mass index	-0.0114	0.4391	-0.0404	0.0175
Uric acid	0.0111	0.4506	-0.0178	0.0401
Coronary calcium score	-0.0108	0.4681	-0.0398	0.0183
TSH	0.0102	0.4912	-0.0188	0.0391
Hemoglobin	-0.0095	0.5236	-0.0385	0.0196
Magnesium	-0.0074	0.6195	-0.0366	0.0218

1					
2					
3	Diastolic blood pressure	0.0064	0.6651	-0.0226	0.0354
4	Eosinophils (% WBC)	-0.0057	0.7011	-0.0346	0.0233
5	GFR MDRD	-0.0054	0.7173	-0.0349	0.0241
6	Neutrophil lymphocyte ratio	0.0053	0.7185	-0.0236	0.0343
7	Calcium	-0.0049	0.7398	-0.0339	0.0240
8	Platelets	0.0039	0.7947	-0.0254	0.0331
9	Cholesterol	-0.0034	0.8172	-0.0324	0.0256
10	HDL	-0.0027	0.8565	-0.0322	0.0267
11	Monocytes (% WBC)	0.0025	0.8652	-0.0266	0.0317
12	Absolute eosinophils	0.0017	0.9082	-0.0274	0.0309
13	Lymphocytes (% WBC)	0.0015	0.9192	-0.0275	0.0305
14	Neutrophil segments (% WBC)	-0.0013	0.9307	-0.0302	0.0277
15	Total neutrophils (% WBC)	-0.0013	0.9307	-0.0302	0.0277
16	Hematocrit	-0.0011	0.9413	-0.0301	0.0279

LASSO regression model 4 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors, medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression), symptoms (except those that are directly related to mental health or depression), and allergies. The LASSO-predicted value was used to estimate a covariate-adjusted effect for all other candidate variables shown.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GFR, glomerular filtration rate; GERD, gastroesophageal reflux disease; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LASSO, least absolute shrinkage and selection operator; LDL, low density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MDRD, modification of diet in renal disease; RBC, red blood cells; TSH, thyroid-stimulating hormone; WBC, white blood cells.

eTable 12. LASSO Regression Results: Model 5

Variable	Estimate	P-value	CI 25%	CI 75%
AST	0.0382	0.0087	0.0096	0.0667
ALT	0.0352	0.0162	0.0065	0.0638
HDL	0.0312	0.0383	0.0017	0.0607
Serum creatinine	0.0220	0.1313	-0.0066	0.0506
LDL	-0.0212	0.1460	-0.0497	0.0074
Blood glucose	0.0207	0.1606	-0.0082	0.0497
MCHC	-0.0199	0.1747	-0.0486	0.0088
Basophils (% WBC)	0.0183	0.2085	-0.0102	0.0469
Chloride	-0.0183	0.2099	-0.0468	0.0103
MPV	0.0181	0.2145	-0.0105	0.0467
Sodium	-0.0179	0.2203	-0.0464	0.0107
Absolute basophils	0.0170	0.2479	-0.0119	0.0460
Protein (serum)	-0.0169	0.2471	-0.0455	0.0117
MCH	-0.0148	0.3137	-0.0437	0.0140
Potassium	-0.0143	0.3259	-0.0429	0.0143
GFR MDRD	-0.0138	0.3535	-0.0430	0.0154
Lymphocytes (total)	0.0133	0.3748	-0.0160	0.0425
Platelets	-0.0127	0.3923	-0.0417	0.0164
WBC count	0.0125	0.4143	-0.0175	0.0424
Monocytes	0.0121	0.4122	-0.0168	0.0409
C-reactive protein	0.0104	0.4880	-0.0190	0.0398
Monocytes (% WBC)	0.0103	0.4818	-0.0185	0.0391
HbA1c	0.0101	0.4930	-0.0188	0.0391
MCV	-0.0101	0.4933	-0.0388	0.0187
TSH	0.0100	0.4930	-0.0186	0.0386
Albumin in urine	-0.0096	0.5130	-0.0383	0.0192
Magnesium	0.0095	0.5205	-0.0195	0.0385
Uric acid	-0.0080	0.5827	-0.0366	0.0206
RBC count	0.0073	0.6161	-0.0213	0.0359
Urine reaction pH	-0.0073	0.6185	-0.0360	0.0214
Neutrophil segments (% WBC)	-0.0072	0.6205	-0.0358	0.0214
Total neutrophils (% WBC)	-0.0072	0.6205	-0.0358	0.0214
Absolute reticulocytes	0.0069	0.6408	-0.0222	0.0361
Neutrophils	0.0068	0.6483	-0.0226	0.0363
Absolute eosinophils	-0.0064	0.6635	-0.0352	0.0224
Calcium	0.0062	0.6691	-0.0224	0.0348
Vitamin D	0.0057	0.7024	-0.0237	0.0352
Lymphocytes (% WBC)	0.0057	0.6944	-0.0229	0.0343
Reticulocytes (% RBC)	0.0057	0.7017	-0.0235	0.0349
Triglycerides	0.0055	0.7075	-0.0233	0.0343
Eosinophils (% WBC)	-0.0047	0.7449	-0.0333	0.0238
Hemoglobin	-0.0047	0.7481	-0.0334	0.0240
Cholesterol	-0.0033	0.8231	-0.0319	0.0254
Urine specific gravity	-0.0029	0.8465	-0.0321	0.0263
Neutrophil lymphocyte ratio	-0.0009	0.9488	-0.0295	0.0276
Creatinine (urine)	0.0006	0.9663	-0.0285	0.0298
Hematocrit	0.0000	0.9974	-0.0286	0.0287


1
2
3 LASSO regression model 5 comprised age, sex, age by sex interaction, race, ethnicity, socioeconomic status, health behaviors,
4 medical conditions (except mental health disorder diagnoses or disorders directly related to mental health or depression), symptoms
5 (except those that are directly related to mental health or depression), allergies, and physical function. The LASSO-predicted value
6 was used to estimate a covariate-adjusted effect for all other candidate variables shown.

7 ALT, alanine aminotransferase; AST, aspartate aminotransferase; GFR, glomerular filtration rate; GERD, gastroesophageal reflux
8 disease; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LASSO, least absolute shrinkage and selection operator; LDL, low
9 density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean
10 corpuscular volume; MDRD, modification of diet in renal disease; RBC, red blood cells; TSH, thyroid-stimulating hormone; WBC,
11 white blood cells.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

eFigure 1. Distribution of PHQ-9 Score Across Risk Groups by Asthma

Risk groups were created based on the LASSO-predicted value using LASSO Model 1 (age, sex, age x sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). "High risk" was defined as the top 50% of the predicted value, while "low risk" was defined as the bottom 50% of the predicted value.


LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9.




eFigure 2. Distribution of PHQ-9 Score Across Risk Groups by Backache

Risk groups were created based on the LASSO-predicted value using LASSO Model 1 (age, sex, age x sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). “High risk” was defined as the top 50% of the predicted value, while “low risk” was defined as the bottom 50% of the predicted value.

LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9.




eFigure 3. Distribution of PHQ-9 Score Across Risk Groups by Memory Change
Risk groups were created based on the LASSO-predicted value using LASSO Model 1 (age, sex, age x sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). “High risk” was defined as the top 50% of the predicted value, while “low risk” was defined as the bottom 50% of the predicted value. LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9.



eFigure 4. Distribution of PHQ-9 Score Across Risk Groups by Body Image Concerns


Risk groups were created based on the LASSO-predicted value using LASSO Model 1 (age, sex, age x sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). “High risk” was defined as the top 50% of the predicted value, while “low risk” was defined as the bottom 50% of the predicted value. LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9.



eFigure 5. Distribution of PHQ-9 Score Across Risk Groups by Sleep Apnea

Risk groups were created based on the LASSO-predicted value using LASSO Model 1 (age, sex, age x sex interaction) and Model 2 (race, ethnicity, socioeconomic-related variables and health behaviors). "High risk" was defined as the top 50% of the predicted value, while "low risk" was defined as the bottom 50% of the predicted value.

LASSO, least absolute shrinkage and selection operator; PHQ-9, Patient Health Questionnaire-9.



Only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-11
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7-11
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	7-11
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-11
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-11
Bias	9	Describe any efforts to address potential sources of bias	7-11
Study size	10	Explain how the study size was arrived at	7-11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-11
		(b) Describe any methods used to examine subgroups and interactions	7-11
		(c) Explain how missing data were addressed	7-11
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7-11
		(e) Describe any sensitivity analyses	n/a

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11-13
		(b) Give reasons for non-participation at each stage	11-13
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11-13
		(b) Indicate number of participants with missing data for each variable of interest	11-13
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	11-13
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	11-13
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-13
		(b) Report category boundaries when continuous variables were categorized	11-13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11-13
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15,16
Generalisability	21	Discuss the generalisability (external validity) of the study results	15,16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.